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No Man Is An Island
No man is an island
Entire of itself
Every man is a piece of the continent
A part of the main
If a clod be washed away by the sea
Europe is the less
As well as if a promontory were
As well as if a manor of thy friend’s
Or of thine own were
Any man’s death diminishes me
Because I am involved in mankind
And therefore never send to know for whom the bell tolls
It tolls for thee. 
  
John Donne
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Leukemia, or blood cancer, occurs in children and adults, and is divided into subgroups 
based on cell type and presentation of the disease. It is therefore important to consider 
how normal blood is formed, which types of leukemia exist, and which mechanisms can 
cause blood cells to become malignant. This information will help developing treatment 
strategies.  
The hematopoietic system
Blood transports nutrients, waste products, hormones, and cells throughout the body. 
Of the cellular components red blood cells transport oxygen, platelets form blood clots 
and mediate wound healing, and the immune system defends the body against pathogens 
with innate and adaptive immune cells. All blood cells are derived from hematopoietic 
stem cells (HSC), which reside in the bone marrow and ensure life-long reconstitution 
of the tissue (Figure 1). The progeny of HSC, so-called progenitor cells, are not yet fully 
mature (differentiated) and undergo further divisions and differentiation steps. They are 
divided into two lineages, the myeloid and the lymphoid lineage. The myeloid lineage 
gives rise to most cells of the innate immune system, platelet-producing megakaryoblasts, 
and erythrocytes. The lymphoid lineage consists of B- and T-lymphocytes, also called B- 
and T-cells. These constitute the adaptive immune system. 
Clinical presentation of acute leukemia, risk factors, and 
chemotherapy
Leukemia is caused by the malignant proliferation of a white blood cell progenitor. It 
originates from the bone marrow, but at the time of diagnosis cells have usually spread 
systemically. Depending on the growth speed and whether a uniform population or a 
mixture of maturation stages is present, clinicians distinguish between acute and chronic 
leukemia. In addition, the leukemia can bear lineage markers of myeloid or lymphoid 
cells. These groups define the four major categories chronic or acute myeloid leukemia 
(CML or AML), and chronic or acute lymphoid leukemia (CLL and ALL). Very rare 
forms of leukemia present markers of both blood cell lineages (mixed-lineage leukemia), 
or are myeloid but can be neither defined as acute nor chronic (juvenile myeolomonocytic 
leukemia, JMML). 
Acute lymphoblastic leukemia usually presents with the immunophenotype of B- or 
T-cell progenitors, and is therefore denominated B-cell precursor ALL (BCP-ALL) and 
T-cell ALL (T-ALL). Some patients present as mixed-lineage or bilineage leukemia, a 
more aggressive type that bears markers of both lymphoid and myeloid lineages. These 
can be further classified according to the genetic changes that initiate the leukemia, and 
provide a biologically more homogeneous classification (discussed below).
Children rarely present with chronic leukemia, while it is more common in adults. In 
Europe, approximately 5000 childhood leukemia cases are diagnosed every year, of which 
three quarters are ALL. BCP-ALL accounts for about 80 to 85% of ALL cases, and is 
therefore the most common leukemia in children.1 They present with symptoms such as 
fatigue, dizziness, anemia, and bone or joint pain. More severe consequences of leukemia 
are infections due to reduced immunity, and bleeding due to deficient coagulation. The 
definitive diagnosis is made after a bone marrow puncture.
Causes and risk factors for children are different compared to adults. In adults, the chance 
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that one of the hematopoietic stem or progenitor cells transforms into a leukemic cell 
increases with age. This is largely explained by the fact that exposure to environmental 
influences (e.g. radiation and carcinogens) increases the frequency at which leukemia-
causing mutations accumulate in hematopoietic stem and progenitor cells. In children, 
the incidence of leukemia peaks around the age of 3 to 5 years, and then declines again. 
While direct causes remain unknown, environmental toxins and genetic predisposition 
are thought to play a minor role. Instead, many studies support the hypothesis of a two-
step model involving common infections: In addition to a genetic lesions in a progenitor 
cell, either the aberrant response to, or active infection with one or more infectious agents 
is thought to promote the development of ALL.2,3 
The therapy of leukemia mainly consists of a combination of cytostatic and cytotoxic 
drugs. Depending on the specific treatment protocols, the exact schedule and therapy 
can differ. However, the backbone of all ALL treatment protocols relies on five major 
components: Prednisolone, a glucocorticoid which is toxic to lymphoid cells at 
high concentrations, vincristine, a spindle-poison which inhibits cell division, and 
L-asparaginase which degrades the amino acid asparagine, and the antimetabolites 
methotrexate and 6-mercaptopurine.1 In the most recent Dutch treatment protocol 
(DCOG-ALL11), children receive up to 14 different drugs over a period of two years. 
In cases with high risk of relapse, the therapy is concluded by a hematopoietic stem cell 
transplantation. 
The risks associated with intense chemotherapy and stem cell transplantation are high, 
and a considerable number of patients die from treatment-related toxicities. Short-term 
Figure 1: The developmental hierarchy of blood cells. 
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side effects include nausea, diarrhea, fatigue, moodiness, sleeplessness, allergic reactions, 
and severe infections. Possible late and long-term side effects are bone necrosis and 
growth retardation, heart problems, learning disabilities, infertility, and an increased 
chance of second cancers. 
Finding cures for all children, especially those with poor response to current therapy, is a 
main goal for childhood cancer research.4 However, because the current therapy achieves 
cure 75% of cases, a second important goal is minimizing short- and long-term side 
effects. Therapy is therefore adjusted depending on individual risk factors. 
Many risk factors have been identified, including white blood cell count at diagnosis, 
age above 10 years, male sex, trisomy 21, certain cytogenetic aberrations (e.g IKZF1-
deletions), T-ALL, central-nervous system involvement, and poor response to prednisone. 
Today, the most robust and accurate factor is the measurement of minimal residual 
disease (MRD).5 MRD is determined in bone marrow aspirates during the first months 
of treatment, using leukemia-specific PCR or flow cytometry. Good responses with fast 
reduction in disease load indicate that further treatment may be safely reduced, but slow 
reductions are indicative for treatment failure and require treatment intensification.5,6 
The identification of risk factors is only a first step, and effective treatment alternatives 
are warranted to successfully treat high risk cases. Intensified chemotherapy for patients 
with poor treatment response largely improved the prognosis in recent protocols, but has 
likely reached the maximum achievable effect.6
In cases of relapse, treatment options are equally limited. The drugs patients receive 
are usually similar to those that have been given in initial therapy. However, it has been 
shown that leukemic cells at relapse are more drug resistant, likely due to selection during 
therapy.7 In addition, relapse therapy often entails stem cell transplantation, which is 
associated with high rates of treatment-related death. Novel relapse therapies are urgently 
needed, and identification of relapse-driving aberrations for targeted therapy and 
immunotherapy are currently investigated in children with hematological malignancies.8 
Pathobiology and genetic aberrations of acute lymphoblastic 
leukemia
Leukemogenesis is a multi-step process (Figure 2). In the case of BCP-ALL, it is initiated 
when a hematopoietic progenitor with B-cell capacities acquires a genetic mutation that 
disrupts differentiation. Initiating lesions largely determine the biology of leukemic 
cells, and are therefore used to distinguish the major cytogenetic subtypes. Many are 
chromosomal translocations that create fusion genes. 
The most frequently detected fusion gene in pediatric BCP-ALL is translocation 
t(12;21), creating the ETV6-RUNX1 fusion gene (~26% of cases). Another very frequent 
aberration is the acquisition of additional chromosomes causing high hyperdiploidy 
(51-67 chromosomes), which is found in approximately 24% of patients. Hypodiploidy 
(<45 chromosomes) and translocations causing MLL-, TCF3-, or BCR-ABL1-fusions are 
rare (1%, 7%, 5%, and 2%, respectively).9 The remaining “B-other” group, accounting for 
one in every four patients, had previously included all cases lacking the aforementioned 
aberrations. Recent advances in genomics and transcriptomics have identified several 
distinct entities in this clinically and biologically heterogeneous group. 
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The largest group are so-called BCR-ABL1-like cases, which are defined by a gene 
expression signature similar to that of BCR-ABL1-positive cases.10,11 Although definitions 
vary, this poor prognostic group constitutes roughly half of all B-other cases and about 
15% of all BCP-ALL cases.12,13 BCR-ABL1-like leukemia is, just as BCR-ABL1-positive 
leukemia, characterized by aberrant activation of signaling pathways. In many cases 
this is due to tyrosine kinase fusions involving receptor-associated kinases (e.g. JAK2, 
ABL1, or ABL2) or receptor-tyrosine kinases (PDGFRB, EPOR, CSF1R).12,14-16 In addition, 
overexpression of the cytokine-receptor CRLF2 is found in about half of BCR-ABL1-
like. It is less frequently found among high hyperdiploid, MLL-rearranged, and non-
BCR-ABL1-like B-other cases (~10% of all BCP-ALL).12,17 In many cases, high CRLF2 
expression is caused by a deletion or translocation that juxtaposes the CRLF2 gene to a 
new promoter.18,19 The prognostic impact of high CRLF2 expression seems to depend on 
the treatment protocol.17,20 
Other exclusive, recurrent aberrations within the BCR-ABL1-like group are internal 
amplification of chromosome 21 (iAMP21, ~2% of all BCP-ALL) and a dicentric 
chromosome containing parts of chromosomes 9 and 20 (dic(9;20), ~5% of BCP-ALL).21-24 
Extensive genomic profiling of the remaining, non-BCR-ABL1-like B-other cases 
has recently identified so-called ETV6-RUNX1-like cases and recurrent fusion genes 
involving MEF2D, ZNF384, and DUX4.25-27 Especially the latter discovery solved an 
important part of the puzzle around ERG-deletions, a common secondary aberration 
observed in BCP-ALL. A distinct gene expression profile that is associated with, but not 
limited to cases with ERG-deletions has been described in 2010.28 Lillebjörn et al. found 
that this so-called ERG-cluster overlaps with DUX4-rearrangements, and Zhang et al. 
provided a mechanistic link between ERG–deletions and DUX4-rearrangements.26,29 
Unlike MEF2D- and ZNF384-fusions, DUX4-rearrangements seem to be associated with 
Figure 2: Genetic aberrations in the development of BCP-ALL.
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a good outcome.28,30,31
Primary leukemogenic aberrations can often be identified in utero, but only a fraction 
of patients with a detectable fusion gene actually develops leukemia.32-35 This penetrance 
varies: while most children with detectable MLL-rearrangements develop disease 
quickly, only about 1% of cases with an ETV6-RUNX1-fusion present in utero develop 
leukemia at a later age. This highlights the relevance of cooperative secondary events for 
a progression to overt leukemia. Besides the postulated infectious stimulus mentioned 
above, many genetic aberrations have been identified to support leukemogenesis.27,36-42 
Most aberrations are not mutually exclusive for a specific subtype, but frequencies often 
vary among cytogenetic groups. 
B-cell transcription factors (e.g. PAX5, IKZF1, TCF3, ETV6, EBF1, ERG, and RUNX1) 
are frequently inactivated or functionally modified by mutations, deletions, or sequence 
duplications. These aberrations are thought to sustain a differentiation block in malignant 
cells. These biological differences have clinical impact: IKZF1-deletions for example, are 
enriched among kinase fusion-positive BCP-ALL and poor prognostic.11,17,43,44
Deregulation of cell cycle and DNA damage response is the result of frequently observed 
CDKN2A/B deletions and less frequent loss of RB1 or p53 function.42 They represent 
important secondary aberrations that promote proliferation and survival. Mutational 
activation of the survival-promoting signaling pathways in BCP-ALL mostly affects 
JAK2/STAT5 and RAS/MAPK signaling, and is discussed below. 
A third group of proteins frequently affected by aberrations are epigenetic 
modulators.39,40,42,45,46 CREBBP, for example, is recurrently mutated or deleted and loss 
of function is postulated to reduce responsiveness to glucocorticoids.45,46 Their role in 
leukemogenesis and suitability as treatment target is only starting to be understood.
Mutations conferring a proliferative advantage or resistance to apoptosis will give a 
competitive edge to expanding (pre-) leukemic cells. This concept of clonal evolution 
is essential for understanding disease initiation, treatment strategies, and relapse.47,48 
While leukemia-initiating aberrations are present in all cells, secondary aberrations are 
subject to evolutionary selection in a Darwinian model. Longitudinal genomic studies of 
matched sampled from diagnosis, remission, and relapse(s) have shown that considerable 
Figure 3: Estimated frequencies of cytogenetic subtypes in childhood BCP-ALL (adapted from 
Pui et al.1).
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genetic heterogeneity exists at diagnosis and many relapse-forming clones are present as 
subpopulation.49-52 Specific genetic mutations such as TP53, CREBBP, or those conferring 
resistance to chemotherapy (e.g. in NT5C2 or NR3C1) are found more frequently at 
relapse.45,53,54 50,52
Inter- and intra-cellular signals: Oncogenic pathways and 
the microenvironment of leukemia.
Cellular signaling pathways are often affected by oncogenic hits in pediatric BCP-ALL. 
The aforementioned kinase fusions are an example of primary aberrations deregulating 
pro-survival signaling. Two major kinase pathways mediate these signals, leading to a 
mechanistic distinction between JAK- and ABL-type fusions.20 ABL-type fusions result 
in strong activation of the MAPK pathway, JAK/STAT pathways, and PI3K/mTOR 
signaling.20,55 JAK2-fusions as well as high CRLF2 expression mainly act oncogenic by 
activating the STAT transcription factors and PI3K/mTOR signaling.56 
The cytokine receptor CRLF2 lacks a kinase domain, and therefore relies on the 
associated kinase JAK2 to activate downstream signaling.19,57 Binding of the ligand TSLP 
is still required and possibly limiting the oncogenic function of CRLF2. At least partial 
ligand-independence can be conferred by activating mutations in JAK2 which occur 
in about 50% of cases with high CRLF2 expression.18,19,58 Interestingly, although PI3K/
mTOR signaling has been shown to be critical for CRLF2-rearranged leukemia, activating 
mutations in this pathway have not been described.56,59
A second essential oncogenic pathway is the MAPK pathway with its core components 
RAS, RAF, MEK and ERK. It is one of the most frequently mutated pathways in cancer.60 
The Ras GTPases (HRAS, NRAS, KRAS) mediate signals of activated receptor-tyrosine 
kinases (RTK). They activate the RAF kinases (ARAF, BRAF, and CRAF), which in turn 
activate MEK1 and MEK2. The only known targets of MEK1/2 are ERK1 and ERK2, but 
these can interact with and phosphorylate several hundred targets.61,62 Cellular functions 
regulated by MAPK signaling include cell cycle progression, cell survival, differentiation, 
and motility. 
In addition to the abovementioned intracellular pathways, extra-cellular signaling 
mediated by cytokines and growth factors have been shown to regulate normal and 
malignant hematopiesis.63,64 The release of these factors from and to the microenvironment 
plays a crucial role for leukemia development and therapy resistance. Leukemic cells 
manipulate the bone marrow niche in their favor.65 The cytokine CXCL12, expressed by 
stromal cells, can modulate leukemic cell egress, homing, and modulate chemotherapy 
resistance.66,67 Adhesion molecules such as ITGA4 modulate leukemic cell survival and 
chemoresistance.68 Tunneling nanotubes represent another, only recently identified 
mechanism of communication between leukemic and bone marrow stromal cells.69
Novel therapeutic approaches for children with acute 
lymphoblastic leukemia
Current treatment for children with leukemia comprises more than a dozen therapeutic 
agents. Decades of clinical trials have massively improved therapy outcomes by optimizing 
the combination of these drugs. However, survival rates are stagnating, which suggests 
that therapy has reached its maximum achievable effect.1 The high cure rate of standard 
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therapy sets the focus on two main goals: identifying cure for those 10 to 15% of cases 
that relapse, and avoiding overtreatment of cases who are cured to reduce side effects and 
treatment-related deaths. 
Further improvements are likely to come from entirely new therapy classes, such as 
targeted therapy or immunotherapy. Targeted therapy designates treatment strategies 
which abrogate the effect of oncogenic drivers and it is often linked to personalized 
cancer treatment. 
Six cellular capacities have been initially suggested to contribute to malignancy in all 
cancer cells. These hallmarks of cancer are: self-sufficiency in growth signals, insensitivity 
to anti-growth signals, evasion of apoptosis, limitless replicative potential, tissue invasion 
and metastasis, and induction of angiogenesis.70 Recently, two more principles have been 
added: Deregulated cellular energetics and evasion from immune destruction.71 Many 
of these core capacities are driven by genetic aberrations, and usually several genetic 
aberrations collaborate to establish a malignant phenotype. Some aberrations can affect 
more than one hallmark, and as a result these aberrations may affect specific hallmarks to 
a varying extend in distinct tumor types and cases. These principles have to be taken into 
account to develop and evaluate targeted therapies. 
The exploration of signaling pathways as therapeutic targets has grown with the next-
generation sequencing revolution. Low costs for sequencing entire genomes facilitate 
molecular characterization of every tumor. Although few aberrations serve as treatment 
targets so far (often called “actionable aberrations”), encouraging examples exist. 
All-trans retinoic acid, for example, specifically induces differentiation in PML-RARA-
rearranged acute promyelocytic leukemia. Arsenic trioxide, which targets the PML 
moiety, induces apoptosis in these cell. The combination of these to drugs now achieves 
a 4-year overall survival of 98% in this once deadly disease.72 
Identification and characterization of the BCR-ABL1-rearrangement led to the 
application of the first kinase inhibitor (TKI) for cancer treatment: imatinib. It has 
drastically improved prognosis for CML and BCR-ABL1-rearranged B-ALL in children 
and adults.73,74 As explained above, tyrosine-kinase fusions represent primary, leukemia-
driving lesions in about 5% of pediatric BCP-ALL cases.15 So far only BCR-ABL1-
rearranged cases receive standard TKI therapy, but preclinical and anecdotal clinical data 
suggest sensitivity towards inhibition of the JAK and ABL class kinases.12,14,16,56,75-77 
Three promises are offered by kinase inhibitors for children with BCP-ALL: First, they 
may serve as treatment options if standard therapy fails. Second, they could be included 
upfront for high risk cases to prevent relapses. Third, their anticipated specificity for 
cancer cells could entail less short-and long-term side effects and allow reduction of 
chemotherapy. 
Despite successful examples such as Imatinib in BCR-ABL1-rearranged CML, 
vermurafinib in BRAF-mutant melanoma, or ERBB2-specific antibodies in breast cancer, 
many other approaches have yielded minor benefits and stayed behind the expectations 
from pre-clinical studies. Pharmacologic hurdles such as competition with high 
concentrations of ATP (imatinib), or short half-lives (momelotinib) may interfere with 
efficacy and applicability of kinase inhibitors.78,79 
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Biologically, clonal evolution has also proven to be a major cause for disease progression 
on therapy. Any therapy represents a shift in selective pressures and mutations causing 
drug resistance, e.g. in CREBBP or ABL1 T315I, are therefore positively selected.45 
Already diagnostic patient samples contain multiple genetically distinct subclones.80 
In BCP-ALL virtually all cells retain leukemia-initiating capacity.34,81,82 Theoretically, 
a mutation occurring in any of the leukemic cells present at diagnosis could therefore 
give rise to a resistant cell. This demonstrates the importance of a combinatorial, multi-
targeted therapy. 
With these advantages and possible limitations in mind, the aim of this thesis is therefore 
to evaluate selected signaling pathways as therapeutic targets in BCP-ALL. Five targets, 
JAK2, the RAS pathway, PDGFRα, FGFR, and EMP1 were selected and assessed for 
different treatment strategies.
Outline of this thesis
Intra- and inter-cellular signaling pathways have become promising candidates for cancer 
therapy, because they are frequently affected by oncogenic aberrations and specific 
small molecule inhibitors are available. The aim of this thesis is to identify and evaluate 
signaling pathways that may be targeted by novel therapeutic approaches in children with 
BCP-ALL. 
In chapter 2, we determined the frequency of JAK2 mutations and translocations in a 
large cohort of BCP-ALL patients at diagnosis and evaluated the ex vivo efficiency of two 
clinically tested JAK inhibitors. We found selective anti-tumor activity of JAK inhibitors 
in cells carrying JAK2 aberrations. However, we also identified stroma mediated drug 
resistance, mutational activation of alternative survival pathways, and a signaling rebound 
effect after inhibitor release as important caveats in JAK inhibitor treatment. 
A second frequently mutated signaling pathway is studied in chapter 3: Next generation 
sequencing was used to detect RAS pathway mutations. We show that clonal or subclonal 
RAS pathway mutations are present in 44% of BCP-ALL cases at diagnosis. Mutations 
were associated with poorer ex vivo response to chemotherapy, and clonal but not 
subclonal mutations associated with a poor prognosis in some treatment groups. RAS 
mutant BCP-ALL cells were ex vivo sensitive to the MEK inhibitor trametinib, which 
suggests that this FDA-approved drug could be used to treat BCP-ALL with RAS pathway 
mutations. 
In chapter 4 we study the role of high PDGFRA expression in the newly discovered ERG-
deleted leukemia. No genetic aberrations within the PDGFRA locus could be identified 
that could explain high levels of PDGFRA transcript. Despite being translated and ligand-
activated, inhibition of PDGFRα was not cytotoxic in PDGFRA-high BCP-ALL. 
Two factors mediating ex vivo glucocorticoid resistance are discussed in the last two 
chapters of this thesis. In chapter 5 we show that FGFR mutations are rare and occur 
outside of classical mutational hotspots. The ligand FGF2, however, can reduce the 
responsiveness of BCP-ALL cells to prednisolone. In chapter 6 we identify EMP1 as a 
poor prognostic biomarker and regulator of glucocorticoid resistance. 
Ch
ap
te
r 1
19General introduction
References
1. Pui CH, Evans WE. A 50-year journey to cure 
childhood acute lymphoblastic leukemia. Semin 
Hematol. 2013;50(3):185-196.
2. Greaves M. Infection, immune responses and the 
aetiology of childhood leukaemia. Nat Rev Cancer. 
2006;6(3):193-203.
3. Francis SS, Wallace AD, Wendt GA, et al. In utero 
cytomegalovirus infection and development of 
childhood acute lymphoblastic leukemia. Blood. 2016.
4. Pui CH, Mullighan CG, Evans WE, Relling MV. 
Pediatric acute lymphoblastic leukemia: where 
are we going and how do we get there? Blood. 
2012;120(6):1165-1174.
5. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et 
al. Prognostic value of minimal residual disease in 
acute lymphoblastic leukaemia in childhood. Lancet. 
1998;352(9142):1731-1738.
6. Pieters R, de Groot-Kruseman H, Van der Velden V, 
et al. Successful Therapy Reduction and Intensification 
for Childhood Acute Lymphoblastic Leukemia Based 
on Minimal Residual Disease Monitoring: Study 
ALL10 From the Dutch Childhood Oncology Group. 
J Clin Oncol. 2016;34(22):2591-2601.
7. Klumper E, Pieters R, Veerman AJ, et al. In vitro 
cellular drug resistance in children with relapsed/
refractory acute lymphoblastic leukemia. Blood. 
1995;86(10):3861-3868.
8. Bhojwani D, Pui CH. Relapsed childhood 
acute lymphoblastic leukaemia. Lancet Oncol. 
2013;14(6):e205-217.
9. Mullighan CG, Downing JR. Global genomic 
characterization of acute lymphoblastic leukemia. 
Semin Hematol. 2009;46(1):3-15.
10. Den Boer ML, van Slegtenhorst M, De Menezes 
RX, et al. A subtype of childhood acute lymphoblastic 
leukaemia with poor treatment outcome: a 
genome-wide classification study. Lancet Oncol. 
2009;10(2):125-134.
11. Mullighan CG, Su X, Zhang J, et al. Deletion 
of IKZF1 and prognosis in acute lymphoblastic 
leukemia. N Engl J Med. 2009;360(5):470-480.
12. Roberts KG, Li Y, Payne-Turner D, et al. 
Targetable kinase-activating lesions in Ph-like 
acute lymphoblastic leukemia. N Engl J Med. 
2014;371(11):1005-1015.
13. Boer JM, Marchante JR, Evans WE, et al. BCR-
ABL1-like cases in pediatric acute lymphoblastic 
leukemia: a comparison between DCOG/Erasmus 
MC and COG/St. Jude signatures. Haematologica. 
2015;100(9):e354-357.
14. Roberts KG, Morin RD, Zhang J, et al. Genetic 
alterations activating kinase and cytokine receptor 
signaling in high-risk acute lymphoblastic leukemia. 
Cancer Cell. 2012;22(2):153-166.
15. Boer JM, Steeghs EM, Marchante JR, et al. Tyrosine 
kinase fusion genes in pediatric BCR-ABL1-like 
acute lymphoblastic leukemia. Oncotarget. 2016.
16. Iacobucci I, Li Y, Roberts KG, et al. Truncating 
Erythropoietin Receptor Rearrangements in 
Acute Lymphoblastic Leukemia. Cancer Cell. 
2016;29(2):186-200.
17. van der Veer A, Waanders E, Pieters R, et al. 
Independent prognostic value of BCR-ABL1-like 
signature and IKZF1 deletion, but not high CRLF2 
expression, in children with B-cell precursor ALL. 
Blood. 2013;122(15):2622-2629.
18. Russell LJ, Capasso M, Vater I, et al. Deregulated 
expression of cytokine receptor gene, CRLF2, is 
involved in lymphoid transformation in B-cell 
precursor acute lymphoblastic leukemia. Blood. 
2009;114(13):2688-2698.
19. Yoda A, Yoda Y, Chiaretti S, et al. Functional 
screening identifies CRLF2 in precursor B-cell acute 
lymphoblastic leukemia. Proc Natl Acad Sci U S A. 
2010;107(1):252-257.
20. Izraeli S. Beyond Philadelphia: ‘Ph-like’ B cell 
precursor acute lymphoblastic leukemias - diagnostic 
challenges and therapeutic promises. Curr Opin 
Hematol. 2014;21(4):289-296.
21. Harewood L, Robinson H, Harris R, et al. 
Amplification of AML1 on a duplicated chromosome 
21 in acute lymphoblastic leukemia: a study of 20 
cases. Leukemia. 2003;17(3):547-553.
22. Harrison CJ. Blood Spotlight on iAMP21 acute 
lymphoblastic leukemia (ALL), a high-risk pediatric 
disease. Blood. 2015;125(9):1383-1386.
23. Rieder H, Schnittger S, Bodenstein H, et al. 
dic(9;20): a new recurrent chromosome abnormality 
in adult acute lymphoblastic leukemia. Genes 
Chromosomes Cancer. 1995;13(1):54-61.
24. Zachariadis V, Gauffin F, Kuchinskaya E, et al. 
The frequency and prognostic impact of dic(9;20)
(p13.2;q11.2) in childhood B-cell precursor acute 
lymphoblastic leukemia: results from the NOPHO 
ALL-2000 trial. Leukemia. 2011;25(4):622-628.
25. Yasuda T, Tsuzuki S, Kawazu M, et al. Recurrent 
DUX4 fusions in B cell acute lymphoblastic leukemia 
of adolescents and young adults. Nat Genet. 
2016;48(5):569-574.
Conclusions and significance of the work presented in this thesis are discussed in 
chapter 7, including future directives for targeted therapy in children with BCP-ALL. A 
summary of the work in English and Dutch is given in chapter 8, and detailed information 
about the author in chapter 9. 
20
26. Lilljebjorn H, Henningsson R, Hyrenius-Wittsten 
A, et al. Identification of ETV6-RUNX1-like and 
DUX4-rearranged subtypes in paediatric B-cell 
precursor acute lymphoblastic leukaemia. Nat 
Commun. 2016;7:11790.
27. Liu YF, Wang BY, Zhang WN, et al. Genomic 
Profiling of Adult and Pediatric B-cell Acute 
Lymphoblastic Leukemia. EBioMedicine. 2016;8:173-
183.
28. Harvey RC, Mullighan CG, Wang X, et al. 
Identification of novel cluster groups in pediatric 
high-risk B-precursor acute lymphoblastic leukemia 
with gene expression profiling: correlation with 
genome-wide DNA copy number alterations, 
clinical characteristics, and outcome. Blood. 
2010;116(23):4874-4884.
29. Zhang J, McCastlain K, Yoshihara H, et al. 
Deregulation of DUX4 and ERG in acute lymphoblastic 
leukemia. Nat Genet. 2016;48(12):1481-1489.
30. Clappier E, Auclerc MF, Rapion J, et al. An 
intragenic ERG deletion is a marker of an oncogenic 
subtype of B-cell precursor acute lymphoblastic 
leukemia with a favorable outcome despite frequent 
IKZF1 deletions. Leukemia. 2014;28(1):70-77.
31. Zaliova M, Zimmermannova O, Dorge P, et al. ERG 
deletion is associated with CD2 and attenuates the 
negative impact of IKZF1 deletion in childhood acute 
lymphoblastic leukemia. Leukemia. 2014;28(1):182-
185.
32. Taub JW, Konrad MA, Ge Y, et al. High frequency of 
leukemic clones in newborn screening blood samples 
of children with B-precursor acute lymphoblastic 
leukemia. Blood. 2002;99(8):2992-2996.
33. Greaves MF, Wiemels J. Origins of chromosome 
translocations in childhood leukaemia. Nat Rev 
Cancer. 2003;3(9):639-649.
34. Greaves M. Molecular genetics, natural history 
and the demise of childhood leukaemia. Eur J Cancer. 
1999;35(14):1941-1953.
35. Mori H, Colman SM, Xiao Z, et al. Chromosome 
translocations and covert leukemic clones are 
generated during normal fetal development. Proc Natl 
Acad Sci U S A. 2002;99(12):8242-8247.
36. Andersson AK, Ma J, Wang J, et al. The landscape 
of somatic mutations in infant MLL-rearranged acute 
lymphoblastic leukemias. Nat Genet. 2015;47(4):330-
337.
37. Fischer U, Forster M, Rinaldi A, et al. Genomics 
and drug profiling of fatal TCF3-HLF-positive 
acute lymphoblastic leukemia identifies recurrent 
mutation patterns and therapeutic options. Nat Genet. 
2015;47(9):1020-1029.
38. Holmfeldt L, Wei L, Diaz-Flores E, et al. The 
genomic landscape of hypodiploid acute lymphoblastic 
leukemia. Nat Genet. 2013;45(3):242-252.
39. Huether R, Dong L, Chen X, et al. The landscape 
of somatic mutations in epigenetic regulators across 
1,000 paediatric cancer genomes. Nat Commun. 
2014;5:3630.
40. Paulsson K, Lilljebjorn H, Biloglav A, et al. 
The genomic landscape of high hyperdiploid 
childhood acute lymphoblastic leukemia. Nat Genet. 
2015;47(6):672-676.
41. Pui CH. Genomic and pharmacogenetic studies of 
childhood acute lymphoblastic leukemia. Front Med. 
2015;9(1):1-9.
42. Zhang J, Mullighan CG, Harvey RC, et al. 
Key pathways are frequently mutated in high-
risk childhood acute lymphoblastic leukemia: a 
report from the Children’s Oncology Group. Blood. 
2011;118(11):3080-3087.
43. van der Veer A, Zaliova M, Mottadelli F, et al. 
IKZF1 status as a prognostic feature in BCR-ABL1-
positive childhood ALL. Blood. 2014;123(11):1691-
1698.
44. Boer JM, van der Veer A, Rizopoulos D, et al. 
Prognostic value of rare IKZF1 deletion in childhood 
B-cell precursor acute lymphoblastic leukemia: 
an international collaborative study. Leukemia. 
2016;30(1):32-38.
45. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP 
mutations in relapsed acute lymphoblastic leukaemia. 
Nature. 2011;471(7337):235-239.
46. Malinowska-Ozdowy K, Frech C, Schonegger A, 
et al. KRAS and CREBBP mutations: a relapse-linked 
malicious liaison in childhood high hyperdiploid acute 
lymphoblastic leukemia. Leukemia. 2015;29(8):1656-
1667.
47. Greaves M, Maley CC. Clonal evolution in cancer. 
Nature. 2012;481(7381):306-313.
48. Shlush LI, Hershkovitz D. Clonal evolution models 
of tumor heterogeneity. Am Soc Clin Oncol Educ 
Book. 2015:e662-665.
49. Mullighan CG, Phillips LA, Su X, et al. 
Genomic analysis of the clonal origins of 
relapsed acute lymphoblastic leukemia. Science. 
2008;322(5906):1377-1380.
50. Oshima K, Khiabanian H, da Silva-Almeida 
AC, et al. Mutational landscape, clonal evolution 
patterns, and role of RAS mutations in relapsed acute 
lymphoblastic leukemia. Proc Natl Acad Sci U S A. 
2016.
51. Ma X, Edmonson M, Yergeau D, et al. Rise and 
fall of subclones from diagnosis to relapse in pediatric 
B-acute lymphoblastic leukaemia. Nat Commun. 
2015;6:6604.
52. Kuster L, Grausenburger R, Fuka G, et al. ETV6/
RUNX1-positive relapses evolve from an ancestral 
clone and frequently acquire deletions of genes 
implicated in glucocorticoid signaling. Blood. 
2011;117(9):2658-2667.
53. Stengel A, Schnittger S, Weissmann S, et al. TP53 
mutations occur in 15.7% of ALL and are associated 
with MYC-rearrangement, low hypodiploidy, and a 
poor prognosis. Blood. 2014;124(2):251-258.
54. Tzoneva G, Perez-Garcia A, Carpenter Z, et al. 
Activating mutations in the NT5C2 nucleotidase gene 
drive chemotherapy resistance in relapsed ALL. Nat 
Med. 2013;19(3):368-371.
55. Cilloni D, Saglio G. Molecular pathways: BCR-
ABL. Clin Cancer Res. 2012;18(4):930-937.
56. Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant 
STAT5 and PI3K/mTOR pathway signaling occurs 
in human CRLF2-rearranged B-precursor acute 
lymphoblastic leukemia. Blood. 2012;120(4):833-842.
57. Hertzberg L, Vendramini E, Ganmore I, et al. 
Ch
ap
te
r 1
21General introduction
Down syndrome acute lymphoblastic leukemia, 
a highly heterogeneous disease in which aberrant 
expression of CRLF2 is associated with mutated JAK2: 
a report from the International BFM Study Group. 
Blood. 2010;115(5):1006-1017.
58. Harvey RC, Mullighan CG, Chen IM, et al. 
Rearrangement of CRLF2 is associated with mutation 
of JAK kinases, alteration of IKZF1, Hispanic/
Latino ethnicity, and a poor outcome in pediatric 
B-progenitor acute lymphoblastic leukemia. Blood. 
2010;115(26):5312-5321.
59. Francis OL, Milford TA, Martinez SR, et al. A novel 
xenograft model to study the role of TSLP-induced 
CRLF2 signals in normal and malignant human B 
lymphopoiesis. Haematologica. 2016;101(4):417-426.
60. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu 
Y, Schultz N, Sander C. Emerging landscape of 
oncogenic signatures across human cancers. Nat 
Genet. 2013;45(10):1127-1133.
61. Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and 
MEK2 inhibitors and cancer therapy: the long and 
winding road. Nat Rev Cancer. 2015;15(10):577-592.
62. Yoon S, Seger R. The extracellular signal-regulated 
kinase: multiple substrates regulate diverse cellular 
functions. Growth Factors. 2006;24(1):21-44.
63. Morrison SJ, Scadden DT. The bone marrow 
niche for haematopoietic stem cells. Nature. 
2014;505(7483):327-334.
64. Sison EA, Brown P. The bone marrow 
microenvironment and leukemia: biology and 
therapeutic targeting. Expert Rev Hematol. 
2011;4(3):271-283.
65. Colmone A, Amorim M, Pontier AL, Wang 
S, Jablonski E, Sipkins DA. Leukemic cells create 
bone marrow niches that disrupt the behavior of 
normal hematopoietic progenitor cells. Science. 
2008;322(5909):1861-1865.
66. Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-
regulation by imatinib induces chronic myelogenous 
leukemia (CML) cell migration to bone marrow 
stroma and promotes survival of quiescent CML cells. 
Mol Cancer Ther. 2008;7(1):48-58.
67. Hoellenriegel J, Zboralski D, Maasch C, et al. The 
Spiegelmer NOX-A12, a novel CXCL12 inhibitor, 
interferes with chronic lymphocytic leukemia cell 
motility and causes chemosensitization. Blood. 
2014;123(7):1032-1039.
68. Hsieh YT, Gang EJ, Geng H, et al. Integrin 
alpha4 blockade sensitizes drug resistant pre-B acute 
lymphoblastic leukemia to chemotherapy. Blood. 
2013;121(10):1814-1818.
69. Polak R, de Rooij B, Pieters R, den Boer ML. 
B-cell precursor acute lymphoblastic leukemia 
cells use tunneling nanotubes to orchestrate their 
microenvironment. Blood. 2015;126(21):2404-2414.
70. Hanahan D, Weinberg RA. The hallmarks of 
cancer. Cell. 2000;100(1):57-70.
71. Hanahan D, Weinberg RA. Hallmarks of cancer: 
the next generation. Cell. 2011;144(5):646-674.
72. Tallman MS, Altman JK. Curative strategies in 
acute promyelocytic leukemia. Hematology Am Soc 
Hematol Educ Program. 2008:391-399.
73. Biondi A, Schrappe M, De Lorenzo P, et al. 
Imatinib after induction for treatment of children 
and adolescents with Philadelphia-chromosome-
positive acute lymphoblastic leukaemia (EsPhALL): 
a randomised, open-label, intergroup study. Lancet 
Oncol. 2012;13(9):936-945.
74. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib 
compared with interferon and low-dose cytarabine 
for newly diagnosed chronic-phase chronic myeloid 
leukemia. N Engl J Med. 2003;348(11):994-1004.
75. David M, Cross NC, Burgstaller S, et al. Durable 
responses to imatinib in patients with PDGFRB 
fusion gene-positive and BCR-ABL-negative chronic 
myeloproliferative disorders. Blood. 2007;109(1):61-
64.
76. Lengline E, Beldjord K, Dombret H, Soulier J, 
Boissel N, Clappier E. Successful tyrosine kinase 
inhibitor therapy in a refractory B-cell precursor acute 
lymphoblastic leukemia with EBF1-PDGFRB fusion. 
Haematologica. 2013;98(11):e146-148.
77. Weston BW, Hayden MA, Roberts KG, et al. 
Tyrosine kinase inhibitor therapy induces remission 
in a patient with refractory EBF1-PDGFRB-
positive acute lymphoblastic leukemia. J Clin Oncol. 
2013;31(25):e413-416.
78. Tyner JW, Bumm TG, Deininger J, et al. CYT387, 
a novel JAK2 inhibitor, induces hematologic 
responses and normalizes inflammatory cytokines 
in murine myeloproliferative neoplasms. Blood. 
2010;115(25):5232-5240.
79. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 
2 trial of ponatinib in Philadelphia chromosome-
positive leukemias. N Engl J Med. 2013;369(19):1783-
1796.
80. Notta F, Mullighan CG, Wang JC, et al. Evolution 
of human BCR-ABL1 lymphoblastic leukaemia-
initiating cells. Nature. 2011;469(7330):362-367.
81. Rehe K, Wilson K, Bomken S, et al. Acute B 
lymphoblastic leukaemia-propagating cells are present 
at high frequency in diverse lymphoblast populations. 
EMBO Mol Med. 2013;5(1):38-51.
82. Ebinger S, Ozdemir EZ, Ziegenhain C, et al. 
Characterization of Rare, Dormant, and Therapy-
Resistant Cells in Acute Lymphoblastic Leukemia. 
Cancer Cell. 2016;30(6):849-862.

Chapter 2
JAK2 aberrations in childhood 
B-cell precursor acute lymphoblastic 
leukemia
Elisabeth M.P. Steeghs*, Isabel S. Jerchel*, Willemieke de Goffau-
Nobel, Alex Q. Hoogkamer, Judith M. Boer, Aurélie Boeree, Cesca van 
de Ven, Marco J. Koudijs, Nicolle J.M. Besselink, Hester A. de Groot-
Kruseman, C. Michel Zwaan, Martin A. Horstmann, Rob Pieters, and 
Monique L. den Boer
*E.M.P. Steeghs and I.S. Jerchel contributed equally to this work 
Oncotarget. 2017 Sep 16;8(52):89923-89938.

25JAK2 aberrations in childhood BCP-ALL
Ch
ap
te
r 2
Summary
JAK2 abnormalities may serve as target for precision medicines in pediatric B-cell 
precursor acute lymphoblastic leukemia (BCP-ALL). In the current study we performed 
a screening for JAK2 mutations and translocations, analyzed the clinical outcome and 
studied the efficacy of two JAK inhibitors in primary BCP-ALL cells. Importantly, we 
identify a number of limitations of JAK inhibitor therapy.
JAK2 mutations mainly occurred in the poor prognostic subtypes BCR-ABL1-like 
and non-BCR-ABL1-like B-other (negative for sentinel cytogenetic lesions). JAK2 
translocations were restricted to BCR-ABL1-like cases. Momelotinib and ruxolitinib were 
cytotoxic in both JAK2 translocated and JAK2 mutated cells, although efficacy in JAK2 
mutated cells highly depended on cytokine receptor activation by TSLP. However, our 
data also suggest that the effect of JAK inhibition may be compromised by mutations in 
alternative survival pathways and microenvironment-induced resistance. Furthermore, 
inhibitors induced accumulation of phosphorylated JAK2 Y1007, which resulted in a 
profound re-activation of JAK2 signaling upon release of the inhibitors. This preclinical 
evidence implies that further optimization and evaluation of JAK inhibitor treatment is 
necessary prior to its clinical integration in pediatric BCP-ALL. 
Introduction
Janus kinase 2 (JAK2) is a member of the non-receptor tyrosine kinase family and mediates 
intracellular signaling upon activation of cytokine receptors, which lack an intrinsic 
tyrosine kinase domain, such as cytokine receptor-like factor 2 (CRLF2). Ligand binding 
(e.g. TSLP for CLRF2) induces dimerization of cytokine receptors chains, resulting in 
activation of JAK proteins via cross-phosphorylation. JAKs activate signal transducers 
of transcription (STATs), which, upon dimerization, migrate to the nucleus and induce 
transcription of genes involved in differentiation and proliferation of hematopoietic cells.1
JAK2 has seven homologous domains (JH1-JH7). The JH1 and JH2 domains are 
C-terminally located and comprise the catalytic kinase (JH1) and pseudokinase (JH2) 
domain. The JH2 domain has a dual regulatory function: exerting a negative regulatory 
effect on the kinase domain, and facilitating JAK2 activation upon receptor activation 
by ligand binding.2 The JH3-JH4 domains share homology with Src homology 2 (SH2) 
domains and mediate protein-protein interactions. The N-terminal located JH6 and JH7 
domains, also known as the FERM domain, are required for binding of JAK2 to cytokine 
receptors.1
In pediatric BCP-ALL patients, gain of function mutations and translocations affecting 
JAK2 have been identified.3-15 Genomic translocations of JAK2 have been observed in 
high-risk BCR-ABL1-like patients. For several of these fusion genes, constitutive JAK2 
kinase activation has been demonstrated.12-14, 16 Point mutations often occur in Down 
Syndrome ALL, mainly affect exon 16 (located in the pseudokinase domain), and 
functionally cooperate with overexpression of the type I cytokine receptor CRLF2.6, 9, 10 
Indeed, requirement for the interaction of mutant JAK2 with a cytokine receptor was 
shown in cell lines models by several groups.6, 8, 9
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Mutations and translocations represent biologically distinct entities, but both are 
potential targets for precision medicines. JAK inhibitors were shown to be effective 
against mutant and translocated JAK2 in vitro.3, 5, 7, 8, 12, 13, 16, 17 However, in vivo mouse 
studies show conflicting data and none has been reported to be curative.13, 17-21 To date, 
clinical data with JAK inhibitors are scarce. The Children’s Oncology Group performed 
a phase 1 dosing study of the JAK inhibitor ruxolitinib, but no cases harboring JAK2 
activating mutations or translocations were included.22
Several papers have reported data with a focus on either fusion genes or mutations of 
JAK2, although often with small sample size or only in specific subtypes of BCP-ALL. 
Furthermore, most reports lack ex vivo efficacy data of JAK inhibitors in primary 
leukemic cells. To assess the clinical potential of JAK inhibitors in pediatric BCP-ALL, 
we performed a comprehensive study to determine the frequency and prognosis of 
JAK2 mutations and translocations among different subtypes of childhood BCP-ALL. 
Furthermore, the biological efficacy of the JAK inhibitors momelotinib and ruxolitinib 
was studied in primary leukemic cells harboring JAK2 aberrations, and the clonal stability 
of JAK2 mutations was investigated in ALL patient derived xenograft models. We show 
that JAK inhibitors are overall effective towards BCP-ALL cells, but also identified a 
number of limitations of JAK inhibitor therapy. 
Results
Frequency and type of JAK2 aberrations in BCP-ALL patients
JAK2 mutation status was analyzed in 461 newly diagnosed BCP-ALL cases representing 
all major subtypes seen in children, with a distribution that is comparable to the general 
pediatric BCP-ALL population. JAK2 exons 16, 20, 21 and 23 were examined by targeted 
amplicon sequencing at a median read depth of 673, 577, 711 and 944, respectively. 
Analyses revealed that 3.5 % (16/461) of these BCP ALL cases harbored JAK2 mutations, 
which were detected in 7.6 % (6/79) of BCR-ABL1-like cases, 11.9 % (8/67) of non-
BCR-ABL1-like B-other cases, and 1.6 % (2/124) of high hyperdiploid cases. No JAK2 
mutations were detected in MLL-AF4 (0/15), BCR-ABL1 (0/26), ETV6-RUNX1 (0/124) 
or TCF3-PBX1 (0/26) cases. The variant allele frequency (VAF) ranged from 1.0 % to 
56 % (Figure 1A). Seven patients carried two different JAK2 mutations, and one patient 
even harbored three different JAK2 mutations. Mutations involved amino acid residue 
R683 in 13 of 16 mutated cases, which is an important amino acid for the JH2 domain 
mediated negative auto-regulation of JAK2 activity [23]. CRLF2 overexpression was 
detected in 87.5 % (14/16) of these cases (Figure 1A, Supplementary Figure 1). One 
CRLF2 low expressing case harbored a subclonal JAK2 mutation, suggesting that CRLF2 
overexpression might be subclonal as well. The other case harbored a JAK2 R923H with 
a VAF of 50 %, suggesting that this mutation in the kinase domain is not associated with 
CRLF2 overexpression. 
The screen for JAK2 fusion genes was confined to 153 BCP-ALL cases, negative for 
sentinel BCP-ALL associated lesions (MLL-rearranged, BCR-ABL1, ETV6-RUNX1, 
TCF3-PBX1, high hyperdiploid), as JAK2 translocations were previously reported in this 
group of patients.12, 13, 24 No JAK2 translocations were detected in 76 non-BCR-ABL1-like 
B-other cases, whereas in five of the 77 (6.5%) BCR-ABL1-like cases JAK2 tyrosine kinase 
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Patient Protocol Risk group
Age 
(years)
WBC 
(x109/L)
Down 
Syndrome
MRD 
(d29/d33) Subtype Translocation
Mutation 1 
(VAF)
Mutation 2 
(VAF)
Mutation 3 
(VAF)
CRLF2 
status
A20 ALL9 HR 14 75 <10 -^3 BCR-ABL1 -like p.R873N 40% p.R683S 2% p.R683G 2% High
A35 ALL9 NHR 1 44 NA BCR-ABL1 -like p.R683T 56% p.R683G 13% High
A38 ALL9 HR 6 128,8 NA BCR-ABL1 -like p.R683G 32% p.T875N 10% High
hgiH%1 E419K.p%2 G386R.prehto-BANseY0544S-RH30LLAOC921A
woL%1 G386R.pdiolpidrepyH hgiHAN934S-RH30LLAOC951A
hgiH%42 G386R.prehtO-BAN3,43S-RL30LLAOC061A
hgiH%8 G386R.p%01 N378D.prehto-BAN039S-RH30LLAOC761A
hgiH%4 G386R.p%03 T386R.prehto-B3-^01017R-RL30LLAOC871A
A186 COALL97 HR-S 11 9,9 10 -^3 BCR-ABL1 -like hgiH%73 N578T.p
A251 COALL97 HR-S 7 115 NA BCR-ABL1 -like hgiH%36 G386R.p
A282 ALL10 SR 3 21 <10 -^3 B-Other p.R683S 25% p.R683G 7% High
hgiH%14 G386R.prehtO-B3-^01<seY6,33RM01LLA513A
hgiH%52 S386R.p%72 G386R.prehto-B3-^01seY0938RM01LLA953A
A404 ALL10 MR 8 222,6 <10 -^3 BCR-ABL1 -like hgiH%62 G386R.p
hgiH%52 G386R.pdiolpidrepyH hgiH3-^01seY9,12RM01LLA334A
woL%05 H329R.prehtO-B3-^01<1,2111RM01LLA125A
A31 ALL9 HR 1 53,8 <10 -^3 BCR-ABL1 -like PAX5-JAK2 Low
A204 COALL03 HR-S 14 4,5 <10 -^3 BCR-ABL1 -like PAX5-JAK2 Low
A286 ALL10 SR 1 3,4 <10 -^3 BCR-ABL1 -like PAX5-JAK2 Low
A214 COALL03 HR-S 11 19,5 10 -^3 BCR-ABL1 -like TERF2-JAK2 Low
A216 COALL03 HR-S 5 204 <10 -^3 BCR-ABL1 -like BCR-JAK2 Low
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Figure 1: JAK2 aberrations in BCP-ALL patients
(A) Type of lesions, clinical characteristics and follow-up of JAK2 lesion positive patients. Treatment 
protocol and risk group assigned to each patient per protocol have been listed (HR-S: High Risk 
Standard. HR: High Risk. MR: Median Risk. SR: Standard Risk. LR-S: Low Risk Standard. LR-R: 
Low Risk Reduced. NHR: Non-High Risk). WBC indicates white blood cell count. Minimal residual 
disease (MRD) levels at day 29/33 of treatment of COALL and DCOG protocol, respectively. Type 
of translocation or mutation is listed. VAF indicates the variant allele frequency (%). CRLF2 status 
indicates gene expression below (low) or above (high) the 90th percentile levels. Right panel: Bar 
plot represents years from diagnosis to event or last contact. In blue: cases in complete clinical 
remission. In red: cases with an event (relapse or death). (B) Cumulative incidence of relapse curves 
for patients with JAK2 lesions (green line), JAK2 wildtype BCR-ABL1-like and B-other cases (grey 
line), and JAK2 wildtype remaining BCP-ALL cases (black line; ETV6-RUNX1, high hyperdiploid, 
TCF3-PBX1). Patients were treated according to ALL8, ALL9, ALL10, COALL97 or COALL03 
protocol. Cumulative incidence of relapse (CIR) was estimated using a competing risk model. 
Relapse and non-response were considered as event, and death as competing event. Non-response 
was counted as event at day 79. The Gray’s test was applied to test for equality of CIRs (JAK2 lesion 
versus remaining BCP-ALL p=0.04; JAK2 wildtype B-other/BCR-ABL1-like versus remaining 
BCP-ALL p=0.04). 
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activating fusion genes were identified. The cases involved three PAX5-JAK2 cases, one 
BCR-JAK2 case and one TERF2-JAK2 case (Figure 1A). The PAX5-JAK2 and BCR-JAK2 
fusions contained identical exons as reported before [12, 13]. The TERF2-JAK2 case 
displayed an in frame fusion of TERF2 exon 10 to JAK2 exon 19. All JAK2 fusion genes 
harbored an intact JH1 kinase domain (Supplementary Figure 2). Gene expression data 
revealed high expression levels of JAK2 in these cases (Supplementary Figure 3). Absence 
of the cytokine receptor-binding FERM domain in JAK2 fusion protein suggests that they 
signal independent of a cytokine receptor.
Clinical characteristics and prognosis of patients harboring 
JAK2 lesions
Ten out of sixteen (62.5%) JAK2-mutated patients remained in continuous complete 
remission at more than 5 years of follow up. The median time to relapse in the six other 
patients was 2.1 years [range 0.71-7.8 years]. Minimal residual disease (MRD) data were 
available for nine out of fourteen patients. The four patients with high MRD levels (≥10-
3) at day 29/33 of treatment (time point 1 of COALL and DCOG protocol, respectively) 
relapsed, whereas the remaining five mutated patients with low MRD levels remained in 
continuous complete remission (p=0.008, Fisher exact test).
Three out of the five cases harboring JAK2 fusion genes remained in continuous complete 
remission at more than 5 years of follow up, whereas two cases suffered from a relapse 
within 2.4 years of diagnosis (Figure 1A). Both patients who relapsed were assigned to the 
High Risk arm of the COALL-03 study protocol because of unfavorable age (>10 years) or 
high white blood cell count at diagnosis (>50 WBC/nl).
Cumulative incidence of relapse in these JAK2 aberrant patients did not differ from JAK2 
wildtype BCR-ABL1-like and B-other cases. Both displayed an unfavorable outcome 
compared to remaining BCP-ALL cases (p=0.04; Figure 1B). These findings underline 
the clinical relevance of JAK2 lesions. Mutations and translocations represent biologically 
distinct entities, but both may be targetable by JAK-inhibitors.
Leukemic cells with JAK2 lesions can be targeted by JAK 
inhibitors
Primary leukemic and patient-derived-xenograft (PDX) cells (Supplementary Figure 4, 
reference 25) were exposed to momelotinib and ruxolitinib. JAK2 translocated cells were 
more sensitive to both momelotinib and ruxolitinib compared to JAK2 wildtype cases 
(P<0.05; Figure 2A-B, Supplementary Figure 5). JAK2 mutated cells were less sensitive to 
these inhibitors than JAK2 fusion positive cells, and were only marginally more sensitive 
than wildtype cells (P<0.05). Leukemic cells without genetic JAK2 aberrations were 
resistant to ruxolitinib, but showed some sensitivity to momelotinib. Importantly, normal 
bone marrow mononuclear cells were resistant to both inhibitors (Supplementary Figure 
5). Both JAK inhibitors effectively reduced levels of phosphorylated STAT5 Y694 and/or 
STAT1 Y701 (Figure 2C-D, Supplementary Figure 6). 
The marginal sensitivity for both inhibitors and the low levels of phosphorylated STAT5 in 
JAK2 mutated cells may be explained by lack of human TSLP ligand to activate the CRLF2 
pathway in our culture conditions. Addition of human TSLP sensitized JAK2 mutated 
cells to ruxolitinib, but not to momelotinib (P<0.01, Figure 3A-B, Supplementary Figure 
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Figure 2: The efficacy of JAK inhibitors on JAK2 translocated and mutated cells
(A-B) Leukemic (PDX or primary patient) cells were incubated for four days with to an increasing 
concentration range of momelotinib or ruxolitinib, after which cell viability was measured using an 
MTT assay. Sensitivity of exposed cells was calculated relative to vehicle treated controls. Individual 
samples were tested in duplicate. Mean±SEM of five JAK2 translocated cases, six JAK2 mutated cases 
and four JAK2 wildtype cases is shown. Cell viability of samples was compared using independent 
sample T-test. **p≤0.01, *p≤0.05, 1JAK2 translocations versus JAK2 wildtype, 2 JAK2 translocations 
versus JAK2 mutations, 3JAK2 mutations versus JAK2 wildtype. (C-D) TERF2-JAK2 and JAK2 
R683G PDX cells were exposed for four hours to vehicle control medium, 1.5 μM momelotinib or 
0.75 μM ruxolitinib, after which (phosphorylated) TERF2-JAK2, JAK2, STAT1 and STAT5 levels 
were analysed using western blot (25 μg lysate).
7A-B). TSLP exposure did not further sensitize JAK2-fusion positive cells, confirming 
cytokine-independent signaling (Figure 3C D, Supplementary Figure 7C-D). These 
results confirm that JAK2 signaling triggered by JAK2 fusion proteins is independent 
of cytokine receptor activation. JAK2 wildtype leukemic cells were not sensitized to 
JAK inhibitors by TSLP treatment (Figure 3E-F, Supplementary Figure 7E F). In the 
presence of TSLP both JAK2 translocated and JAK2 mutated cells were sensitive to JAK 
inhibitors (Figure 3G-H). At the protein level, TSLP exposure upregulated the levels of 
phosphorylated STAT1 Y701 and STAT5 Y694 in JAK2 R683S mutated cells, whereas no 
effect was observed in JAK2 fusion positive and JAK2-wildtype leukemic cells (Figure 
3I-K). Notably, TSLP triggered the phosphorylation and hence activation of the MEK/
ERK pathway in JAK2 R683S mutated cells, but not in JAK2 R683G mutated cells (Figure 
3I, 3L), suggesting that this activation is context-dependent. Phosphorylation of STAT1 
Y701 and STAT5 Y694 was inhibited by momelotinib and ruxolitinib (Figure 3L).
JAK2 inhibition results in accumulation of phosphorylated 
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Exposure of primary leukemic cells, harboring TERF2-JAK2 or PAX5-JAK2, to 
momelotinib and ruxolitinib resulted in accumulation of phosphorylated JAK2 Y1007 
fusion proteins (Figure 2C, Supplementary Figure 6). Wash out of both inhibitors induced 
a slight rebound effect with upregulation of pSTAT1 Y701 and pSTAT5 Y694 in TERF2-
JAK2 cells (Figure 4A).
This rebound effect was also observed in the JAK2 V617F -positive leukemic cell line HEL 
(Supplemental Figure 7). Phosphorylated JAK2 Y1007 accumulated upon exposure to 
ruxolitinib. Removal of the inhibitor resulted in reactivation of JAK2 signaling, observed 
by a clear increase in phosphorylated STAT 5Y694 levels within 4 hours (time point 100 
hours; Supplementary Figure 7A-B). The inhibitory effect of momelotinib was more 
transient compared to ruxolitinib, resulting in an earlier reactivation of JAK2, observed 
by high levels of phosphorylated STAT5 Y694 after 48 hours of momelotinib exposure 
(Supplemental Figure 7A).
Mesenchymal stromal cells protect against JAK inhibitors
Leukemic cells reside in the bone marrow microenvironment, where they disrupt 
normal hematopoietic stem cell niches.26 This abnormal niche protects ALL cells against 
chemotherapy.27,28 To study whether the bone marrow microenvironment protects 
against JAK inhibitors, we mimicked this niche by co-culturing PDX cells with bone 
marrow mesenchymal stromal cells (MSCs) derived from a leukemia patient. Survival of 
leukemic cells was improved in co-cultures together with MSCs compared to leukemic 
cells cultured without MSCs (Figure 5A). In these PDX/MSC co-cultures, JAK inhibitors 
decreased leukemic cell survival (Supplementary Figure 9A-G). However, leukemic 
cells were more resistant to ruxolitinib in PDX/MSC co-culture compared to culture 
without MSCs (P<0.05). A similar trend was observed for momelotinib (Figure 5B-C, 
Supplementary Figure 9H-I). 
Different outgrowth pattern in xenografts 
The outgrowth patterns of primary leukemic cells (>90% blast purity) in three NSG mice 
Figure 3 (opposite page): The effect of TSLP stimulation on the efficacy of JAK inhibitors
Cells (PDX or primary ALL) were pre-incubated for 1 hour with or without 25 ng/ml TSLP, after 
which cells were exposed for four days to indicated concentrations of momelotinib or ruxolitinib. 
Cell viability was measured using an MTT assay. Sensitivity was calculated relative to vehicle treated 
controls. Individual samples were tested in duplicate. (A-B) Efficacy of momelotinib and ruxolitinib 
on JAK2 mutated cells with or without TSLP pre-incubation. Mean±SEM of six independent 
samples is shown. (C-D) Efficacy of momelotinib and ruxolitinib on cells with JAK2 translocations. 
Mean±SEM of two independent samples is shown. (E-F) Efficacy of momelotinib and ruxolitinib 
on JAK2 wildtype PDX cells. Mean±SEM of three independent samples is shown. (G-H) Combined 
graph of the efficacy of momelotinib (G) and ruxolitinib (H) on TSLP stimulated cells with 
JAK2 mutations (n=6), JAK2 translocations (n=2), or JAK2 wildtype cells (n=3). Mean±SEM of 
independent samples is shown. Cell viability of samples was compared using the independent 
sample T-test. **p≤0.01, *p≤0.05. 1JAK2 translocations versus JAK2 wildtype, 2JAK2 wildtype versus 
JAK2 mutations. (I-K) Western blot of JAK2 R683S, TERF2-JAK2 and JAK2wt PDX cells with or 
without TSLP stimulation (25 ng/ml for 1 hour). (L) JAK2 R683G cells were pre-incubated for 1 
hour with or without 25 ng/ml TSLP, after which cells were exposed for four hours to vehicle control 
medium, 1.5 μM momelotinib or 0.75 μM ruxolitinib. Levels of (phosphorylated) JAK2, STAT1, 
STAT5, MEK1/2 and ERK1/2 were analysed using western blot.
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per patient was determined by paired-end deep-sequencing of JAK2 hot spot regions 
(exon 16, 20, 21 and 23; median read depth 554, 465, 411 and 593, respectively). PDX 
cells originating from a JAK2 R863G mutated case had a different VAF profile compared 
to the original patient sample (Figure 6A, Supplementary Figure 10A). The primary 
sample contained a major JAK2 R683G clone at a VAF of 63% and a minor KRAS G12D 
clone at VAF 14%. In two out of three PDX samples generated, the VAF of the JAK2 
R683G mutation increased to 98% (PDX1) and 99% (PDX3), whereas in the remaining 
PDX sample the VAF decreased to 49% (PDX2). In contrast, the KRAS G12D mutation 
increased to a VAF 23% in this PDX2 sample, whereas this mutation was not detected 
in PDX1 and PDX3. The reduced VAF of the JAK2 clone in PDX2 did not result in a 
decreased efficacy of momelotinib or ruxolitinib (Figure 6B). However, levels of pMEK1/2 
S217/221 and pERK1/2 T202/Y204 in this sample were increased compared to the other 
two PDX samples (Figure 6C). Exposure to both JAK inhibitors did not decrease the 
levels of phosphorylated MEK and ERK.
Sanger sequencing of JAK2 R683S and JAK2 R683T PDX models also indicated a change 
in the VAF of PDX cells compared to the primary sample. In PDX cells from three NSG 
mice injected with JAK2 R683S cells, the A/T peak ratio at nucleotide position 2049 
differed, suggesting heterogeneity in frequency of JAK2 mutations between samples 
(Supplementary Figure 10B). Strikingly, two mice injected with JAK2 R683T mutated 
leukemic cells developed JAK2 wildtype leukemia (Supplementary Figure 10C). Although 
the JAK2 mutation was lost, CRLF2 expression levels remained high (Supplementary 
Figure 10D-E). TSLP stimulation activated the JAK2 pathway signaling (Supplementary 
Figure 10F), but cells were not sensitive for JAK2 inhibition (Supplementary Figure 10G-
H).
Discussion
This study aimed to evaluate the clinical need (frequency of lesions and prognostic 
value) and potential of JAK inhibitors in pediatric BCP-ALL. For this purpose pediatric 
BCP-ALL patients were screened for JAK2 lesions. JAK2 point mutations were found 
in 3.6% of our BCP-ALL patients, of which the majority were JAK2 R683 mutations. 
These mutations were solely detected in BCR-ABL1-like, B-other and high hyperdiploid 
patients, but not in MLL-AF4, BCR-ABL1, ETV6-RUNX1 or TCF3-PBX1 patients. JAK2 
translocations were detected in the poor prognostic BCR-ABL1-like group, but not in 
non-BCR-ABL1-like B-other cases. The prognosis of patients with JAK2 aberrations was 
as poor as JAK2 wildtype BCR-ABL1-like and non-BCR-ABL1-like B-other patients. 
JAK2 mutations were not detected as frequently in our DCOG/COALL sequencing 
cohort as reported for COG high-risk cohorts.5, 10 Two independent classifiers are used 
to describe BCR-ABL1-like BCP-ALL.29-31 Differences in genetic ancestry between the 
American COG and European DCOG/COALL cohorts likely affected the signatures to 
classify patients as BCR-ABL1-like. Hence, genetic differences, or more specifically the 
lack of Hispanic/Latino cases10, 32 might explain the lower frequencies of JAK2 mutations, 
as well as the difference in treatment outcome. 
A targeted approach was used to detect JAK2 translocations. All cases with high JAK2 
expression levels harbored one of the known fusion genes, making it therefore unlikely 
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Figure 4: Accumulation of pJAK2 Y1007 results in a rebound effect of JAK2
(A) TERF2-JAK2 PDX cells were incubated for four hours with or without 1.5 μM momelotinib or 
0.75 μM ruxolitinib, after which cells were washed to remove the JAK inhibitors. Half of the cells 
were exposed for another 1.5 hours to 1.5 μM momelotinib or 0.75 μM ruxolitinib, whereas the 
other cells were incubated in vehicle control (Ctr) medium. Protein expression levels were examined 
by western blot (25 μg lysate). (B) HEL cells were incubated with or without 1.5 μM momelotinib or 
0.75 μM ruxolitinib for 4 hours, 24 hours, 48 hours, 72 hours and 96 hours, after which cells were 
lysed and protein expression levels were examined using western blot (25 μg lysate). (C) After 96 
hours of exposure to JAK inhibitors (indicated by * in panel B), cells were washed in normal culture 
medium, to remove momelotinib and ruxolitinib. Subsequently, half of the cells were incubated 
with 1.5 μM momelotinib or 0.75 μM ruxolitinib for another 4 hours, 24 hours or 48 hours, whereas 
the remaining cells were incubated in vehicle control (Ctr) medium. Protein expression levels were 
examined using western blot (25 μg lysate).
that novel fusion genes were missed. 
The poor outcome of cases harboring JAK2 lesions underline the clinical relevance of 
activated JAK2, which can be targeted by precision medicines. The therapeutic potential 
of JAK2 was demonstrated by the efficacy of JAK inhibitors in JAK2 mutated and JAK2 
translocated primary BCP-ALL cells. JAK2 translocated cells were sensitive to both JAK 
inhibitors, independent of CRLF2 activation. 
The strong association between CRLF2 overexpression and JAK2 mutations suggests that 
these genetic lesions cooperate.3, 6 As JAK2 aberrations might be targeted with precision 
medicines, we studied the clinical relevance and the efficacy of JAK inhibitors in these 
cases. In contrast to JAK2 translocations, JAK2 R683 mutated leukemic cells only became 
sensitive to ruxolitinib upon activation of CRLF2 by TSLP, confirming the requirement 
for type I cytokine receptor activation as reported before.3, 5, 7, 8, 17 Besides emphasizing 
differences between the genomic context of JAK2 translocations and mutations, these 
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Figure 5: Efficacy of JAK inhibitors in co-culture
The response of CD19+ PDX cells, co-cultured with MSCs (hCD19-), to increasing concentrations 
of momelotinib and ruxolitinib, was assessed after four days of culture using flow cytometry. Cells 
were stained with Brilliant Violet 421 anti-human CD19 antibody, FITC Annexin V, and PI. Viability 
was calculated relative to vehicle controls. (A) Survival of PDX cells in mono-culture, or PDX/MSC 
co-culture. Individual samples were tested in duplicate. Bars represent the mean±SEM of two BCR-
JAK2, two TERF2-JAK2, one PAX5-JAK2, three JAK2 R683G and two JAK2 wildtype samples. Cell 
viability of samples in mono-culture versus co-culture was compared using the independent sample 
T-test. *p≤0.05. (B-C) The effect of 1.5 μM and 3.0 μM momelotinib or ruxolitinib on the viability 
of PDX cells with JAK2 translocations in mono-culture, or in co-culture with primary MSCs. 
Mean±SEM of three JAK2 translocated samples is shown. Cell viability of samples was compared 
using independent sample T-test. *p≤0.05.
results highlight the importance of TSLP in in vitro and in vivo studies involving JAK2 
mutations. Since human CRLF2 cannot be activated by mouse TSLP, conventional 
mouse xenograft models are not suitable to test the efficacy of ruxolitinib and other 
JAK inhibitors on JAK2 mutated cells. Absence of human TSLP in ALL xenograft mouse 
models might therefore explain the disappointing efficacy of JAK inhibitors in in vivo 
models.18-21 The recently engineered xenograft model which synthesizes human TSLP 
may overcome this limitation.33 
Despite the need for human TSLP, we and others observed engraftment of primary JAK2 
mutated cells in NSG mice, giving rise to leukemia within months after intra-femoral 
injection.18, 19, 21 This implies that the proliferation of JAK2 mutated leukemic cells in the 
mouse bone marrow does not (solely) depend on CRLF2 signaling, but may be supported 
by activation of alternative pathways.34, 35 This argues against targeted monotherapy, as 
cells might escape via an alternative pathway, such as the RAS pathway.35, 36 This is further 
strengthened by a study in Down syndrome ALL, in which a switch was observed from 
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Figure 6: Outgrowth pattern of JAK2 mutated samples in xenografts
(A) VAF of JAK2 R683G and KRAS G12D in primary leukemic cells and three PDX samples of 
the same patient was determined using targeted amplicon sequencing. (B) PDX cells were pre-
incubated for 1 hour with 25 ng/ml TSLP, after which they were exposed for four days to indicated 
concentrations of momelotinib or ruxolitinib in the presence of TSLP. Cell viability was measured 
using an MTT assay. Cell survival was calculated relative to vehicle treated controls. Samples were 
tested in duplicate. Mean±SD of each sample is shown. (C) Protein expression levels of PDX samples, 
exposed to 1.5 μM momelotinib or 0.75 μM ruxolitinib for four hours.
a JAK2 mutation at initial diagnosis to a RAS-mutation at relapse.37 In the current study, 
we also observed co-occurrence of JAK2 and KRAS lesions in non-Down syndrome 
BCP-ALL cells. More importantly, these JAK2 and KRAS mutations showed different 
outgrowth patterns in NSG xenograft models. Co-occurrence of these mutations suggests 
that a combination of JAK and RAS pathway inhibitors may be more effective for JAK2-
aberrant cases. Moreover our results indicate that JAK2 mutations by itself might not 
be drivers of leukemic outgrowth, which is also corroborated by the outgrowth of JAK2 
wildtype leukemic cells in mice injected with JAK2 R683T cells. Taken together, these 
data imply that 1) the expansion properties of JAK2 mutated leukemic cells vary, 2) other 
subclones (e.g. KRAS G12D) can grow out at the expense of the major JAK2 mutated 
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clone, 3) JAK2 mutations can get lost while leukemia progresses. Therefore, JAK2 
mutations are most likely secondary lesions, in contrast to JAK2 translocation, which are 
primary lesions. The selection of alternative pathways indicates a potential risk for use 
of JAK inhibitors in JAK2 mutated cases without detailed monitoring of the mutational 
status of leukemic cells in time.
Interestingly, we observed a difference in the cytotoxicity of momelotinib and ruxolitinib. 
Both agents fully inhibited JAK/STAT signaling by downregulation of phosphorylation 
levels of STAT1 and STAT5. However, only momelotinib affected JAK2 wildtype and non-
TSLP stimulated JAK2 mutated cells, regardless of activation of STAT5. Therefore, it is 
likely that momelotinib also affects alternative targets.38, 39 In addition, our data revealed 
that exposure to JAK inhibitors, especially ruxolitinib, resulted into accumulation of 
phosphorylated JAK2 Y1007, which consequently induced a profound re-activation 
of downstream STAT signaling. Accumulation of phosphorylated JAK2 Y1007 is in 
concordance with other reports.20, 40-42 The rebound effect observed in the present study 
identifies an important limitation of these agents. As type I inhibitors bind JAK2 in its 
active conformation, reactivation of JAK2 may be overcome by type II inhibitors, which 
bind JAK2 in its inactive conformation.17, 43 Preclinical in vitro and in vivo data indicate 
high efficacy of the type II inhibitor CHZ868. Clinical data of this inhibitor and other 
novel inhibitors are warranted.
Besides studying the mechanism of action, we showed influences of the bone marrow 
microenvironment on the efficacy of JAK inhibitors. Microenvironment-induced 
resistance of leukemic cells has been reported for conventional drugs, e.g. prednisolone 
and asparaginase, for imatinib in BCR-ABL1-positive cells, and for JAK inhibitors in the 
present study.44-46 These data imply that the local tumor environment can stimulate a 
survival program, which may provide leukemic cells a way to escape from JAK inhibitors.
Taken together, JAK2 lesions are infrequently found in children with newly diagnosed 
BCP-ALL and are mainly restricted to BCR-ABL1-like and non-BCR-ABL1-like B-other 
cases (negative for sentinel cytogenetic lesions). Although mutations and translocations 
represent biologically distinct entities, both may be targetable by JAK-inhibitors, 
demonstrated the efficacy of momelotinib and ruxolitinib in JAK2 translocated and 
JAK2 mutated primary leukemic cells. As both inhibitors have a short half-life (less than 
half a day), the observed rebound effect may be therapeutically of risk.47, 48 Although it 
should be confirmed by functional in vivo studies, our data suggest that the effect of JAK 
inhibition may be compromised by microenvironment-induced resistance and induction 
of alternative survival pathways. In conclusion, JAK inhibitors may be considered to be 
added to, but not substitute, chemotherapy for patients with JAK2 aberrations, especially 
for those at high risk of relapse due to high MRD levels upon induction therapy. 
Therapeutic monitoring for activation of alternative pathways (e.g. RAS) is highly 
recommended.
Methods
Primary patient-derived material
Bone marrow and/or peripheral blood samples were obtained from children (1-18 
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years) with newly diagnosed ALL. Written informed consent was obtained from parents 
or guardians to use excess diagnostic material for research purposes, as approved by 
the institutional review board. These studies were conducted in accordance with the 
Declaration of Helsinki. Mononuclear cells were isolated and processed as described 
previously.49 Samples were enriched towards > 90% leukemic cells by depletion of non-
leukemic cells using immunomagnetic beads. The major cytogenetic subtypes were 
determined using fluorescent in situ hybridization, (RT-)PCR, and the 110-probeset 
gene expression classifier.30 Patients were treated according to the DCOG ALL8, ALL9 
or ALL10 protocol, or the COALL-06-97 and COALL-07-03 study protocols.50-54 Patient 
characteristics were provided by the central study centers of DCOG (The Hague, the 
Netherlands) and COALL (Hamburg, Germany).
Mesenchymal stromal cells (MSCs) were isolated from the bone marrow aspirate of 
a BCR-ABL1-like patient as described previously.55 Purity of MSCs was assessed by 
negativity for the hematopoietic markers CD34, CD45, and CD19, and positivity for the 
mesenchymal markers CD13, CD29, CD44, CD54, CD73, CD90, CD105, CD146 and 
CD166, as detected by flow cytometry (MACS Quant). Expression was measured using 
the human mesenchymal stem cell marker antibody panel (R&D Systems, Minneapolis, 
Minnesota, USA), and CD13-APC, CD29-APC, CD34-PE, CD54-PE, CD73-PE, IgG1-
PE, and IgG1-APC (BD Biosciences, San Jose, California, USA).
Cell lines
The human erythroleukemia cell line HEL was obtained from the German Collection 
of Microorganisms and Cell lines (DSMZ, Braunschweig, Germany) and cultured in 
RPMI-1640 medium, supplemented with 10% fetal calf serum (Bodinco BV, Alkmaar, 
Netherlands), 100 units/ml penicillin, 100 μg/ml streptomycin and 0.125 μg/mL 
fungizone (Life Technologies, Bleiswijk, Netherlands). The identity of the cell line was 
routinely verified by DNA fingerprinting. Additionally, presence of Mycoplasma was 
excluded every 25 passages by PCR.
Patient-derived-xenograft cells
Primary leukemic cells were transplanted by intra-femoral injection in 7-12 weeks 
old female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (Charles River, Wilmington, 
Massachusetts, USA; three NSG mice per patient), as approved by the animal ethics 
committee (EMC 2863). Mice were sacrificed upon overt leukemia or 6 months after 
injection. Leukemic cells were isolated from bone marrow and spleen. The percentage 
of human leukemic cells was analyzed by flow cytometry (APC anti-human CD19, PE 
anti-human CD45 and FITC anti-mouse CD45; Biolegend, London, UK) and May-
Grünwald-Giemsa staining. Patient-derived-xenograft cells (PDX) were enriched for > 
90% human leukemic cells using anti-human-CD19 immunomagnetic beads (MACS 
Miltenyi, Leiden, Netherlands). 
JAK2 mutations
JAK2 mutations status was analyzed in 461 BCP-ALL cases, representing the major 
cytogenetic subtypes (6% BCR-ABL1, 17% BCR-ABL1-like, 15% non-BCR-ABL1-like 
B-other, 27% ETV6-RUNX1, 27% high hyperdiploid, 3% MLL-AF4, 6% TCF3-PBX1). 
Genomic DNA was isolated using Trizol reagent (Life Technologies), or in some cases 
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using the DNeasy blood and tissue kit (Qiagen) according to manufacturer’s instructions, 
and quantified using the Qubit dsDNA Broad Range Assay Kit (Life Technologies). 100-
250ng genomic DNA was used to prepare sequencing libraries according to manufacturer’s 
instructions. Successful library preparation, correct amplicon length and concentration 
were assessed using the Labchip GX genomic analyzer (Caliper Life Sciences Benelux 
N.V.) with the HT DNA 12K Reagent Kit, Version 2. Samples were pooled equi-molarly 
and sequenced on an Illumina MiSeq in paired-end reads of 250bp each. The custom 
amplicons covered the exons 16, 20, 21 and 23 and represent the mutational hotspot 
region of JAK2.
Sequence reads were exported in fastq format and, aligned to the standard 1000 genomes 
human reference sequences (version b37, from the GATK resource bundle provided by 
the Broad institute, USA), using BWA version 0.7.10 and the GATK indel realigner version 
3.3-0. Freebayes version 0.9.18-24, Varscan version 2.3.7, Bcftools version 1.0, and GATK 
version 3.3-0 were used to call single nucleotide variants. The resulting variant call format 
files were annotated using snpEff and snpSift version 4.1a and the dbNSFP version 2.7 
database. Variants were combined and filtered based on several criteria using an in-
house developed pipeline: variants were excluded if they were not located in targeted 
regions, were reported by only one caller, had coverage of < 100 reads, or had < 10 reads 
supporting the variant allele. Furthermore, variants had to occur at least once with a 
VAF above 2% in any sample and to be distributed equally between runs according to a 
chi-square test. Additionally only variants were taken into account if they were reported 
in the COSMIC V73 GRCh37 database, lead to an amino acid change, were unlikely 
to be a germline variant and not a known SNP. SNPs were defined as having a mean 
population frequency of ≥ 5% across the 1000Gp1 complete human population, 1000Gp1 
population of European decent, and the ESP-6500 population of European decent allele 
frequency databases. Variants found in ≥ 10 samples with a mean and median VAF > 40% 
were labelled as possible germline. Sufficient coverage was crucial to detect subclonal 
mutations, which could be reliably detected ≥ 5% VAF in on average 91% of the cases. 
Detection of variants with a frequency of 1% was limited to a smaller group (26%), and is 
therefore a conservative estimate in the present study.
Genomic DNA of PDX cells was used to identify JAK2 mutations in exon 
16. Samples were analyzed by Baseclear B.V. using Sanger sequencing 
(forward primer 5’-ATGCCTCCAAATTATTATACTATCA-3’, reverse primer 
5’-ATCACCTCACAGTCCATGGTTAT-3’).
JAK2 translocations 
Presence of ten recurrently reported JAK2 translocations was examined by RT-PCR in 153 
BCP-ALL cases, negative for sentinel BCP-ALL associated lesions (n=77 BCR-ABL1-like, 
n=76 non-BCR-ABL1-like B-other). Total RNA was extracted from leukemic cells using 
Trizol reagents (Life Technologies). cDNA was synthesized using random hexamers and 
oligodT primers, and M-MLV reverse transcriptase (Promega, Leiden, Netherlands). RT-
PCR was performed in a final volume of 25 µl, containing 0.3 µM forward primer, 0.3 µM 
reverse primer, 200 µM dNTPs, 1x PCR buffer II, 4 mM MgCl2, 0.125 µl AmpliTaq DNA 
polymerase (Promega) and 2.5 µl cDNA. Primer sequences are shown in Supplementary 
Table 1. PCR products were Sanger sequenced by Baseclear B.V. (Leiden, Netherlands). 
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CRLF2 status
As P2RY8-CRLF2 and IGH-CRLF2  are linked to high CRLF2 mRNA expression levels 
in different studies.10, 56-58 CRLF2 status was determined by Affymetrix gene expression 
microarrays (U133 Plus 2.0; Santa Clara, California, USA), of a previously published 
cohort of pediatric BCP-ALL patients at initial diagnosis.56 Of 406 cases, both CRLF2 
gene expression data and JAK2 mutation status was available. Signal intensity of probeset 
208303_s_at above the 90th percentile levels was classified as CRLF2 high, as described 
previously.56
In addition, CRLF2 expression in primary leukemic and PDX samples was 
determined using RT-qPCR and SYBR green. CRLF2 expression (forward primer 
5’-ACGGGGATCTCCTCTATG-3’, reverse primer:  5’-GAGGCGTTGG TGTCTCT-3’) 
was calculated relative to RSP20 expression (forward primer 5’-AAGGGCTGAGGATTTT 
TG-3’, reverse primer  5’-CGTTGCGGCTTGTTAG-3’), using the comparative cycle time 
(Ct) method; 2 ΔCt x 100%, whereby ΔCt = CtCRLF2 – CtRPS20. RT-qPCR expression 
values were correlated to Affymetrix microarray data of probeset 208303_s_at. 
JAK2 expression levels
JAK2 expression levels were analyzed using Affymetrix gene expression microarrays, in a 
previously published pediatric BCP-ALL cohort.56 Signal intensity of probeset 205841_at 
was used to quantify JAK2 gene expression.
Ex vivo drug cytotoxicity assays
Cell-intrinsic resistance towards momelotinib and ruxolitinib (Selleck Chemicals, 
Kirby Drive, Houston, USA) was evaluated as described previously.49 Briefly, leukemic 
cells were exposed to a concentration range (24μM to 750nM) of these compounds 
for four days and cytotoxicity was quantified using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). For TSLP stimulation, cells were pre-incubated for 
1 hour with 25 ng/ml TSLP (R&D systems, Oxon, UK).  In addition to single cell cultures, 
leukemic cells (1×106 cells) were co-cultured with primary MSCs (5×104 cells) for four 
days in a 24 well plate in the presence of a dilution series of momelotinib and ruxolitinib. 
Cell survival was quantified using flow cytometry (MACSQuant, FlowJo 10.0.8r1), and 
cells were stained with Brilliant Violet 421 anti-human CD19 antibody (Biolegend), FITC 
Annexin V (Biolegend), and Propidium Iodide (PI; Invitrogen, Bleiswijk, Netherlands), 
as described previously.44
Western blotting
Leukemic cells were lysed in lysis buffer supplemented with freshly added protease 
and phosphatase inhibitors. 25μg (BCA method; Thermo Scientific) lysate was loaded 
on 10% mini protean precast gels (BioRad, Veenendaal, Netherlands), and transferred 
to a nitrocellulose membrane (Biorad). Primary antibody incubation was performed 
according to manufacturer’s protocol. Anti-JAK2 (#3230), anti-phospho-JAK2-Y1007 
(#4406), anti-phospho-STAT5-Tyr694 (#9351), anti-phospho-STAT1-Tyr701 (#9167), 
anti-Stat1 (#9175), anti-phospho-MEK1/2-Ser217/221 (#9154), anti-MEK1/2 (#4694), 
anti-phospho-Erk1/2-T202/Y204 (#4370), anti-Erk1/2 (#91078), and anti-αTubulin 
(#2144) were obtained from Cell Signaling Technology (Danvers, Massachusetts, USA). 
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Anti-β-actin (ab6276) was obtained from Abcam (Cambridge, UK), and anti-STAT5 
(sc-835) from Santa Cruz (Heidelberg, Germany). Blots were stained with secondary 
antibodies (IRDye 680RD- or 800CW-labelled anti‐rabbit and IRDye 680RD- or 800CW‐
labelled anti‐mouse; Li‐Cor Biosciences, Leusden, Netherlands) and scanned using the 
Odyssey infrared imaging system (Li-Cor Biosciences). To reprobe membranes, they 
were stripped in NewBlot Nitrocellulose stripping buffer (Li-Cor Biosciences) according 
to manufacturer’s protocol. BCR-JAK2, PAX5-JAK2 and TERF2-JAK2 proteins were 
separated from wildtype JAK2 based on size (~94, 57, 95 and 125 kDa, respectively). 
Statistics
Cumulative incidence of relapse (CIR) was estimated using a competing risk model. 
Relapse and non-response (counted at day 79) were considered as event, and death as 
competing event. The Gray’s test was applied to test for equality of CIRs.59 Outcome 
analyses were performed in R 3.0.1, using the packages cmprsk version 2.2-760, mstate 
version 0.2.761, and survival version 2.37-462.
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Supplemental Data
PCR program
50°C 2 minutes
95°C 10 minutes
95°C 15 seconds
60°C 1 minute           8 cycles
72°C 30 seconds
95°C 15 seconds
57°C 1 minute           8 cycles
72°C 30 seconds
95°C 15 seconds
54°C 1 minute           8 cycles
72°C 30 seconds
95°C 15 seconds
51°C 1 minute           8 cycles
72°C 30 seconds
95°C 15 seconds
48°C 1 minute           8 cycles
72°C 30 seconds 
Supplementary Table 1: RT-PCR primers used for the detection of JAK2 translocations
Gene 
fusion
Forward 
Primer ID
Forward sequence 5' to 3' Reverse 
Primer ID
Reverse sequence 5' to 3'
ATF7IP-
JAK2
ATF7IP_ 
exon12_F2
aacccatacaaccagcaccgcctct JAK2_ 
exon20_R4
tgttgtcatgctgtagggatttcagga
BCR-
JAK2
BCR_ 
exon1_F1
gtgccataagcggcaccggcact JAK2_ 
exon18_R1
aggcctgaaatctggttcata
EBF1-
JAK2
EBF_ 
exon14_F2
cacgagcatgaacggatacggctct JAK2_ 
exon20_R4
tgttgtcatgctgtagggatttcagga
ETV6-
JAK2
ETV6_ 
exon3_F1
atggcaaagctctcctgctgctgac JAK2_ 
exon20_R4
tgttgtcatgctgtagggatttcagga
PAX5-
JAK2
PAX5_ 
exon3_F2
acaatgacaccgtgcctagcgtcag JAK2_ 
exon19_
tcaaaggcaccagaaaac
PPFIBP1-
JAK2
PPFIBP1_ 
exon10_F1
tgcaagatgaaaggagaaggggttga JAK2_ 
exon20_R4
tgttgtcatgctgtagggatttcagga
SSBP2-
JAK2
SSBP2_ 
exon7_F1
ggcacttggaggtgtcccaggaagt JAK2_ 
exon20_R4
tgttgtcatgctgtagggatttcagga
STRN3-
JAK2
STRN3_ 
exon7_F3
tgaaggagctggagaagcacggagt JAK2_ 
exon20_R4
tgttgtcatgctgtagggatttcagga
TPR-
JAK2
TPR_ 
exon38_F1
tggaaatgcctcttccaaagaagttga JAK2_ 
exon20_R4
tgttgtcatgctgtagggatttcagga
TERF2-
JAK2
TERF2_ 
exon10_F1
tggggaaggaaactgg JAK2_ 
exon20_R4
tgttgtcatgctgtagggatttcagga
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Supplementary Figure 1: CRLF2 expression values
2log expression levels of Affymetrix probeset 205841_at in 405 pediatric BCP-ALL cases, which 
were tested for JAK2 aberrations. * represents patient A159. ** represents patient A521.
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AAG GAT CGC TGG CGG ACC ATG AAA AGA CT T GAT TAT GAA CTA T TA ACA GAA AAT GAC ATG T TA CCA AATTERF2e10-JAK2e19
Sequence
AAG GAT CGC TGG CGG ACC ATG AAA AGA CT T GGC ATG AAC TGA
ATA CGA GAT CT T AAC AGT T TG T T T ACT CCA GAT TAT GAA CTA T TA ACA GAA AAT GAC ATG T TA CCA AAT
TERF2
JAK2
1132
Kinase domain
Rho-GAP domain
C2 domain
Pleckstrin homology domain
Dbl homology domain
FERM domain
Scr Homology 2 domain
Pseudokinase domain
12
71
CN
JAK2
711
CN
BCR
426
CN
BCR-JAK2
426
0
FERM domain
Scr Homology 2 domain
Pseudokinase domain
Kinase domain
Paired domain
Inhibitory domain
Transac va on domain
Par al homeodomain
Octapep de
CN
JAK2
812
PAX5
N C
201
N C
PAX5-JAK2
201
1132
0
1132
CN
JAK2
812
TRFH dimeriza on domain
Myb-type HTH domain
Nuclear localiza on signal
Kinase domain
FERM domain
Scr Homology 2 domain
Pseudokinase domain
TERF2
N C
539
N C
TERF2-JAK2
539
0
GCC GAC ACC AAC AAG CGC AAG AGA GAC GAA GAT TAT GAA CTA T TA ACA GAA AAT GAC ATG T TA CCA AATPAX5e5-JAK2e19
Sequence
GCC GAC ACC AAC AAG CGC AAG AGA GAC GAA GGT AT T CAG GAG TCT CCG GTG CCG AAC GGC CAC TCG CT T
ATA CGA GAT CT T AAC AGT T TG T T T ACT CCA GAT TAT GAA CTA T TA ACA GAA AAT GAC ATG T TA CCA AAT
PAX5
JAK2
AAC GAT GGC GAG GGC GCC T TC CAT GGA GAC GCA GT T CT T CAG GAG AGA ATA CCA TGG GTA CCA CCT GAA TGC AT TBCRe1-JAK2e17
Sequence
AAC GAT GGC GAG GGC GCC T TC CAT GGA GAC GCA GAT GGC TCG T TC GGA ACA CCA CCT GGA TAC GGC TGC GCT GCA
CCT GGC AT T AGT AT T ACA GT T T TG CCA AAG GAC AT T CT T CAG GAG AGA ATA CCA TGG GTA CCA CCT GAA TGC AT T
BCR
JAK2
A
B
C
Supplementary Figure 2: Sequencing results of JAK2 translocations 
(A-C) Presence of fusion genes was examined on cDNA level using RT-PCR, followed by Sanger 
sequencing to detect BCR-JAK2, PAX5-JAK2 and TERF2-JAK2 translocations.
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Supplementary Figure 3: JAK2 expression values
2log expression levels of Affymetrix probeset 205841_at in 77 BCR-ABL1-like and 76 B-other cases, 
which were tested for JAK2 translocations. JAK2 mutation status is also indicated. (Information was 
added to the three cases with high JAK2 expression levels, without JAK2 translocations.)
AAG GAT CGC TGG CGG ACC ATG AAA AGA CT T GAT TAT GAA CTA T TA ACA GAA AAT GAC ATG T TA CCA AATTERF2e10-JAK2e19
A219_PDX1
AAG GAT CGC TGG CGG ACC ATG AAA AGA CT T GAT TAT GAA CTA T TA ACA GAA AAT GAC ATG T TA CCA AATTERF2e10-JAK2e19
A219_PDX2
AAG GAT CGC TGG CGG ACC ATG AAA AGA CT T GGC ATG AAC TGA
ATA CGA GAT CT T AAC AGT T TG T T T ACT CCA GAT TAT GAA CTA T TA ACA GAA AAT GAC ATG T TA CCA AAT
TERF2
JAK2
GCC GAC ACC AAC AAG CGC AAG AGA GAC GAA GAT TAT GAA CTA T TA ACA GAA AAT GAC ATG T TA CCA AAT
GCC GAC ACC AAC AAG CGC AAG AGA GAC GAA GGT AT T CAG GAG TCT CCG GTG CCG AAC GGC CAC TCG CT T
ATA CGA GAT CT T AAC AGT T TG T T T ACT CCA GAT TAT GAA CTA T TA ACA GAA AAT GAC ATG T TA CCA AAT
PAX5e5-JAK2e19
PAX5
JAK2
A286_PDX2
AAC GAT GGC GAG GGC GCC T TC CAT GGA GAC GCA GAT GGC TCG T TC GGA ACA CCA CCT GGA TAC GGC TGC GCT GCA
CCT GGC AT T AGT AT T ACA GT T T TG CCA AAG GAC AT T CT T CAG GAG AGA ATA CCA TGG GTA CCA CCT GAA TGC AT T
BCR
JAK2
B
C
A
A216_PDX1
BCRe1-JAK2e17 AAC GA T GGC GAG GGC GCC T T C CA T GGA GAC GCA GT T C T T CAG GAG AGA A T A CCA TGG GT A CCA CC T GAA TGC A T T
A216_PDX2
BCRe1-JAK2e17 AAC GA T GGC GAG GGC GCC T T C CA T GGA GAC GCA GT T C T T CAG GAG AGA A T A CCA TGG GT A CCA CC T GAA TGC A T T
Supplementary Figure 4: JAK2 aberrations in PDX cells
(A-C) Presence of JAK2 translocation in PDX cells was validated on cDNA level using Sanger 
sequencing of cDNA. 
48
Reverse
Forward
A
15
0_
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JAK2 CT GC TT AT CA GA GA AG AA GA C
CT GC TT AT CA GA GA AG AA GA C
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Supplementary Figure 4: JAK2 aberrations in PDX cells (continued)
(D-E) Genomic DNA of PDX cells was used to identify the absence (D) or presence (E) of JAK2 
mutations in exon 16. 
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Supplementary Figure 5: The efficacy of JAK inhibitors on JAK2 translocated and mutated cells 
per type of aberration
Leukemic (PDX or primary patient) cells were incubated for four days to indicated concentrations 
of momelotinib or ruxolitinib, after which viability was measured using an MTT assay. Sensitivity 
of exposed cells was calculated relative to vehicle treated controls. Individual samples were tested 
in duplicate. Data derived from samples with identical JAK2 lesions were grouped for analyses. 
(A-B) Efficacy of momelotinib and ruxolitinib on PDX cells with JAK2 translocations: BCR-JAK2 
(n=2), TERF2-JAK2 (n=2) and PAX5-JAK2 (n=1). Mean±SD of individual samples (in duplicate) 
are shown. (C-D) Efficacy of momelotinib and ruxolitinib on JAK2 mutated cells: JAK2 R683G 
(n=4) and JAK2 R683S (n=2) Mean±SEM of individual samples is depicted. (E-F) Efficacy of 
momelotinib and ruxolitinib on JAK2 wildtype PDX cells and normal bone marrow cells. Mean±SD 
of individual samples (in duplicate) are shown. (H-I) Efficacy of momelotinib and ruxolitinib on 
Down syndrome and non-Down syndrome JAK2 R683G cells. Mean±SD of individual samples (in 
duplicate) are shown.
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Supplementary Figure 6: Quantified expression levels western blots Figure 2
(A-C) TERF2-JAK2, PAX5-JAK2 and JAK2 R683G PDX cells were exposed for four hours to vehicle 
control medium, 1.5 μM momelotinib or 0.75 μM ruxolitinib, after which (phosphorylated) TERF2-
JAK2, PAX5-JAK2, JAK2, STAT1 and STAT5 levels were analyzed using western blot (25 μg lysate). 
Expression levels of phospho-proteins were quantified relative to total protein or loading control.
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Supplementary Figure 7: The effect of TSLP stimulation on the efficacy of JAK inhibitors per 
type of aberration
Leukemic (PDX or primary patient) cells were pre-incubated for 1 hour without or with 25 ng/
ml TSLP, after which they were exposed for four days to indicated concentrations of momelotinib 
or ruxolitinib. Viability was measured using an MTT assay. Sensitivity was calculated relative to 
vehicle treated controls. Individual samples were tested in duplicate. (A-B) Efficacy of momelotinib 
and ruxolitinib on JAK2 mutated samples with or without TSLP pre-incubation: Mean±SEM four 
JAK2 R683G and two JAK2 R683S samples is shown. (C-D) Efficacy of momelotinib and ruxolitinib 
on cells with JAK2 translocations (n=2). Mean±SD of sample duplicates from a TERF2-JAK2 and 
PAX5-JAK2 sample are shown. (E-F) Efficacy of momelotinib and ruxolitinib on JAK2 wildtype 
PDX cells (n=3). Mean±SD of sample duplicates are shown.
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Supplementary Figure 8: Down syndrome and the efficacy of JAK inhibitors on JAK2 mutated 
cells
Cells were exposed for four days to indicated concentrations of momelotinib or ruxolitinib. Viability 
was measured using an MTT assay. Sensitivity of exposed cells was calculated relative to vehicle 
treated controls. Individual samples were tested in duplicate. Mean±SD of sample duplicates is 
shown.
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Supplementary Figure 9: Quantified expression levels western blots Figure 3
(A-C) Western blot of JAK2 R683S, TERF2-JAK2 and JAK2wt PDX cells with or without TSLP 
stimulation (25 ng/ml for 1 hour). Expression levels of phospho-proteins were quantified relative to 
total protein or loading control (β-actin).
(D) JAK2 R683G cells were pre-incubated for 1 hour with or without 25 ng/ml TSLP, after which 
cells were exposed for four hours to vehicle control medium, 1.5 μM momelotinib or 0.75 μM 
ruxolitinib. Levels of (phosphorylated) JAK2, STAT1, STAT5, MEK1/2 and ERK1/2 were analyzed 
using western blot. Expression levels of phospho-proteins were quantified relative to total protein or 
loading control (α-Tubulin). 
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Supplementary Figure 10: Quantified expression levels western blots Figure 4
TERF2-JAK2 PDX cells were incubated for four hours with or without 1.5 μM momelotinib or 0.75 
μM ruxolitinib, after which cells were washed to remove the JAK inhibitors. Half of the cells were 
exposed for another 1.5 hours to 1.5 μM momelotinib or 0.75 μM ruxolitinib, whereas the other 
cells were incubated in vehicle control (Ctr) medium. Protein expression levels were examined by 
western blot (25 μg lysate). Expression levels of phospho-proteins were quantified relative to total 
protein.  
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Supplementary Figure 12: Quantified expression levels western blots Supplementary Figure 8 
(continued on next page)
(A-N) HEL cells were incubated with or without 1.5 μM momelotinib or 0.75 μM ruxolitinib for 4 
hours, 24 hours, 48 hours, 72 hours and 96 hours. After 96 hours of exposure to JAK inhibitors, cells 
were washed in normal culture medium, to remove momelotinib and ruxolitinib. Subsequently, half 
of the cells were incubated with 1.5 μM momelotinib or 0.75 μM ruxolitinib for another 4 hours, 
or 24 hours, whereas the remaining cells were incubated in vehicle control (Ctr) medium. Protein 
expression levels were examined using western blot (25 μg lysate). Expression levels of phospho-
proteins were quantified relative to total protein.
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Supplementary Figure 12: Quantified expression levels western blots Supplementary Figure 8 
(continued)
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Supplementary Figure 13: The efficacy of JAK inhibitors in PDX/MSC co-cultures
The response of PDX cells (CD19+) co-cultured with MSCs (CD19-) to increasing concentrations of 
momelotinib and ruxolitinib was assessed after four days of culture using flow cytometry. Viability 
was calculated relative to untreated controls. Mean±SEM is shown. (A) Gating strategy. (B-G) 
Percentage of viable PDX cells being JAK2 translocated (BCR-JAK2 n=2; TERF2-JAK2 n=2; PAX5-
JAK2 n=1), JAK2 mutated (JAK2 R683G n=3), or JAK2 wildtype cells (JAK2 wildtype n=2), co-
cultured with patient MSCs, after four days exposure to momelotinib and ruxolitinib. (H-I) The 
effect of 1.5 μM and 3.0 μM momelotinib or ruxolitinib on the viability of JAK2 translocated PDX 
cells in mono-culture, or in co-culture with patient MSCs. TERF2-JAK2 n=2; PAX5-JAK2 n=1, JAK2 
wildtype n=2. 
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Abstract
RAS pathway mutations have been linked to relapse and chemotherapy resistance 
in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, 
comprehensive data on the frequency and prognostic value of subclonal mutations 
in well-defined subgroups using highly sensitive and quantitative methods is lacking. 
Targeted deep sequencing of 13 RAS-pathway genes was performed in 461 pediatric BCP-
ALL cases at initial diagnosis and in 19 diagnosis-relapse pairs. Mutations were present 
in 44.2% of patients, with 24.1% carrying a clonal mutation. Mutation frequencies were 
highest in high hyperdiploid, infant t(4;11)-rearranged, BCR-ABL1-like, and B-other 
cases (50-70%), whereas mutations were less frequent in ETV6-RUNX1-rearranged, and 
rare in TCF3-PBX1- and BCR-ABL1-rearranged cases (27 to 4%). RAS-pathway mutated 
cells were more resistant to prednisolone and vincristine ex vivo. Clonal, but not subclonal 
mutations were linked to unfavorable outcome in standard and high risk-treated patients. 
At relapse, most RAS pathway mutations were clonal (9 of 10). RAS-mutant cells were 
sensitive to the MEK-inhibitor trametinib ex vivo, and trametinib sensitized resistant 
cells to prednisolone. We conclude that RAS pathway mutations are frequent, and that 
clonal, but not subclonal mutations are associated with unfavorable risk parameters in 
newly diagnosed pediatric BCP-ALL. These mutations may designate patients eligible for 
MEK-inhibitor treatment.
Introduction
The prognosis of children with B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) has improved considerably over the past decades, and nowadays about 80% 
of the patients are cured.1 However, especially medium and high risk cases still show 
dissatisfying rates of relapse despite intense chemotherapy.2-4 Relapsed ALL is treated 
with the same drugs as the initial leukemia, but cells of relapsed cases are more resistant.5 
New, targeted approaches are therefore warranted. 
Activating mutations in KRAS, NRAS, and HRAS are among the most frequent mutations 
in cancer.6-9 The RAS GTPases are convert extracellular growth signals into a complex 
intracellular response. Upon activation of a growth factor receptor, RAS-guanidine 
exchange factors (e.g. SHP2 encoded by PTPN11) activate RAS by enabling binding of 
GTP, which activates the RAF and PI3 kinases and RALGDS. The RAF-MEK-ERK kinase 
axis is crucial for mediating the oncogenic effects of RAS, demonstrated by the efficacy 
of MEK-inhibitors in RAS-mutated cancers.10-12 Clinical trials are ongoing, and benefits 
were reported for RAF-mutated melanomas, ovarian cancer, and thyroid cancer.13-18
RAS mutations have been initially reported in about 15% of pediatric BCP-ALL.19-21 
However, these studies were often restricted to N- and KRAS, certain subtypes or high 
risk groups, or were technically limited in sensitivity (therefore overlooking subclonal 
mutations), and did not compare mutation frequencies between cytogenetic subtypes.22-26 
Mutations were reported in the context of recent genomic studies but not studied for their 
prognostic impact in isolation. Therefore, the clinical significance of RAS mutations is 
still debated, and it is unknown whether the recent inclusion of minimal residual disease 
levels as risk criterion influences the prognostic effect of RAS pathway mutations in 
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contemporary protocols. Recent studies found that mutations in NRAS, KRAS, FLT3, 
and PTPN11 are more frequently observed at relapse (34-38%), and in part confer a poor 
prognosis.26-29 We previously observed in a small cohort of 26 patients that RAS-pathway 
mutations are more frequent in ex vivo prednisolone-resistant cases, which are sensitized 
to prednisolone by RAS-pathway inhibition.30 Backtracking has shown that RAS-mutant 
relapse-forming clones may exist as small subclones at initial diagnosis.27, 31, 32 However, 
these retrospective analyses rely on selected cases, and the predictive value of (sub)
clonal RAS pathway mutations at initial diagnosis of BCP-ALL treated in contemporary 
protocols is unknown.
Here we report deep next-generation sequencing of thirteen RAS pathway genes 
together with a risk-stratified survival analysis in a clinically and biologically well-
characterized cohort of 461 initial diagnosis patients with BCP-ALL, treated according to 
a contemporary, MRD-based ALL treatment protocol (DCOG ALL10). In addition, we 
report links between RAS mutation status, clonality, ex vivo cellular drug resistance and 
ex vivo response to MEK inhibition.
Material and Methods
A detailed description of all methods can be found in the online supplement.
Patient material and patient-derived xenografts (PDX)
This study comprised children with newly diagnosed BCP-ALL with an age range of 0 to 
18 years. These studies were conducted in accordance with the Declaration of Helsinki; 
written informed consent was obtained from parents or guardians and approval given 
by institutional review boards. Mononuclear cells were isolated using density gradient 
centrifugation with Lymphoprep (Axis Shield, Norway) as described previously.33 Animal 
experiments were approved by the animal ethics committee (EMC 2863 (103-12-08)). In 
some cases, xenografts of primary patient material were established in three 7-12 week-
old female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice per patient (Charles River, France). 
Leukemic cells were isolated and subsequently used for sequencing, western blot, and 
trametinib (GSK1120212) cytotoxicity assays. For all samples leukemic blast percentage 
was at least 90%, in relapse samples blast percentage was at least 80%. Subtypes were 
determined by karyotype, fluorescence in-situ hybridization (FISH) and/or fusion-gene 
specific PCR. BCR-ABL1-like cases were identified using microarray gene expression 
profiling by means of a 110 probe set classifier.34, 35 The composition of analyzed groups is 
described in a flow diagram (Figure S1).
Ex vivo cytotoxicity assays
Sensitivity towards chemotherapeutics was evaluated as previously described.36 In 
brief, freshly isolated primary ALL cells were incubated with a concentration range 
of prednisolone, vincristine, daunorubicin, L-asparaginase, 6-mercaptopurine, and 
6-thioguanine. After four days, cell viability was evaluated by adding MTT and 
measuring formazan-conversion with optical density measurement. LC50-values were 
calculated (concentration at which 50% conversion activity was measured relative to no-
drug control cells) and compared between groups using Mann-Whitney U tests. Ex vivo 
sensitivity towards trametinib was measured similarly (5µM-0.6nM). 
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Sequencing and code availability
DNA and RNA were isolated using Trizol reagent (Life Technologies), or using DNeasy 
(Qiagen) in two cases (used only for trametinib sensitivity assay) and the cell line 697. 
For TruSeq Custom Amplicon sequencing (Illumina, USA), sequencing libraries were 
prepared from 100-250ng genomic DNA. Successful library preparation was confirmed 
using the Labchip GX genomic analyzer (Caliper Life Sciences Benelux N.V., the 
Netherlands). Samples were then pooled equimolarly and sequenced on an Illumina 
MiSeq in paired-end reads of 250bp each. 49 amplicons of 425bp covered mutational 
hotspot regions in thirteen RAS pathway genes (Table S1). The analysis script will be 
provided upon request. 
Sequence reads were aligned to the 1000 genomes human reference sequences (version 
b37, GATK resource bundle, Broad Institute, USA) using BWA v0.7.1037 and GATK 
indel realigner v.3.3-0. Single nucleotide variants were called with Freebayes v0.9.18-
2438, Varscan v.2.3.739, Bcftools v1.040, and GATK v3.3-041. The resulting variant call 
format files were annotated using snpEff and snpSift v.4.1a42 and dbNSFP v.2.743. For 
reliable detection of high-confidence mutations, variants were filtered based on several 
criteria: For each sample, variants were excluded if they were reported by only one caller, 
coverage was <100 reads, or <20 reads supported the variant allele. Overall, variants were 
excluded if variant allele frequency (VAF) never exceeded 2% or distribution was unequal 
between runs. Furthermore, variants were only considered if they were reported in the 
COSMIC V73 GRCh37 database44, non-synonymous, unlikely to be germline variants 
and not known SNPs (see Supplemental Methods for detail). Read depth per amplicon is 
summarized in Table S1. An estimate of cases missed due to insufficient coverage is given 
in Table S2. In a comparison with 25 samples that were sequenced previously (Ariës et 
al.30), all variants could be identified by both platforms, indicating a low false-positive 
rate. Only Exon 3 of NRAS was sequenced using Sanger sequencing in 248 ALL10 samples 
since primer design for this exon in a multiplex amplicon setting failed. Chromatograms 
were visually inspected for presence of mutations in codons 59 to 63 as well as analyzed 
by the R package sangerseqR in combination with the tools above to call and annotate 
detected variants.
Clinical characteristics and statistics
Clinical characteristics were compared using Fisher’s exact test in R (version 3.2.1). We 
analyzed cases from the Dutch Childhood Oncology Group (DCOG) and Cooperative 
Study Group for Children with ALL (COALL) (n=432). We restricted the RAS pathway 
mutated group to those carrying a verified MAPK pathway activating mutation (codons 
12, 13, and 146 of NRAS or KRAS and FLT3 or PTPN11). Event-free survival (EFS) and 
cumulative incidence of relapse and non-response after induction therapy (CIR) were 
evaluated in 244 eligible cases treated within one protocol (DCOG ALL10), stratified 
for risk group. The COALL97/03 cohort consisted of patients treated in the consecutive 
COALL 06-97 and COALL 07-03 protocols (n=131). For details see Escherich et al.45 
Treatment intensity in arms LR-R and LR-S is comparable to DCOG ALL10 standard 
risk treatment; LR-I, HR-R, and HR-S treatment is comparable to DCOG ALL10 medium 
risk treatment. In the COALL97/03 cohort, no patient was treated with an intensity 
comparable to that of the DCOG ALL10 high risk arm. CIR was estimated using a 
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competing risks model and compared using Gray's test. EFS probabilities were estimated 
using the actuarial Kaplan-Meier method and compared using the log-rank test. Hazard 
ratios were calculated in SPSS v21 using Cox’s proportional hazard model. Outcome 
analyses were performed in R 3.2.1, using the packages cmprsk46 version 2.2-7, mstate 
version 0.2.747, and survival version 2.38-348. 
Results
Frequency and clonality of RAS pathway mutations in newly 
diagnosed pediatric BCP-ALL
Targeted amplicon deep-sequencing was used to identify RAS pathway mutations in 
samples from 461 children with BCP-ALL at initial diagnosis. Mutational hotspots in 13 
key members of the RAS pathway were analyzed with 49 amplicons. The median read 
depth per amplicon was 1085 reads per sample (IQR: 527-2647) (Table S1 and Figure S2). 
Most recurrent lesions were activating mutations in NRAS and KRAS (79%), followed by 
mutations in PTPN11 and FLT3 (9.3% and 10.1% respectively, Figure 1A and Figure S3). 
Mutations in BRAF, NF1, CBL, and other genes occurred sporadically. Overall, variants 
in RAS pathway genes were observed in 44.2% of pediatric BCP-ALL cases. Clonal 
mutations (VAF ≥25%) were found in 24.1% of all patients (median: 40.5% VAF Figure 
S4), and subclonal mutations (VAF<25%) were exclusively found in 20.1% of patients 
(median: 4.3% VAF). 
Most cases with RAS pathway mutations were high hyperdiploid or those with rare or 
negative for BCR-ABL1, ETV6-RUNX1, TCF3-PBX1, MLL-rearrangement, and high 
hyperdiploidy (51-67 chromosomes), including non-BCR-ABL1-like “B-other” and 
BCR-ABL1-like cases (Figure 1B, Table S3). Mutation frequencies were high in BCR-
ABL1-like (49.4%), B-other (41.8%), high hyperdiploid (72.6%), and t(4;11)-rearranged 
(MLL-AF4, 73.3%) cases, with clonal mutations observed in 31.6%, 25.4%, 41.9%, and 
20%, respectively (Figure 1B). Comparison of each subtype to the remaining BCP-ALL 
cases showed significantly more mutations in cases with MLL-rearrangement and high 
hyperdiploid karyotype (Odds ratio 3.8 and 5.7, respectively), and significantly less 
mutations in cases with ETV6-RUNX1-, TCF3-, and BCR-ABL1- rearrangement (Odds 
ratios <0.3, Table S4). Interestingly, within the BCR-ABL1-like group RAS pathway 
mutations were mutually exclusive with ABL/JAK class tyrosine kinase fusions, but 
not with high CRLF2 expression (Figure S5). ETV6-RUNX1-rearranged cases showed 
an intermediate frequency (26.6%, 10.5% clonal), and TCF3-PBX1- or BCR-ABL1-
rearranged cases had the lowest frequencies with 8% (0% clonal) and 4% (4% clonal) of 
cases being affected, respectively. 
Frequent secondary aberrations in clonal RAS pathway mutant cases were chromosome 21 
aberrations, dic(9;20) chromosomes, 9p-deletion, PAX5 amplifications, and CDKN2A/B 
deletions. Opposed to that, significantly less BTG1 deletions and ETV6 deletions were 
detected in cases with clonal RAS pathway mutations. Cases with subclonal RAS pathway 
mutations also more frequently carried chromosome 21 aberrations and additionally 
more often expressed high CRLF2 and harbored less mutations in IKZF1 and PAX5 
(Table S5). 
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Figure 1. Frequency and distribution of RAS pathway mutations in pediatric BCP-ALL. 
(A) Overview of all clonal or subclonal mutations found in pediatric BCP-ALL cases at initial 
diagnosis. Top bar represents the cytogenetic subtype. Black boxes represent clonal mutations 
(variant allele frequency (VAF) ≥25%), grey boxes represent subclonal mutations (VAF <25%). 
(B) Frequency of clonal and subclonal RAS pathway mutations overall and within the cytogenetic 
subtypes. ER: ETV6-RUNX1-rearranged, MLL: t(4;11)-rearranged, HD: High hyperdiploid, BO: 
B-other, TCF3: TCF3-PBX1-rearranged, BA: BCR-ABL1-rearranged, BAL: BCR-ABL1-like. (C) 
Co-occurrence of RAS pathway mutations: Bar heights indicate the frequency of mutated cases 
carrying the number of RAS pathway mutations indicated on the x-axis. Segmentation of each bar 
indicates the distribution of mutated genes.
Table 1. Incidence of clonal RAS pathway mutations among BCP-ALL patients with clinical 
risk factors
Risk parameter Incidence of clonal mutations among Statistics (clonal vs. wildtype)
Risk parameter: 
Yes Risk parameter: No
Fisher’s Odds 
ratiob 95%-CIp=a
Age ≥10 22/75 (29%) 90/357 (25%) 0.88
Male 55/227 (24%) 57/205 (24%) 0.56
High WBC (>50/nL) 34/99 (34%) 78/331 (24%) 0.24
Down Syndrome 2/16 (13%) 105/305 (27%) 0.10 0.3 0.03 1.38
CNS+ 0/1 (0%) 24/248 (10%) 1
PPR 7/17 (41%) 51/181 (21%) 0.15 2.220 0.649 7.418
MRD high d33 ALL10 16/48 (33%) 35/147 (18%) 0.01 2.99 1.27 7.05
MRD high d79 ALL10 2/8 (25%) 47/171 (20%) 1
WBC: White blood cell count; CNS+: non-traumatic puncture and >5 WBC/μl CSF with identifiable leukemic cells; patients 
with a traumatic lumbar puncture were not included; PPR: Prednisone poor responder, i.e. ≥1000 leukemic blasts/μl in 
peripheral blood on day 8 of induction therapy; MRD high: Minimal residual disease ≥10-3; d33: at the end of induction 
therapy (day 33); d79: at the end of consolidation therapy (day 79); a Fisher’s Exact test p-values <0.05 are printed in bold 
font; b Odds ratios are only given if p-values in Fisher’s Exact test were <0.2.
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All except three NRAS mutations and three quarters of the KRAS mutations affected the 
codons 12 and 13 (Figure S6). 
Although clonal RAS pathway mutations were mutually exclusive (Figure 1A), additional 
subclonal mutations were present in 41% of cases with a clonal mutation and in 49% of 
cases with a subclonal mutation (46.2% of all mutated patients, Figure 1C). Most of these 
additional RAS pathway mutations were present at a VAF <10% (Figure S4). 
Clinical characteristics and outcome
Clinical characteristics were compared between BCP-ALL cases with clonal RAS pathway 
mutations (n = 110, KRAS, NRAS, PTPN11, or FLT3) and wildtype cases (n = 235). Age, 
white blood cell count, gender, Down syndrome, CNS status at diagnosis, and prednisone 
window response at day 8 of therapy did not differ significantly (Table 1). In DCOG 
ALL10 patients clonal mutations were enriched among cases with high minimal residual 
disease (MRD) levels (≥10-3) after 4 weeks of induction treatment (33% in of MRD-high 
versus 18% in MRD-low cases, p = 0.01). This had an impact on mutation frequencies 
in the actual treatment arms: 13.5% of cases in the standard risk arm carried a clonal 
RAS pathway mutation, compared to 21.9% in medium risk and 40.9% in the high risk 
treatment arm (Table S6, p=0.02). 
In contrast, subclonal mutations were not associated with poor risk features. These 
mutations were significantly more common among younger children (p=0.04), those 
with low white blood cell counts (<50 cells/nL, p=0.02), and those in the medium risk 
treatment arm (p=0.01, Table S7). 
The prognostic value of RAS pathway mutations was analyzed in 244 newly diagnosed 
BCP-ALL patients treated according to the DCOG ALL10 protocol (for baseline 
characteristics and cohort composition see Table S8 and Figure S1). In the total cohort, 
clonal and subclonal RAS pathway mutations did not associate with an inferior clinical 
outcome (Table 2 and Figure 2A). In the DCOG ALL10 study, patients are risk-stratified by 
minimal residual disease response on day 33 and day 79 into standard risk, medium risk, 
and high risk treatment arms. In standard and high risk treated cases clonal RAS pathway 
mutations were associated with a significantly worse event-free survival compared to 
wildtype cases, caused in part by a higher incidence of relapse and non-response (Table 
2 and Figure 2B, red lines). Significantly fewer relapses occurred in medium risk-treated 
patients harboring clonal mutations compared to wildtype cases, which resulted in a 
trend for better event-free survival. Subclonal mutations were not predictive for outcome 
(Figure 2B, blue lines). 
Univariate analysis of RAS pathway status in these 3 risk arms revealed that clonal but not 
subclonal mutations in RAS pathway genes were predictive for an unfavorable outcome in 
the standard risk treated group (Hazard Ratio 4.6, p=0.047), which remained prognostic 
in a multivariate analysis including WBC and age (Hazard Ratio 5.4, p=0.032, Table S9). 
Univariate analysis of RAS pathway mutations in the medium risk and high risk group 
did not reveal statistical significant associations with event-free survival in this DCOG 
ALL10 study cohort.
The impact of RAS pathway mutations on clinical outcome was also evaluated in the 
COALL97/03 cohort (Figure S7). These patients had been stratified into treatment arms 
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Figure 2. Clinical outcome of patients carrying clonal or subclonal RAS pathway mutations. 
Event-free survival (left panel) and cumulative incidence of relapse and non-response (CIR, right 
panel) (A) within the ALL10 cohort (n=244) and (B) divided by the three risk arms of ALL10. SR: 
Standard-risk group, MR: Medium-risk group, HR: High-risk group. ptrend represents the p-value 
in a log-rank (EFS) or Gray-test (CIR) across all three groups, pcl represents the p-value in a log-rank 
or Gray-test comparing wildtype patients and those with a clonal RAS pathway mutation.
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according to white blood cell count, age, immunophenotype, and ex vivo drug response. 
Small group sizes are limiting this analysis and differences were not statistically significant, 
but the trends support our results of the DCOG ALL10 study. In standard risk-treated 
cases, those with clonal but not subclonal mutations more often suffered from a relapse 
than did non-mutated cases, whereas this prognostic impact was absent in the medium 
risk-treated group (Figure S7). 
Ex vivo resistance to chemotherapeutic agents
Ex vivo cytotoxicity data of prednisolone, L-asparaginase, vincristine, daunorubicin, 
6-mercaptopurine, and 6-thiopurine was available for 211 cases. RAS pathway mutated 
cells were median 3-fold more resistant to prednisolone compared to wildtype cases 
(Figure 3A; p=0.024). Leukemic cells harboring clonal or subclonal KRAS G13 mutations 
were most resistant to prednisolone: these cells were median >2000-fold more resistant 
compared to wildtype cells (p=0.001 and p=0.006, respectively, Table S9, Figure 3A 
and Figure S8). Clonal NRAS G13 mutations showed a trend, but the difference was 
not significant (p=0.18). NRAS and KRAS G12 mutations did not significantly affect 
resistance towards prednisolone, although several cases were highly resistant. Mutations 
in PTPN11 and FLT3 were not associated with cellular prednisolone resistance (Table S10 
and Figure S8A).
Ex vivo cytotoxicity of the tubulin-inhibitor vincristine was also reduced in RAS 
pathway mutated cells (Figure 3B): Cases with a clonal KRAS or PTPN11 mutations were 
significantly more resistant to vincristine compared to wildtype cases (15-fold, p=0.005 
and 5-fold, p=0.041, respectively). A trend was observed for clonal NRAS G13 mutations 
(3-fold, p=0.074). No significant difference was observed for KRAS G12 mutations, and 
an inverse trend was found in cases carrying an NRAS G12 mutation (5-fold decrease, 
p=0.057, see also Figure S8B). 
Table 2. Clinical outcome of patients with clonal or subclonal RAS pathway mutations.
Mutation 
Status n=
EFS CIR
5-year EFS 
in % (s.e.)
Cox’s hazard 
ratioa
Log-rank 5-year CIR in 
% (s.e.)
Gray’s test
pcl= pcl=
ALL10b Wildtype 135 92 (2) 8 (2)Mutated 109 86 (3) 11 (3)
ALL10b Wildtype 135 92 (2) 8 (2)
Subclonal 59 88 (4) 11 (4)
Clonal 50 84 (5) 10 (4)
SR Wildtype 49 96 (3) 4 (3)
Subclonal 15 93 (6) 7 (7)
Clonal 10 69 (15) 4.57 (CI: 1.02-20.5) 0.027 21 (14)
MR Wildtype 75 88 (4) 12 (4)
Subclonal 42 85 (6) 12 (5)
Clonal 31 97 (3) 0.058 0 0.01
HR Wildtype 11 100 0
Subclonal 2 n/ac n/ac
Clonal 9 56 (16.6) 0.015 33 (17) 0.044
Only p-values <0.1 are shown. EFS: Event-free survival; CIR: Cumulative incidence of relapse and non-response; pcl: p-value 
for comparison clonal vs. wildtype cases; SR: Standard risk; MR: Medium risk; HR: High risk; a Only shown if significantly 
different, reference group: wildtype cases; b all tests stratified for risk arms of this protocol (SR, MR, and HR). c 5-year follow-
up only reached by one patient.
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Figure 3. RAS pathway mutations and ex vivo cytotoxicity of chemotherapeutic agents. 
Ex vivo sensitivity of 211 primary patient samples towards (A) prednisolone and (B) vincristine, 
distinguished by RAS mutation status. Only clonally mutated cases are considered. Only KRAS and 
NRAS mutated groups are shown due to low recurrence of other mutations (see also supplement). 
Combined: All cases with a clonal mutation in NRAS, KRAS, PTPN11, FLT3. Groups were 
compared by Mann-Whitney U test, * p<0.05, ** p<0.01. LC50-values were evaluated by MTT 
assays as reported previously.
In K/NRAS G13 mutated cases the glycine (G) was replaced by an aspartic acid (D) in 13 
of 15 cases. In contrast, the type of amino acid being substituted at the G12 position was 
more variable (see also Figure S6). As visualized in Figure S9 the substituting amino acid 
was not predictive for ex vivo prednisolone or vincristine resistance.
In contrast, wildtype cases tended to be more resistant towards L-asparaginase ex vivo 
than RAS pathway mutated cases, however, this trend was not significant (Table S10). 
No consistent association of mutation status with ex vivo drug response was observed for 
daunorubicin, 6-thioguanine, and 6-mercaptopurine (Figure S10). 
RAS pathway mutations at relapse
RAS pathway mutations were detected in 13 out of 19 cases with matched initial diagnosis 
and relapse samples (Figure 4). Ten mutations were found at diagnosis, and ten at relapse 
(53%). From diagnosis onwards, the evolution of RAS pathway mutations followed three 
distinct patterns: In three cases, a clonal RAS pathway mutation was detected at initial 
diagnosis and at relapse (“Retained”). In seven cases, a subclonal mutation (four patients) 
or no mutation (three patients) was observed at diagnosis, but at relapse a RAS pathway 
mutation was detected with higher VAF (“Gained”). In six of these relapses the mutation 
was clonal, in one it was subclonal. One of these cases was remarkable in that five different 
subclones were observed at diagnosis but only one of these mutations (NRAS G12S) was 
found at relapse. Loss of one and selection of a second clone was observed in two cases, 
where they constituted the major clone in all subsequent relapses. In three cases, the 
initially observed RAS pathway mutation was not detected at relapse (“Lost”). For all 
“lost”mutations VAF at initial diagnosis was lower than 10%. Remarkably, in nine out of 
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ten relapse cases a single, clonal mutation was observed (VAF of 27% or higher). 
MEK-inhibitors as therapeutic option
The MEK-inhibitor trametinib was cytotoxic to RAS mutant but not wildtype leukemic 
cells in a range of concentrations (Figure 5A and Figure S11A). This effect is also illustrated 
by individual data points at a fixed concentration of 0.14µM (Figure 5B, p=0.001). High 
levels of MEK1/2 and ERK1/2 phosphorylation indicated an activated RAS pathway in 
mutant but not in wildtype cells (Figure 5C). The cytotoxicity of increasing trametinib 
concentrations corresponded with effective reduction of ERK1/2 phosphorylation (Figure 
S11B). In addition, we found that intrinsic resistance to prednisolone could be reversed 
by trametinib irrespective of RAS mutation status (Figure 5D), which corroborates our 
previous findings.30
Discussion
The RAS pathway is the most frequently mutated pathway in cancer, and may serve as 
treatment target.7, 8, 49 Recent reports suggest that RAS pathway mutations are recurrent 
in pediatric BCP-ALL.20, 27, 30, 31, 50 However, frequency and prognostic value of subclonal 
mutations at initial presentation was unknown. In this study we addressed the clinical 
value of mutations in thirteen key members of the RAS pathway using deep targeted 
sequencing, which allowed detection of subclones down to 1% VAF. Our study cohort 
contained 461 newly diagnosed cases and represents all subtypes and risk groups of BCP-
ALL, with a distribution comparable to the general pediatric BCP-ALL population. 
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Figure 4. Evolution of clonal and subclonal RAS pathway mutations between initial diagnosis 
and subsequent relapse in thirteen BCP-ALL cases.
Variant allele frequency of all RAS pathway mutations found at initial diagnosis and/or relapse(s) 
is shown for cases with RAS pathway mutations detected at either time point (13 of 19). Colours 
distinguish affected genes, symbols distinguish observed variants. Dx: Initial diagnosis sample; R: 
relapse sample.
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Figure 5. The MEK-inhibitor trametinib effectively kills RAS mutant primary BCP-ALL cells. 
(A) Sensitivity towards the MEK-inhibitor trametinib in primary or xenograft-derived BCP-ALL 
cells. Mean and standard deviation are shown. (B) Relative cell survival at 0.14µM trametinib split 
up per case. Grey circles represent wildtype cases, red triangles represent RAS pathway mutant 
cases. Bars represent group mean. Groups were compared by Mann-Whitney U test, ***p=0.001. 
(C) Western blot analysis of phospho-ERK (T202/Y204) and phospho-MEK (S217/S221) in a subset 
of samples tested in panel A. †Sample isolated after thawing, cells previously tested positive. (D) Ex 
vivo response to trametinib (left panels) and sensitization towards prednisolone (right panels) in 
one NRAS G12D-mutant and one RAS pathway wildtype case.
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We identified clonal RAS pathway mutations (≥25% VAF) in 24.1% and subclonal 
mutations (<25% VAF) in 20.1% of patients at initial diagnosis. This total of 44.2% is 
considerably higher than the 15% mutation frequency previously detected by Sanger 
sequencing, and shows that RAS pathway activation cooperates with several primary 
oncogenic lesions.20, 31 The vast majority of mutations (98%) occurred in NRAS, KRAS, 
FLT3, and PTPN11, revealing a central role of these genes in pediatric BCP-ALL. 
We observed high mutation frequencies among high hyperdiploid, MLL-AF4-rearranged, 
BCR-ABL1-like, and B-other cases, moderate frequencies among ETV6-RUNX1 cases, 
and rarely observed them in TCF3-PBX1 and BCR-ABL1-rearranged cases, confirming 
reports of smaller sample sets.23, 27, 32, 51
The BCR-ABL1 fusion is known to require MAPK signaling, but the low mutation 
frequency suggests independent RAS pathway activation is not required for this 
aggressive disease.52-56 BCR-ABL1-like cases, who bare strong similarities with BCR-
ABL1-positive leukemia, frequently carry RAS pathway mutations. These were mutually 
exclusive with tyrosine kinase-fusions, suggesting divergent pathogenic mechanisms. 
Our data further show that RAS pathway activating mutations play a role in about half 
of all B-other patients. The largest group of RAS pathway mutated cases was observed 
within high hyperdiploid cases. Our extensive screen extends the existing knowledge 
by revealing frequent subclonal events.27, 32, 57, 58 Our data advocate MEK inhibitors as 
treatment option in high hyperdiploid cases with poor therapy response. We further 
identified several secondary aberrations that co-occurred less or more frequently with 
RAS pathway mutations. Interestingly, RAS pathway mutant cases infrequently carried 
BTG1 deletions, which have recently been linked to glucocorticoid resistance and may 
represent a distinct resistance mechanism in RAS pathway wildtype cases.59
In the largest dataset analyzed so far (n=211), we confirmed the association of RAS 
pathway mutations with prednisolone resistance.30, 60, 61 Additionally, RAS pathway mutant 
cells were ex vivo resistant to vincristine, but not to L-asparaginase, daunorubicin, and 
thiopurines. This suggests that patients with RAS pathway mutations could profit from 
intensification of these drugs.
Patients with high MRD levels (≥10-3 after induction or consolidation) are at higher risk 
for relapse and treated more intensely, also in DCOG ALL10.4, 62 Patients with clonal RAS 
pathway mutations treated in the DCOG standard risk arm had an unfavorable clinical 
outcome despite negative MRD levels. Since the prognosis of clonally mutated patients is 
highly favorable in the medium risk group (5-year EFS 97%, CIR 0%; Figure 2B), MRD-
low risk patients with clonal RAS pathway mutations may benefit from medium risk 
treatment which includes intensive PEG-asparaginase and dexamethasone/vincristine 
pulses during maintenance therapy.4 This is further supported by RAS mutated patients 
being relatively sensitive to asparaginase ex vivo. The prognosis of those 20.1% of patients 
with subclonal mutations was similar to wildtype cases, and they generally presented with 
good risk features. Therefore, subclonal mutations in RAS pathway genes should not be 
used to assign patients to a higher risk group or treatment with a MEK-inhibitor. 
Evaluation of 19 cases with matched diagnosis and relapse material gave an important 
insight into the evolution of RAS pathway mutations: 1) Clonal mutations at diagnosis 
were preserved at relapse, 2) subclonal mutations detected at initial diagnosis were 
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often found at relapse, and 3) a single, clonal mutation was found in nine out of ten 
relapses. These observations confirm that RAS pathway mutations are frequent at relapse 
in pediatric BCP-ALL.28, 29, 63, 64 The reduced mutational diversity at relapse suggests 
outgrowth of a single clone with stronger dependence on MAPK signaling, which may 
increase the chance of success for RAS-targeted therapy. 
NRAS and KRAS mutations increase the risk for therapy failure at relapse, demanding 
alternative treatment options.27, 28 These patients may be eligible for MEK-inhibitors 
such as trametinib. Leukemic cells with RAS pathway mutations were sensitive to 
trametinib, while wildtype cells were not. We further confirm our previous finding that 
MEK-inhibition can synergize with prednisolone.30 Interestingly, nine of eleven RAS 
mutated cases allocated to the high risk arm had a poor in vivo response to prednisone 
after one week of therapy. This provides a rationale to combine MEK-inhibitors with 
glucocorticoids. Notably, within our data no correlation was observed between the 
response to prednisolone and the response to trametinib.
In conclusion, clonal mutations in NRAS, KRAS, PTPN11, and FLT3 are associated 
with therapy resistance. Given that clonal mutations at initial diagnosis were retained at 
relapse and that subclonal mutations often expanded at relapse, RAS pathway mutations 
may serve as a biomarker to identify patients eligible for MEK/ERK targeted therapy. 
The synergistic effect between MEK-inhibition and prednisolone may be of additional 
advantage. While our results and supremacy of MEK inhibitors require confirmation 
in independent cohorts, our data suggests screening a) all cases that are eligible for 
treatment reduction based on MRD, and b) patients for whom treatment intensification 
is advised and who may benefit from adjuvant MEK inhibitor treatment. Methodically, 
accurate detection of any clonal RAS pathway mutation should be ensured, but detection 
of subclonal mutations is not required. 
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Full online Material and Methods
Patient material, patient-derived xenografts (PDX), cell lines, 
and subtype classification
This study comprised children with newly diagnosed BCP-ALL enrolled in consecutive 
Dutch Childhood Oncology Group trials (DCOG ALL-8, ALL-9 and ALL-10) and 
German Cooperative ALL trials (COALL 06-97 and 07-03). Written informed consent 
was obtained from parents or guardians and institutional review boards approved the 
use of excess of diagnostic material for research purposes. These studies were conducted 
in accordance with the Declaration of Helsinki. Mononuclear cells were isolated using 
density gradient centrifugation with Lymphoprep (Axis Shield, Norway) as described 
previously.1 If not indicated otherwise, samples contained at least 90% leukemic blasts 
evaluated by morphological examination. In some cases this was achieved by negative 
selection using immunomagnetic beads. Animal experiments were approved by the 
animal ethics committee (EMC 2863 (103-12-08)). Xenografts of primary patient material 
were established in three 7-12 week-old female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) 
mice (Charles River, France) per patient, using intra-femoral injection. Animals were 
randomly assigned to receive leukemia cell injections.Mice were sacrificed upon signs of 
overt leukemia or 180 days after transplantation. Leukemic cells were isolated from bone 
marrow and spleen, and subsequently used for sequencing, western blot, and trametinib 
cytotoxicity assays. Blast percentage was above >90% by morphological evaluation in all 
samples, in one case achieved by positive selection using immunomagnetic beads directed 
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to human CD19 (Miltenyi Biotec, Germany). The leukemic cell line 697 was obtained 
from the German Collection of Microorganisms and Cell Cultures, regularly checked for 
mycoplasma contamination, and its identity verified using DNA fingerprinting (DSMZ, 
Germany).
Subtypes were determined by karyotype, fluorescence in-situ hybridization (FISH) 
and/or fusion-gene specific PCR, subdividing patients into ETV6-RUNX1-rearranged, 
BCR-ABL1-rearranged, high hyperdiploid karyotype (51-65 chromosomes and/or DNA 
index ≥1.16 and <1.5), MLL-rearranged (t(4;11)), TCF3-PBX1-rearranged, and B-lineage 
other (B-other). BCR-ABL1-like cases were identified using microarray gene expression 
profiling by the means of a 110 probeset classifier with proven independent prognostic 
relevance.2, 3 In 11 cases all subtypes have been excluded, except the extremely rare TCF3-
HLF fusion. As this is extremely rare, we consider it safe to allocate these cases to the 
B-other group.
Cell culture 
Primary cells were cultured in RPMI-1640 Dutch modified supplemented with 20% 
FCS, Penicillin, Streptomycin, Fungizone, gentamicin, insulin, selenite, transferrine, 
and L-Glutamine (all Life Technologies Europe BV, the Netherlands). Cell line 697 
was cultured in RPMI-1640 +GlutaMAX, supplemented with 10% FCS, Penicillin, 
Streptomycin, and Fungizone.
Ex vivo drug cytotoxicity assays
Cell-intrinsic resistance towards common chemotherapeutics was evaluated as previously 
described.4 In brief, freshly isolated primary leukemic cells were incubated with a range 
of concentrations of prednisolone (0.076 - 250µg/mL), vincristine (0.05 – 50µg/mL), 
daunorubicin (0.002 – 1.2µg/mL), L-asparaginase (0.003 – 10IU/mL), 6-mercaptopurine 
(0.002 – 0.05µg/mL) and 6-thioguanine (0.02 – 0.5µg/mL). After four days, cell viability 
was evaluated by adding 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide 
(MTT) and measuring formazan-conversion with optical density measurement. LC50-
values were calculated (concentration at which 50% conversion activity was measured 
relative to untreated control) and compared between groups using a Mann-Whitney U 
test. Ex vivo sensitivity towards trametinib was measured similarly (range 5µM to 0.6nM 
and four days incubation). Both primary material and patient-derived xenograft samples 
were used to evaluate trametinib sensitivity.
Protein isolation and western blot
Leukemic cells were lysed either using radioimmunoprecipitation buffer (Thermo Fisher 
Scientific) with fresh phosphatase and protease inhibitors (Sigma Aldrich) or in protein 
lysis buffer pH 7.4 containing 25mM Tris base, 150mM NaCl, 5mM EDTA pH 8.0, 1% 
Triton X-100, 10% glycerol, 10mM sodium pyrophosphate, 1mM sodium orthovanadate, 
10mM glycerolphosphate, dithiothreitol, phenylmethylsulfonyl fluoride, Aprotinin, and 
Sodium-Fluoride (all Sigma Aldrich). Samples were blotted on nitrocellulose membranes 
using the BioRad Trans-blot Turbo system and membranes probed with anti-MEK1/2 
(#4694), anti-phospho-MEK1/2 S217/221 (#9154), anti-ERK1/2 (#9107), anti-phospho-
ERK1/2 T202/Y204 (#4370), and anti-alpha-tubulin (#2144) according to manufacturer’s 
instructions (all Cell Signaling Technologies). 
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DNA isolation and sequencing 
Genomic DNA and RNA were isolated using Trizol reagent according to manufacturer’s 
protocol (Life Technologies), or in some cases using the DNeasy blood and tissue kit 
(Qiagen). Genomic DNA concentration was determined using the Qubit dsDNA Broad 
Range Assay Kit (Life Technologies). For TruSeq Custom Amplicon sequencing (Illumina, 
USA), 100-250ng genomic DNA was used to prepare sequencing libraries according to 
manufacturer’s instructions. Successful library preparation, correct amplicon length, 
and concentration was assessed using the Labchip GX genomic analyzer (Caliper Life 
Sciences Benelux N.V., the Netherlands) with the HT DNA 12K Reagent Kit, Version 
2. Samples were then pooled equimolarly sequenced on an Illumina MiSeq in paired-
end reads of 250bp each. In total, 49 amplicons of mutational hotspot regions in 13 RAS 
pathway genes were sequenced (Supplemental Table S1). Detailed information on the 
design and analysis script will be provided upon request.
Sequence reads were exported in fastq format and aligned to the standard 1000 genomes 
human reference sequences (version b37, from the GATK resource bundle, the Broad 
institute, USA) using BWA version 0.7.10⁵. We applied the GATK indel realigner version 
3.3-0 to remove artefacts caused by indels. Reads mapping outside targeted regions (e.g. 
due to false priming or poor quality) were excluded. Single nucleotide variants were 
called with Freebayes version 0.9.18-246, Varscan version 2.3.77, Bcftools version 1.08, and 
GATK version 3.3-09. The resulting variant call format files were annotated using snpEff 
and snpSift version 4.1a10 and dbNSFP version 2.7 database11. All variants were combined 
into a single table and filtered based on several criteria using an in-house developed 
pipeline: For each sample, variants were excluded if they were reported by only one caller, 
had coverage of less than 100 reads, or had less than 20 reads supporting the variant allele. 
Overall, variants were excluded if they did not occur at least once with a variant allele 
frequency (VAF) >2% or were not distributed equally between runs according to a chi-
square test. Furthermore only variants were taken into account that were reported in the 
COSMIC V73 GRCh37 database (cancer.sanger.ac.uk)12, lead to an amino acid change, 
were unlikely to be a germline variant (see below), and not a known SNP. A variant was 
considered to be a SNP if it had a mean population frequency of 5% or higher across 
the 1000Gp1 complete human population, 1000Gp1 population of European decent, and 
the ESP-6500 population of European decent allele frequency database. Variants were 
labelled as a possible germline variant if they were found in more than 10 samples with a 
mean and median VAF of more than 40%. 
Clonal and subclonal mutations were distinguished based on VAF: assuming 
heterozygosity, a mutation was considered to be clonal if VAF exceeded 25% (representing 
50% of the cells) and subclonal if VAF was <25%. Since a minimum number of 20 variant 
reads was required for variant calling, sufficient coverage was crucial to detect subclonal 
mutations. In the 7 most frequently mutated amplicons, coverage allowed detection of 
clonal mutations in on average 99% of the samples (Supplemental Tables S1 and S2). 
Subclonal mutations could be reliably detected up to 3% VAF in most cases and amplicons 
(average 87% of cases). Because detection of variants with a frequency of 1% was limited 
to a smaller group, the frequency of subclonal mutations is a conservative estimate. 
However, based on the observed frequencies we calculated that only a small number 
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of 9 subclonal mutations might be missed in our study (Supplemental Table S2B). In a 
comparison with 25 samples that were sequenced previously (Ariës et al.13), all variants 
could be identified by both platforms, indicating a low false-positive rate.
Exon 3 of NRAS was sequenced using Sanger sequencing in 253 ALL10 samples, which 
were part of the clinical outcome analyses. 248 yielded good quality chromatograms. 
Samples were analyzed by visual inspection of codons 59 to 63 as well as the R package 
sangerseqR in combination with the tools above to call and annotate detected variants. 
Primer sequences are available upon request.
Clinical characteristics and statistics
Clinical characteristics were compared using Fisher’s exact test in R (version 3.2.1). We 
analyzed cases from the DCOG and COALL diagnosed between 1992 and 2013 with 
diagnostic data available (n=432). We restricted the RAS pathway mutated group to 
those carrying a verified activating mutation in amino acid positions 12, 13, and 146 
of NRAS or KRAS or carrying a variant in FLT3 or PTPN11. Event-free survival (EFS) 
and cumulative incidence of relapse and non-response after induction therapy (CIR) 
were evaluated in 244 eligible cases treated within one protocol (DCOG ALL10), and 
analyses were stratified for risk group. Non-eligible were cases who had resided less than 
3 months in the Netherlands or who were not treated in a childhood oncology center. 
Since induction death precludes risk-group allocation these cases (n=5) were excluded. 
The COALL97/03 cohort consisted of patients treated in the consecutive COALL 06-97 
and the COALL 07-03 protocols (n=131). For details see Escherich et al.14 Treatment 
intensity in arms LR-R and LR-S was considered comparable to DCOG ALL10 standard 
risk treatment; LR-I, HR-R, and HR-S treatment is comparable to the DCOG ALL10 
medium risk treatment. In the COALL97/03 study, no high risk treatment is given that 
is comparable to the intensity given in the DCOG ALL10 high risk arm. Mean follow-up 
for patients at risk was 7.7 years (±1.86 years) in ALL10 and 8.6 years (±2.63 years) for 
COALL97/03. CIR was estimated using a competing risks model and compared using 
Gray’s test. EFS probabilities were estimated using the actuarial Kaplan-Meier method 
and compared using the log-rank test. Hazard ratios were calculated in SPSS v21 using 
Cox’s proportional hazard model. All reported tests are two-sided, adjustments for 
multiple testing were deemed expendable due to low numbers of comparisons. Outcome 
analyses were performed in R 3.2.1, using the packages cmprsk15 version 2.2-7, mstate 
version 0.2.716, and survival version 2.38-317.
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Supplemental Tables and Figures
Supplemental Table S1: Median coverage per sample itemized by amplicon. Amplicons are 
indicated by chromosome and start/end coordinates according to GRCh37. Amplicon ID consists 
of gene name and a consecutive number, + or – indicate targeted strand. ULSO: Upstream Locus-
Specific Oligo, DLSO: Downstream Locus-Specific Oligo
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1 115258677 115259080 NRAS_1_+ 2 1912 GAGGTAGAATTGCGTAA-
CAGCTCTCT
AACTTCCGGTCTG-
GACGCGCAGTGC
2 39249582 39249982 SOS1_1_+ 11 3405 GAGTCCTGAGACCA-
GAAAGTTACAAGA
CTTCAATTATATACCC-
GAAAAGTCTGC
2 39249854 39250256 SOS1_2_+ 11 4303 GTCAGCTGAAGAGAAAAA-
CAATTGGATG
CAACCAAAGACCTCTTTTC-
TTTGACTAAA
2 39250176 39250579 SOS1_3_+ 11 3126 CACTAGGCAGCCTCATCT-
GCTCCTCTTT
CTTCCATTATAAATTCATTA-
CAACACTGTC
2 39278250 39278665 SOS1_4_+ 7 908 AACATTAGCACAATCAGAC-
TGGAAGAA
CAAATCACAAGTGTGACT-
TAAAACAGG
3 12625886 12626290 RAF1_1_+ 17 3037 CTCTAGAGGAAGCAGGAGA-
CAGGG
CAAACCCACAGCGGTCC-
CTGGG
3 12626160 12626560 RAF1_2_+ 16 3993 GCAATATAAGGTGG-
GAGTGTTTTGTTTTGT
AGAAGCTGCTGCTAAGGAC-
CTTCTAG
3 12626432 12626835 RAF1_3_+ 15+16 5824 AACAAAGCCCAAGAATGCT-
CTCATTAG
ACAAGTCCTAACCCTC-
TAGCTGCTTA
3 12626708 12627112 RAF1_4_+ 15 8246 AAAGGGACAGCCTGGCCCC-
TAGATGTC
GGATATGCCTCCCCAGATC-
TTAGTAAG
3 12627036 12627437 RAF1_5_+ 14 5165 AAACTGAATGGGTTGT-
TATCCTGCATTC
GAAATGTACAGAAACGCTT-
TAAGTTTGC
3 12629037 12629445 RAF1_6_+ 13 628 TGAACTGATGGCCCAGT-
GAACTAATG
GACCCAG-
GCATCAAATTTGTCCCTAA
3 12632242 12632688 RAF1_7_+ 12 1282 CAGAGGGACTGGACCGC-
CAGCTTTCTA
AGGTTAACTGCTATCGCTA-
CAGTTAGG
3 12633174 12633623 RAF1_8_+ 11 54 AGAAAAACCTCGTTG-
GAAATTAGAATAC
TTGGGGCCCTCCCTTTAC-
TAACTGCA
3 12641157 12641607 RAF1_9_+ 10 604 CTGCATGATCACAGGTCCT-
CTAAACAT
ATCTAAGAGGCCTGCC-
CACATCCCTCAT
7 140453074 140453511 BRAF_1_+ 16 2800 GGAGGAAAGAAGAAATTAC-
CAGAGGTC
CCATTACCATCTTGGACC-
TGGAAGAAG
11 533746 534150 HRAS_1_+ 3 636 CAAGAGAATATCTGGGCC-
TACATTGCT
CAGTTGTCTGGATC-
CATTTTGTGGATG
11 534080 534480 HRAS_2_+ 2 343 AGGATAGGGCTGGCT-
GCAGCCCCTGG
AGTACAGGTGAACCCCGT-
GAGGCTGG
11 119148789 119149238 CBL_1_+ 8 1529 TTCTGAGTGGAATCCCTGC-
CACAAATCC
GAGGCACTCCGCTCAATC-
TTGG
11 119149169 119149569 CBL_2_+ 9 597 AGCCCTGACCTTCTGATT-
CCTGC
GTTAACAGAAAAAGTGAA-
GACTTGTTTCC
12 25378499 25378910 KRAS_1_+ 4 1413 GAAACCTTAGGAAGTT-
CAGTGCAGAGA
TAGTGACAGCCAGCCT-
CAGGGCAATTGT
12 25380234 25380683 KRAS_2_+ 3 926 CCTGAGAACATCAGAACC-
TTTCTGCAT
TCTGGATGGTTTTGGGAA-
CGTCAATAT
12 25398208 25398635 KRAS_3_+ 2 2064 CCAGCAATGCACAAA-
GATTTCAGTGTC
AATGAGGGACCAGTACAT-
GAGGACTG
12 112888116 112888551 PTPN11_1_+ 3 2576 TAGAGCTGAGAAGCCTT-
CGGGGAGTAA
CCACTTTGTAGATGAATAT-
GATCCCAC
12 112926839 112927258 PTPN11_2_+ 13 1053 ATGCAACCCCTATAGGAT-
GAGTGTAAG
GTGGGTGACAGCTCCATTT-
CTTCTAAA
13 28592577 28593002 FLT3_1_+ 20 1381 GCAGAACAGCAGTCTG-
GCTATTTAGAT
TGTGGACGAATATGATC-
CAACAATAGA
13 28608193 28608596 FLT3_2_+ 13+14 1051 CTTTTGCTCGGAATCT-
GCAAAAGATCT
TGTGAGGCTGCTATTTCC-
TACTTATTT
13 28610091 28610494 FLT3_3_+ 11 172 AATGTCACACAGGAATTC-
TGTTTCATC
TGGTAAGAATGGAATGT-
GCCAAATGTT
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15 38545247 38545694 SPRED1_1_+ 1 529 GCAATCATTGTGCTTTT-
TAGAACACTGAA
GCCAAACATGAGAGA-
CACATATTTCTCTTT
15 38591535 38591950 SPRED1_2_+ 2 1906 CTTCCATCCATC-
CACATTATTCCCTCT
ACAGGGGCCTCAC-
CATGGTGGATGC
15 38614381 38614826 SPRED1_3_+ 3 293 CCCATCCCCCAA-
CAAATGTGTATCAAT
GCAAAGATCAGGAAT-
TAGCTTTTCCAT
15 38643086 38643489 SPRED1_4_+ 7 3114 CATGCAATTGACATAGAC-
TATGATGTG
ACATATATCAAATGCATC-
TAATGTAGCTC
15 38643358 38643759 SPRED1_5_+ 7 3957 ATTTTTAATGAGGAAGGCT-
GCGTCTTA
TTCTGGACATTTCTATGA-
TATGTTTTTGG
15 38643684 38644084 SPRED1_6_+ 7 1655 GATTCCAGTATTCAGTTTT-
CTAAACCAGAC
CTTGCGATGGTTAGCCC-
TGGTAGCTTT
15 66727334 66727751 MAP2K1_1_+ 2 434 CTGCAAATACTCTACAACC-
TGTAACAAAAC
GTCACACGAACAGG-
GATCAGAAAAATCT
15 66729037 66729486 MAP2K1_2_+ 3 529 TATTGACTTGTGCTCCC-
CACTTTGGA
TTGCCCAGGCTGGTGT-
GCAACCTCCAT
17 29528006 29528443 NF1_1_+ 10 1085 TTCCCTAAATTTAGAACC-
GAGCAGTCA
CTCCCAGTAGCCGGGAC-
CACAGGCAT
17 29652753 29653190 NF1_2_+ 37 2647 CTGAGCCAGGCAGATCTA-
TAGAAAAAG
ACAAAAGCCTTTAAATACC-
CATGCAGT
17 29654472 29654917 NF1_3_+ 38 4061 CATAAAATAAAATTGAT-
TAGTGGCATCTGT
GAACAACAGAAACTACCT-
GCTGCCA
17 29677138 29677547 NF1_4_+ 50 2071 GGTCTCATTTTAAAAGCAA-
CAAACCCC
CGGGGTGAAGTGGAGAA-
GAATTAAACT
19 4099156 4099558 MAP2K2_1_+ 7 179 TGAGCACTTGGGA-
CACGTTTCTGTGTG
AACAGAGCATGTTGGGGA-
GAAGGAAG
19 4110438 4110845 MAP2K2_2_+ 3 775 GGATCCTTTCCTTCTACAC-
CATGAACC
AGTGGTGGGGAAGGTCCC-
CCTGGAAA
19 4117360 4117773 MAP2K2_3_+ 2 1255 AACTATGAGAGGTGCTC-
TAGGTACACC
AGAGAGGTTTTATGAAA-
GAAAGAGGGA
X 47426580 47427029 ARAF_1_+ 10 454 CTGCATGATCACAGGTCCT-
CTAAACAT
ATCTAAGAGGCCTGCC-
CACATCCCTCAT
X 47428072 47428517 ARAF_2_+ 11+12 61 CTTTTGAGAGAGATA-
CAAGGTTTCTGT
ACAGATCTGTTTTCT-
GCAAAATCATAA
X 47428811 47429228 ARAF_3_+ 13 420 TTGTAATTCCCAGAACCCC-
CACAAGAG
AGTGTCAGAGGTGGGGAG-
GAAAAATAG
X 47429159 47429559 ARAF_4_+ 14 287 AGATCCCACTGGC-
CACACAGGGTAC
ATCCTGACCAGGAGCCCC-
TTAATATCA
X 47430152 47430552 ARAF_5_+ 15 220 GTCTGGACTCCTCATGTC-
CCACCT
AACCTAAAATTTTCTAGGA-
TAAGGACTCCC
X 47430424 47430824 ARAF_6_+ 16 527 CTCATGGTGAAA-
CACACACACACACA
AGCTGGGGTACTGTCAG-
TATCAAGG
X 47430758 47431158 ARAF_7_+ 16 360 GGGGCTGGACACC-
TTGGGTGGGTGACT
CCCAGGCCGATGAGTTGC-
CTGCCT
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Supplemental Table S2: Estimate of false negative cases missed due to low coverage in the 8 most 
frequently mutated regions. 
The frequency of 1-3%VAF mutations, 3-5% VAF mutations, and 5-10%VAF mutations was 
calculated in a set of samples with sufficient coverage (>2000rds). This frequency was used to 
estimate the number of cases that would be expected in the group of cases where coverage was below 
the required minimum. All missed cases in these three groups were summed up. WT: Wildtype for 
RAS pathway mutations.
Estimated number of <3%VAF mutations missed in cases with coverage <666, based on the frequency 
of 1-3%VAF mutations observed in a group that did reach the coverage of >2000
Amplicon cases with enough 
coverage
mutation frequency 
VAF 1-3%
WT cases with 
coverage <666
Estimate missed cases
NRAS_1_+ 210 10.5 20 2
KRAS_1_+ 118 2.5 57 1
KRAS_2_+ 10 0.0 59 0
KRAS_3_+ 248 4.8 20 1
PTPN11_1_+ 327 2.4 9 0
PTPN11_2_+ 32 0.0 41 0
FLT3_1_+ 95 4.2 24 1
FLT3_2_+ 40 0.0 46 0
ΣMissed cases  6
Estimated number of 5-10%VAF mutations missed in cases with coverage <200, based on the 
frequency of 5-10%VAF mutations observed in a group that did reach the coverage of >2000
Amplicon cases with enough 
coverage
mutation frequency 
VAF 5-10%
WT cases with 
coverage <666
Estimate missed cases
NRAS_1_+ 446 4.7 8 0
KRAS_1_+ 396 0.3 28 0
KRAS_2_+ 437 0.0 5 0
KRAS_3_+ 448 4.5 7 0
PTPN11_1_+ 454 0.4 2 0
PTPN11_2_+ 427 0.0 3 0
FLT3_1_+ 443 0.5 11 0
FLT3_2_+ 432 0.5 16 0
ΣMissed cases  1
Estimated number of 3-5%VAF mutations missed in cases with coverage <400, based on the 
frequency of 3-5%VAF mutations observed in a group that did reach the coverage of >2000
Amplicon
cases with enough 
coverage
mutation frequency 
VAF 3-5%
WT cases with 
coverage <400 Estimate missed cases
NRAS_1_+ 210 3.8 12 0
KRAS_1_+ 118 1.7 35 1
KRAS_2_+ 10 0.0 16 0
KRAS_3_+ 248 2.0 10 0
PTPN11_1_+ 327 0.6 6 0
PTPN11_2_+ 32 0.0 18 0
FLT3_1_+ 95 0.0 13 0
FLT3_2_+ 40 0.0 21 0
ΣMissed cases  2
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Supplemental Table S3: Frequency and total number of clonal and subclonal RAS pathway 
mutations per subtype and gene. 
WT: Wildtype, n: number of cases, 1-10: mutations with 1 to 10% VAF, 50+: 50 to 100% VAF, all: 
all mutations summed up. ER: ETV6-RUNX1-rearranged; MLL: t(4;11)-rearranged, HD: high 
hyperdiploid, BO: B-other, TCF3: TCF3-rearranged, BA: BCR-ABL1-rearranged, BAL: BCR-ABL1-
like. 
total n 
tested
Wildtype  1-10% 10-20% 20-30% 30-40% 40-50% >50% all
n % of total n
% of 
total n
% of 
total n
% of 
total n
% of 
total n
% of 
total n
% of 
total n
% of 
total
ER
KRAS 124 107 86.3 6 4.8 3 2.4 1 0.8 5 4.0 2 1.6 0 0.0 17 13.7
NRAS 124 110 88.7 10 8.1 0 0.0 1 0.8 2 1.6 0 0.0 1 0.8 13 10.5
FLT3 124 119 96.0 4 3.2 0 0.0 0 0.0 0 0.0 1 0.8 0 0.0 5 4.0
PTPN11 124 120 96.8 3 2.4 0 0.0 0 0.0 1 0.8 0 0.0 0 0.0 4 3.2
other 124 122 98.4 2 1.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 1.6
t(4
;1
1)
KRAS 15 9 60.0 3 20.0 1 6.7 0 0.0 2 13.3 0 0.0 0 0.0 6 40.0
NRAS 15 9 60.0 2 13.3 3 20.0 1 6.7 0 0.0 0 0.0 0 0.0 6 40.0
FLT3 15 13 86.7 1 6.7 0 0.0 1 6.7 0 0.0 0 0.0 0 0.0 2 13.3
PTPN11 15 13 86.7 2 13.3 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 13.3
other 15 15 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
H
D
KRAS 124 69 55.6 19 15.3 7 5.6 10 8.1 7 5.6 12 9.7 0 0.0 55 44.4
NRAS 124 82 66.1 18 14.5 5 4.0 8 6.5 4 3.2 6 4.8 1 0.8 41 33.1
FLT3 124 110 88.7 5 4.0 4 3.2 1 0.8 0 0.0 2 1.6 2 1.6 12 9.7
PTPN11 124 110 88.7 4 3.2 4 3.2 1 0.8 1 0.8 4 3.2 0 0.0 14 11.3
other 124 122 98.4 0 0.0 0 0.0 1 0.8 0 0.0 0 0.0 1 0.8 1 0.8
BO
KRAS 67 52 77.6 6 9.0 2 3.0 1 1.5 2 3.0 3 4.5 1 1.5 14 20.9
NRAS 67 48 71.6 7 10.4 3 4.5 1 1.5 4 6.0 3 4.5 1 1.5 18 26.9
FLT3 67 62 92.5 4 6.0 0 0.0 0 0.0 1 1.5 0 0.0 0 0.0 5 7.5
PTPN11 67 65 97.0 2 3.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 3.0
other 67 66 98.5 1 1.5 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.5
TC
F3
KRAS 26 25 96.2 0 0.0 1 3.8 0 0.0 0 0.0 0 0.0 0 0.0 1 3.8
NRAS 26 25 96.2 1 3.8 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 3.8
FLT3 26 26 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
PTPN11 26 26 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
other 26 26 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
BA
KRAS 26 26 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
NRAS 26 26 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
FLT3 26 25 96.2 0 0.0 0 0.0 0 0.0 0 0.0 1 3.8 0 0.0 1 3.8
PTPN11 26 26 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
other 26 26 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
BA
L
KRAS 79 61 77.2 7 8.9 1 1.3 3 3.8 3 3.8 3 3.8 1 1.3 17 21.5
NRAS 79 58 73.4 9 11.4 2 2.5 0 0.0 2 2.5 7 8.9 1 1.3 20 25.3
FLT3 79 72 91.1 2 2.5 1 1.3 2 2.5 0 0.0 1 1.3 1 1.3 6 7.6
PTPN11 79 72 91.1 3 3.8 0 0.0 1 1.3 0 0.0 3 3.8 0 0.0 7 8.9
other 79 78 98.7 1 1.3 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 1.3
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Supplemental Table S4: Frequencies of RAS pathway mutations among cytogenetic subtypes of 
BCP-ALL. 
Fisher’s Exact test comparing the frequency of each cytogenetic subtype to the remaining BCP-
ALL subtypes. ER: ETV6-RUNX1-rearranged, MLL: t(4;11)-rearranged, HD: high hyperdiploid 
karyotype, BO: B-other, TCF3: TCF3-rearranged, BA: BCR-ABL1-rearranged, BAL: BCR-ABL1-like 
gene expression profile. OR: Odds ratio. P-values < 0.05 are printed in bold. CI: confidence interval.
Wildtype Mutated Total Frequency Fisher’s Exact p-value OR 95% CI of OR
ER 96 28 124 22.6% 8.2E-08 0.3 0.2 0.5
MLL 4 11 15 73.3% 1.8E-02 3.8 1.1 16.8
HD 34 90 124 72.6% 4.7E-15 5.7 3.5 9.3
BO 39 28 67 41.8% 0. 90 1.0 0.5 1.7
TCF3 26 0 26 0.0% 3.6E-07 0.0 0.0 0.2
BA 25 1 26 4.0% 7.5E-06 0.0 0.0 0.3
BAL 40 39 79 49.4% 0.21 1.4 0.8 2.3
total 264 197 461
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Supplemental Table S6: Distribution of clonal and subclonal RAS pathway mutations among 
the treatment arms of DCOG ALL10. 
SR: Standard risk treatment arm; MR: medium risk treatment arm; HR: high risk treatment arm.
Within Mutated, clonal Mutated, subclonal
ALL10 SR 10/75 (13%) 15/75 (20%)
ALL10 MR 33/151 (22%) 46/151 (30%)
ALL10 HR  9/22 (41%) 2/22 (9%)
Fisher test, p= 0.024 0.047
Supplemental Table S7: Clinical characteristics of BCP-ALL patients with subclonal RAS 
pathway mutations. 
WBC: White blood cell count; CNS+: non-traumatic puncture and >5 WBC/μl CSF with identifiable 
leukemic cells; patients with a traumatic lumbar puncture were not included; PPR: Prednisone poor 
responder, i.e. ≥1000 leukemic blasts/μl in peripheral blood on day 8 of induction therapy; MRD 
high: Minimal residual disease ≥10-3; d33: at the end of induction therapy (day 33); d79: at the end 
of consolidation therapy (day 79); aFisher’s Exact test p-values <0.05 are printed in bold font; bOdds 
ratios are only given if p-values in Fisher’s Exact test were <0.2.
 
 
Risk parameter
Incidence of subclonal mutations 
among Statistics
Risk parameter: 
Yes
Risk parameter: 
No
Fisher’s Odds 
ratiob 95%-CIp=a
Age ≥10 8/75 (15%) 80/357 (30%) 0.04 0.43 0.17 0.97
Male 49/227 (28%) 39/205 (38%) 0.53      
High WBC 
(>50/nL) 10/99 (15%) 77/331 (30%) 0.02 0.42 0.18 0.88
Down 
Syndrome 1/16 (7%) 86/391 (28%) 0.12 0.18 0 1.26
CNS+ 0/1 (0%) 38/248 (15%) 1      
PPR 2/17 (20%) 63/244 (32%) 0.73      
MRD high d33 
ALL10 15/48 (45%) 44/191 (23%) 0.06 2.24 0.95 5.23
MRD high d79 
ALL10 0/8 (0%)  60/231 (32%) 0.18 0 0 1.82
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Supplemental Table S8: Baseline characteristics of the ALL10 and COALL97/03 cohorts.
WBC: white blood cell count; MRD: Minimal residual disease, MRD positive: MRD ≥ 10-3; PPR: 
poor prednisone window response. Color intensities are used to indicate the treatment intensity. 
Treatment intensity: COALL treatment arms LR-R and LR-S are comparable to ALL10 standard 
risk treatment (labeled standard); LR-I, HR-R and HR-R are comparable to ALL10 medium risk 
treatment (labeled medium, see method section for details).
ALL10 COALL97/03
  n % Median 25th 75th   n % Median 25th 75th 
Total 244 100%   Total 131 100%  
Treatment intensity
Standard 22 9%   Stanard 31 24%  
Medium 148 61%   Medium 100 76%  
High 74 30%     -  
Risk characteristics
Age 5 3 8 Age 4 2 9
WBC 11 4.9 32.2 WBC 24.1 9.5 55
MRD positive 
d33 48/239 20%  
MRD 
positive d29 20/61 33%  
MRD positive 
d79 8/239 3%  
MRD 
positive d79 N/A  
PPR 15 6%   PPR N/A  
Down S. 8 3%   Down S. 3/110 3%  
Events 32 13%   Events 29 22%  
Relapse 28 11%       Relapse 26 20%      
Supplemental Table S9: Univariate and multivariate analysis of Cox’s proportional hazard ratio 
in Standard-risk treated DCOG ALL10 cases. 
WBC: White blood cell count; Clonal mutation: VAF ≥ 25%; subclonal VAF < 25%; 95% CI: 95% 
confidence interval.
  Univariate Multivariate
Variable HR (95% CI) p-value HR (95% CI) p-value
Age (≥10 years) 0.05 (0 - >1000) 0.66 0 (0-∞) 0.99
WBC (≥ 50/nL) 1.1 (0.1-9.2) 0.91 0.7 (0.08 – 5.9) 0.73
RAS pathway status 0.11 0.074
Clonal 4.6 (1.0 – 21) 0.047 5.4 (1.2 - 25) 0.032
subclonal 0.9 (0.1 – 7.8) 0.9 0.9 (0.1 – 7.7) 0.9
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Supplemental Table S10: Median ex vivo LC50-values per RAS pathway mutations. 
The allocated group is determined by the largest clone. LC50-values are given in IU/mL for 
L-asparaginase and in µg/mL for all other chemotherapeutic agents. p-value is determined with a 
Mann-Whitney U test. Significant p-values are printed in bold. wt: wildtype, Combined: all RAS 
pathway mutations taken together. PRED: Prednisolone, VCR: Vincristine, ASP: L-asparaginase, 
DNR: Daunorubicine, 6TG: 6-Thioguanine, 6MP: 6-Mercaptopurine. Values containing ≥ or ≤ 
represent the highest or lowest concentration in the range, which was used as IC50 if limits were 
exceeded.
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PRED wildtype 111 0.10 ≤0.0076 ≥250 . . 111 0.10 ≤0.0076 ≥250 . .
PRED combined 49 0.32 ≤0.0076 ≥250 3.2 0.02 34 0.17 ≤0.0076 ≥250 1.7 0.34
PRED KRAS G13 8 >250 0.280 ≥250 >2000 0.00 7 >250 0.06 ≥250 >2000 0.01
PRED KRAS G12 15 0.25 0.025 ≥250 2.5 0.19 6 0.35 0.04 ≥250 3.4 0.37
PRED NRAS G13 6 1.47 0.041 ≥250 14.4 0.18 0 NA . .
PRED NRAS G12 11 0.23 ≤0.0076 154.89 2.2 0.37 13 0.06 0.01 ≥250 0.6 0.98
PRED FLT3 3 0.10 0.028 14.84 1 1 5 0.55 0.16 ≥250 5.4 0.06
PRED PTPN11 4 0.10 ≤0.0076 ≥250 1 0.66 2 159.24 68.48 ≥250 1566 0.06
PRED KRAS other 2 0.03 0.015 0.05 0.3 0.22 1 0.36 0.36 0.36 3.5 0.54
VCR wildtype 110 0.49 ≤0.049 44.68 . . 110 0.49 ≤0.049 44.68 . .
VCR combined 49 0.73 ≤0.049 ≥50 1.5 0.15 35 0.50 ≤0.049 >50 1 0.91
VCR KRAS G13 8 7.09 0.397 43.95 14.6 0.01 7 0.67 0.12 >50 1.4 0.33
VCR KRAS G12 15 0.77 ≤0.049 ≥50 1.6 0.21 6 0.51 ≤0.049 2.26 1 0.77
VCR NRAS G13 6 1.44 0.191 36.50 3 0.07 0 NA . .
VCR NRAS G12 11 0.09 ≤0.049 3.03 0.2 0.06 14 0.45 ≤0.049 2.66 0.9 0.86
VCR FLT3 3 0.05 ≤0.049 2.03 0.1 0.21 5 0.41 ≤0.049 1.65 0.8 0.95
VCR PTPN11 4 2.48 0.488 43.38 5.1 0.04 2 3.41 0.10 6.72 7 0.94
VCR KRAS other 2 0.32 0.157 0.48 0.7 0.50 1 1.51 1.51 1.51 3.1 0.37
ASP wildtype 109 0.22 ≤0.003 ≥10 . . 109 0.22 ≤0.003 ≥10 . .
ASP combined 49 0.04 ≤0.003 ≥10 0.2 0.18 35 0.07 ≤0.003 ≥10 0.3 0.48
ASP KRAS G13 8 0.06 ≤0.003 1.58 0.3 0.55 7 0.13 ≤0.003 ≥10 0.6 0.86
ASP KRAS G12 15 0.03 ≤0.003 ≥10 0.1 0.56 6 0.05 ≤0.003 1.68 0.2 0.51
ASP NRAS G13 6 0.87 0.009 1.98 3.9 0.52 0 NA . .
ASP NRAS G12 11 0.02 ≤0.003 1.58 0.1 0.21 14 0.01 ≤0.003 ≥10 0.1 0.09
ASP FLT3 3 0.10 ≤0.003 0.13 0.4 0.36 5 0.03 0.01 0.27 0.1 0.33
ASP PTPN11 4 0.56 ≤0.003 1.31 2.5 0.72 2 0.01 0.01 0.02 0.1 0.23
ASP KRAS other 2 0.01 0.010 0.01 0.1 0.14 1 0.01 0.01 0.01 0.1 0.31
DNR wildtype 109 0.05 ≤0.002 0.32 . . 109 0.05 ≤0.002 0.32 . .
DNR combined 48 0.03 ≤0.002 1.13 0.5 0.64 34 0.05 ≤0.002 1.18 1 0.79
DNR KRAS G13 8 0.09 0.018 0.25 1.7 0.15 7 0.03 0.02 0.42 0.6 0.66
DNR KRAS G12 15 0.03 ≤0.002 1.13 0.6 0.87 6 0.05 0.01 0.15 0.9 0.82
DNR NRAS G13 6 0.03 0.020 0.10 0.5 0.36 0 NA . .
DNR NRAS G12 11 0.02 0.007 0.12 0.4 0.14 14 0.04 ≤0.002 0.22 0.8 0.67
DNR FLT3 3 0.02 0.006 0.27 0.4 0.59 5 0.05 0.02 0.08 1 0.84
DNR PTPN11 3 0.19 ≤0.002 0.23 3.7 0.44 1 1.18 1.18 1.18 22.9 0.09
DNR KRAS other 2 0.02 0.022 0.02 0.4 0.23 1 0.12 0.12 0.12 2.4 0.21
6TG wildtype 83 0.00 ≤0.002 0.02 . . 83 0.00 ≤0.002 0.02 . .
6TG combined 37 0.00 ≤0.002 ≥0.05 1.1 0.89 25 0.00 ≤0.002 0.02 0.9 0.73
6TG KRAS G13 5 0.00 ≤0.002 0.02 1.4 0.31 4 0.00 0.00 0.02 0.8 0.58
6TG KRAS G12 9 0.00 ≤0.002 ≥0.05 1.3 0.40 5 0.00 0.00 0.00 0.8 0.08
6TG NRAS G13 5 0.01 ≤0.002 0.01 1.8 0.80 0 NA . .
6TG NRAS G12 11 0.00 ≤0.002 0.01 0.7 0.25 12 0.00 ≤0.002 0.01 0.9 0.45
6TG FLT3 3 0.01 ≤0.002 0.01 1.5 0.85 2 0.01 0.01 0.01 2.8 0.03
6TG PTPN11 2 0.00 0.003 0.00 1 0.81 1 0.01 0.01 0.01 2.3 0.25
6TG KRAS other 2 0.00 ≤0.002 0.00 0.6 0.08 1 0.00 ≤0.002 0.00 0.4 0.11
6MP wildtype 82 0.09 ≤0.016 ≥0.5 . . 82 0.09 ≤0.016 ≥0.5 . .
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6MP combined 32 0.06 ≤0.016 ≥0.5 0.7 0.07 25 0.08 ≤0.016 ≥0.5 0.9 0.39
6MP KRAS G13 4 0.14 0.044 ≥0.5 1.6 0.43 4 0.04 0.02 0.09 0.4 0.07
6MP KRAS G12 8 0.05 ≤0.016 ≥0.5 0.5 0.15 5 0.10 0.02 0.10 1.1 0.41
6MP NRAS G13 5 0.07 ≤0.016 ≥0.5 0.8 0.70 0 NA .
6MP NRAS G12 10 0.09 ≤0.016 0.36 1 0.57 12 0.03 ≤0.016 0.27 0.3 0.01
6MP FLT3 1 0.04 0.038 0.04 0.4 0.22 2 0.38 0.27 ≥0.5 4.3 0.05
6MP PTPN11 2 0.02 ≤0.016 0.03 0.2 0.03 1 0.12 0.12 0.12 1.4 0.52
6MP KRAS other 2 0.05 0.034 0.06 0.5 0.15 1 0.02 0.02 0.02 0.2 0.14
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Supplemental Figure S2: Amplicon coverage across samples. 
Coverage was calculated from the number of reads mapped for each sample. Amplicons are 
identified by their amplicon ID (see also Supplemental Table S1). Boxes represent first and third 
quartile, whiskers represent outer two quartiles (max. 1.5-times the inner quartile range), and bar 
represents group median.
Supplemental Figure S1: Diagram with detailed information about the patient cohorts. 
(A) Subtype distribution among patients with complete subtype information, used to determine RAS 
pathway mutation frequency among genetic subtypes of BCP-ALL (red) and subtype distribution 
among cases used to compare clinical characteristics in wildtype or RAS pathway mutated patients 
(green). (B) Treatment protocols of cases used for analysis of clinical characteristics (green) and 
those used for analysis of event-free survival and cumulative incidence of relapse (blue). Cases with 
ex vivo drug sensitivity (yellow frame) data were treated in the COALL97/03 and DCOG ALL10 
cohorts, but only a subset of these cases had data available (n=211). Observation patient: not eligible 
for follow-up, only baseline characteristics analyzed 
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Supplemental Figure S3: Relative frequency of NRAS, KRAS, PTPN11, FLT3 and other RAS 
pathway mutations. 
Supplemental Figure S4: Histogram of observed variant allele-frequencies. 
Histogram of the VAF of all mutations in RAS pathway genes identified in our dataset. Dashed lines 
depict median VAF of all clonal or subclonal mutations. Background shading represents subclonal 
(light) and (dark) clonal mutations.
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Supplemental Figure S5: Frequency of clonal and subclonal RAS pathway mutations among 
tyrosine kinase (TK) fusion positive BCR-ABL1-like cases, CRLF2-high BCR-ABL1-like cases, 
and TK fusion negative BCR-ABL1-like cases with low CRLF2 expression. 
TK fusions were identified as described by Boer et al. (manuscript submitted) and included the 
following fusions: EBF1-PDGFRB (3 cases), PAX5-JAK2 (3), BCR-JAK2 (1), FOXP1-ABL1 (1), 
SSBP-CSFR (1), TERF2-JAK2 (1), and ZMIZ1-ABL1 (1). High CRLF2 expression was, as previously, 
defined as the 90th percentile of the entire BCP-ALL cohort.
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Supplemental Figure S6: Overview of amino acid changes in RAS mutated cases. 
(A) Relative frequency of different KRAS and NRAS variants observed in pediatric BCP-ALL. 
(B) Histogram of amino acid substitutions in KRAS, NRAS, FLT3 and PTPN11 variants. 
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Supplemental Figure S7: Event-free survival and cumulative incidence of relapse in the 
COALL97/03 cohort. 
ptrend  = p-value for the analysis comparing wildtype, subclonal, and clonal mutation cases; pcl  = 
p-value for the analysis comparing wildtype to cases with clonal RAS pathway mutations.
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Supplemental Figure S8: Ex vivo sensitivity to prednisolone (A) and vincristine (B) in BCP-ALL 
cases carrying subclonal or clonal RAS pathway mutations including FLT3 and PTPN11. 
Sensitivity of primary patient cells towards prednisolone and vincristine, distinguished by RAS 
mutation status. LC50-values of cases with clonal and subclonal mutations are depicted. “All”: All 
cases with a mutation in NRAS, KRAS, PTPN11, or FLT3. In cases with multiple mutations, the 
mutation with the highest VAF (largest clone) was used to classify cases.
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Supplemental Figure S9: Ex vivo chemotherapeutic sensitivity of RAS mutated BCP-ALL cases 
distinguished by the amino acid variant in the NRAS or KRAS gene. 
In cases with multiple mutations, the mutation with the highest VAF (largest clone) was used to 
classify cases. (A) Prednisolone sensitivity. (B) Vincristine sensitivity. 
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Supplemental Figure S10: RAS pathway mutations and ex vivo cytotoxicity of chemotherapeutic 
agents. 
Ex vivo sensitivity of 211 primary patient samples towards (A) L-asparaginase, (B) daunorubicin, 
(C) 6-thioguanine, and (D) 6-mercaptopurinol, distinguished by RAS mutation status. Only clonally 
mutated cases are depicted. Only KRAS and NRAS mutated groups are shown due to low recurrence 
of other mutations (see also supplement). Combined: All cases with a clonal mutation in NRAS, 
KRAS, PTPN11, FLT3. Groups were compared by Mann-Whitney U test, * p<0.05, ** p<0.01. LC50-
values were evaluated by MTT assays as reported previously.
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Supplemental Figure S11: Efficacy of the MEK-inhibitor trametinib in RAS pathway mutant 
BCP-ALL. 
(A) Ex vivo sensitivity of primary BCP-ALL cases towards trametinib. Red lines represent RAS 
pathway mutated cases, black lines represent RAS pathway wildtype cases. (B) Western blot of 
phosphorylated ERK1/2 to confirm effective MEK-inhibition by a range of trametinib concentrations. 
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Abstract
Several oncogenic aberrations of receptor tyrosine kinases have been reported in pediatric 
B-cell precursor acute lymphoblastic leukemia. Here we describe a subgroup of patients 
lacking sentinel chromosomal aberrations with high expression of PDGFRA. Given the 
implications of PDGFRA rearrangements in myeloid malignancies, we tested for genetic 
aberrations in PDGFRA and evaluated the inhibition of PDGFRα as treatment option. 
By means of fusion gene-specific RT-PCR, fluorescence in situ hybridization (FISH), and 
targeted locus amplification (TLA), we confirmed absence of genetic aberrations affecting 
PDGFRA. Instead, array-based comparative genomic hybridization data revealed ERG 
deletions in 63% of cases (10 of 16), compared to 0% in PDGFRA low BCP-ALL cases 
(n=71). Expression and activation of PDGFRα were confirmed by western blot in a cell 
line and primary BCP-ALL cells. Ex vivo drug sensitivity assays with and without bone 
marrow-derived mesenchymal stromal cells (MSC) revealed no sensitivity of PDGFRA 
high BCP-ALL cells towards two PDGFR inhibitors (imatinib and CP673451). We 
therefore conclude that high expression of wildtype PDGFRA is characteristic for ERG-
deleted leukemia and might serve as a biomarker, but not as treatment target. 
Introduction
Current event-free survival rates of pediatric B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL) have reached approximately 85%.1 A large part of relapses occurs 
in the genetically heterogeneous group that lacks sentinel chromosomal aberrations, a 
group which is widely referred to as “B-other” cases. Even after identification of the BCR-
ABL1¬-like subtype, B-other cases still constitute a considerable proportion (about 18%) 
of BCP-ALL patients.1-3 Genetic aberrations that define distinct subtypes are essential for 
diagnosis and risk evaluation. The primary oncogenic aberration driving the leukemia 
is also likely to be the most effective treatment target, and revealing these aberrations is 
crucial to identifying novel treatment targets and improving the prognosis for B-other 
cases.
Gene expression profiling and extensive sequencing has been performed to further 
classify B-other ALL, and several characteristic but not mutually exclusive aberrations 
have been found. Among the genes that are recurrently affected by aberrations are B-cell 
transcription factors (PAX5, IKZF1, ETV6, ERG) and components of signaling pathways 
(NRAS, KRAS, JAK2, CRLF2). 
Patients carrying intragenic deletions of the ERG gene on chromosome 21 have a favorable 
outcome, but the severe side effects and risks associated with chemotherapy still call 
for new therapeutic approaches.4-6 A distinct gene expression profile (referred to as R6 
cluster) has been identified to be characteristic of, but not limited to ERG-deleted cases.7 
In a recent report, Lilljebjörn et al. found a strong overlap of DUX4-rearrangements 
and ERG deletions, and provide evidence that the DUX4-rearrangement is the origin 
of this exclusive gene expression profile.8 In this newly described subtype of BCP-ALL, 
a truncated copy of the usually silenced germline transcription factor DUX4 is inserted 
into an actively transcribed region and aberrantly expressed.8, 9 Zhang et al. showed that 
aberrant DUX4 induces the expression of an alternative isoform of ERG, thereby directly 
106
linking the function of these two transcription factors.10 
Transcription factors are difficult to target with small molecule inhibitors and other targets 
such as kinases should therefore be investigated. We here describe high expression of the 
receptor tyrosine kinase PDGFRα in cases with ERG deletions. Given its implication in 
other hematological malignancies we evaluated possible genetic aberrations and assessed 
the response of primary BCP-ALL cells with high PDGFRA expression to two PDGFR 
inhibitors.
Methods
Primary leukemic cells, cell lines, and mesenchymal stromal 
cells
The study comprised children with newly diagnosed BCP-ALL with age at diagnosis 
ranging from 0 to 18 years. Written informed consent was obtained from parents or 
guardians, and institutional review boards approved the use of excess diagnostic material 
for research purposes. Clinical characteristics were kindly provided by the Dutch 
Childhood Oncology Group (the Hague, Netherlands). These studies were conducted 
in accordance with the Declaration of Helsinki. Mononuclear cells were isolated using 
density gradient centrifugation with Lymphoprep (Axis Shield, Norway) as previously 
described.11 All samples contained at least 90% leukemic blasts. Cytogenetic subtypes 
were determined by karyotype, fluorescence in-situ hybridization (FISH), and/or fusion-
gene specific PCR. BCR-ABL1-like cases were identified using microarray gene expression 
profiling by the means of a 110 probeset classifier.4 Animal experiments were approved by 
the animal ethics committee (EMC 2863 (103-12-08)). Xenografts of BCP-ALL cells from 
patient D were established as previously reported (Steeghs et al., submitted manuscript) 
in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (Charles River, France) using intra-
femoral injection. Leukemic cells were isolated from the spleen, frozen as viable cells, and 
subsequently thawed for protein isolation and ex vivo co-culture assays. Leukemic cell 
lines were obtained from the German Collection of Microorganisms and Cell Cultures 
(DSMZ, Germany) and routinely validated by DNA fingerprinting. Mesenchymal 
stromal cells (MSCs) were isolated from the bone marrow aspirate taken from a BCP-
ALL patient after consolidation therapy as previously described.12 MSCs were negative 
for hematopoietic markers and positive for mesenchymal markers.12, 13 
Gene expression profiling and RT-qPCR
RNA and DNA was isolated using Trizol reagent (Life technologies) according to 
manufacturer’s instructions and RNA subsequently used for gene expression profiling 
and RT-qPCR. Gene expression profiling was performed using Affymetrix U133 
plus 2.0 GeneChips. Detailed methods have been reported previously14, and data is 
deposited at NCBI’s Gene Expression Omnibus with accession numbers GSE13351 and 
GSE13425. High PDGFRA expression was defined based on the probe set 203131_at, 
with a cut-off at log2 expression value 5.9 (see also Figure 1A). cDNA was generated 
using the SensiFAST cDNA synthesis kit (Bioline), and RT-qPCR was performed 
in a standard SYBR green-based assay (ThermoFisher) on the ABI-PRISM 9700HT 
Fast Real-Time PCR System. Primer sequences were as follows: exon 3 forward: 5’ 
TTGGGGAGAGTGAAGTGA-3’, exon 3/4 reverse: 5’ TGGGTCTGGCACATAGAT-3’, 
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exon 12 forward: 5’ GCTGCCTTATGACTCAAG-3’, exon 14 reverse: 5’ 
GCTCCCAGCAAGTTTACA-3’, exon 17 forward: 5’ CCGAGGAATGGAGTTTTT-3’, 
exon 18 reverse: 5’ TGCCTTTCGACACATAGTT-3’.  
Genetic aberrations of B-other cases
Genetic aberrations were determined by array-based comparative genomic hybridization 
and multiplex-ligated probe assays as previously reported.2, 15 As previously, cases with a 
signal intensity of the probe set 208303_s_at above the 90th percentile of the total BCP-
ALL group were classified as CRLF2-high.4
RT-PCR for detection of known fusion genes
RT-PCR was performed on cDNA of 49 BCP-ALL cases from the B-other and BCR-ABL1-
like subtype, including 24 of the 26 patients with high PDGFRA expression identified by 
microarray profiling. Primer sequences are reported in Supplemental Table 1. Forward 
primers were used as previously reported, except for an adaptation in BCR-ex7 forward 
(new sequence: 5’ TACAAGCCTGTGGACCGTGT-3’).16-20 Forward primers for known 
fusion partners of PDGFRA were confirmed to be functional in an RT-PCR using a 
reverse primer located within the partner gene. All forward primers were combined with 
PDGFRA exon 14 reverse (see above), but an additional PCR run with FIP1L1-forward 
combined with PDGFRA-R2 as published by Cools et al.18 PCR products were amplified 
as follows: 2min 50°C, 10min 95°C, five times 8 cycles of 15s 95°C and 1min at 60°C, 
57°C, 54°C, 51°C, or 48°C, followed by 30s at 72°C. PCR products were separated on 
agarose gel and evaluated for bands by visual inspection under UV light. 
Fluorescence in situ hybridization (FISH)
FISH was performed using the FIP1L1/CHIC2/PDGFRA deletion probes by Cytocell 
(Cambridge, UK). Cytospins were made from freshly isolated cells or from viable frozen 
cells after thawing. They were dried and stored at -80°C until used. Prior to hybridization, 
samples were treated with 20 µg/mL pepsin in 0.01 M HCl at 37°C for 10 min and fixated 
in PBS containing 1% formaldehyde and 200 g/L MgCl2 for 10 min. Denaturation was 
performed for 5 min at 75°C and probes hybridized at 37°C overnight. Nuclei were stained 
with DAPI antifade and results evaluated and recorded with a Leica AF6000 workstation 
and Leica LAF LS imaging software version 2.0.0 build 1929 (Wetzlar, Germany). 
Visibility of blue DAPI signals in Figure 2A were enhanced using Adobe Photoshop CS6. 
Targeted locus-amplification (TLA)
The precise methods for targeted locus amplification have been published previously.21 
In brief, viable frozen cells of BCP-ALL cases were thawed and directly used for the 
procedure. Crosslinking and DNA isolation were performed according to manufacturer’s 
instruction. Custom primers were designed by Cergentis (Utrecht, Netherlands) to 
amplify regions of PDGFRA that were previously reported to be involved in structural 
aberrations, and PCR products sequenced by Illumina paired-end sequencing. Raw reads 
in FASTQ format were aligned to GRCh37 using BWA mem. Whole genome coverage in 
a sliding window of 10 kb was calculated using Samtools view, and per base pair coverage 
near the PDGFRA gene using the GATKs DepthOfCoverage tool. Coverage plots in a 
sliding window of 10 kb and 100 bp were then generated using R language. 
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Protein isolation and western blot
Primary BCP-ALL cells and cell lines were treated with recombinant human PDGF-BB 
(#8912, Cell Signaling, Danvers, USA) and inhibitors imatinib (10 µM) and CP673451 (1 
µM, both Selleckchem, Munich, Germany) for the indicated time span and lysed using 
caspase lysis buffer (150 mM NaCl, 50 mM Tris, 10 mM EDTA, 1% Triton-X, 1mM DTT, 
1mM PMSF, 2µg/ml Aprotinin, 1mM Sodium-Pervanadate, and 10mM Sodium-Fluoride, 
all Sigma Aldrich, St. Louis, USA). Nalm6 cells were serum starved for 2 hours, which was 
omitted in primary BCP-ALL cells to avoid massive cell death. Protein concentrations 
were quantified using a BCA assay (Thermo Fisher Scientific, Waltham, USA), and 25µg 
loaded and separated on precast polyacrylamide gels (BioRad, Hercules, USA). Proteins 
were transferred to nitrocellulose membranes using 1.3 A and 25 V for 13 minutes in the 
Bio-Rad Trans-blot Turbo system. Membranes were blocked with 5% BSA (w/v) in TBS 
containing 0.1% Tween-20 (TBST) for 2 h and probed with anti-PDGFRα #3174, anti-
phospho-PDGFRα (Y762) #12022, (both Cell Signaling) or anti-β-actin ab6276 (Abcam, 
Cambridge, UK). Fluorescent-labeled secondary antibodies were obtained from Li-COR 
(Lincoln, USA), and blots were scanned using the Odyssey system (Li-COR). Odyssey 
software version 3.0 was used for image acquisition and signal quantification.
Cell culture, ex vivo drug sensitivity and co-culture model
Cell lines were cultured in RPMI-1640 GlutaMAX supplemented with penicillin, 
streptomycin, and fungizone (all Life technologies, Bleiswijk, Netherlands) and 10% 
(Nalm6) or 20% (EOL1) FCS. Primary BCP-ALL cells were cultured in RPMI-1640 
Dutch modified supplemented with glutamine, insulin, transferrin, selenium, penicillin, 
streptomycin, fungizone, gentamycin, and 20% FCS. For MTT-based ex vivo cytotoxicity 
assays, cells were exposed to a range of Imatinib (100 µM – 0.003 µM) or CP673451 (10 
µM – 0.0003µM) for four days and survival analyzed using 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium (MTT). For ex vivo co-culture assays, MSC were seeded one day 
prior to start. Leukemic cells were cultured at a concentration of 2*106/mL in presence or 
absence of MSC, in presence or absence of 50 ng/mL recombinant human PDGF-BB, and 
with three different concentrations of Imatinib (12.5 µM, 1.6 µM, 0.2 µM) or CP673451 
(1.25 µM, 0.16 µM, 0.02 µM). After four days, cells were harvested and analyzed by flow 
cytometry. Viable leukemic cells were quantified within a fixed volume by combined 
staining for CD19-APC (positive), Annexin-V-FITC (negative, both BioLegend, San 
Diego, USA), and propidium iodide (negative, Sigma Aldrich). The gating strategy was 
as previously reported.13 
Results
PDGFRA expression in pediatric BCP-ALL
Gene expression microarray analysis of 654 pediatric ALL cases of all cytogenetic subtypes 
identified elevated PDGFRA expression in 26 BCP-ALL cases by two different probe sets 
(Figure 1A). The high PGFRA expression levels was confirmed by RT-qPCR in 23 of 
25 tested cases (Figure 1B and Figure S1). All cases belonged to the B-other (n=22) or 
BCR-ABL1-like (n=4) subtype. High PDGFRA was also maintained in xenograft-derived 
cells of a PDGFRA high case, and found in the BCP-ALL cell line Nalm6 (Figure S1). 
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Figure 1: Gene expression of PDGFRA. 
(A) Gene expression of PDGFRA in the genetic subtypes of pediatric BCP-ALL. Expression 
was measured on Affymetrix U133 plus 2.0 GeneChips using two different probe sets. (B) 
Confirmation of PDGFRA mRNA levels by RT-qPCR using primer pairs located in three regions 
of the transcript. Expression values are given relative to RPS20 housekeeping gene. Numbers on 
x-axis represent patient identifiers with reference to the samples used in in vitro experiments. 
*identifies the xenograft-derived sample of patient A.
The FIP1L1-PDGFRA-positive chronic eosinophilic leukemia cell line EOL1 served as a 
positive control in all experiments.22 
Clinical characteristics of PDGFRA expressing BCP-ALL cases
Since high PDGFRA expression was mainly found in the B-other subtype, we restricted 
our analysis of clinical characteristics to this group. Age, white blood cell count (WBC), 
gender, risk stratification arm, and the frequency of relapse, death, and events were not 
significantly different between PDGFRA high and low B-other cases (Table 1). However, 
patients with high PDGFRA expression were more sensitive to prednisolone ex vivo (p = 
0.03, see also Figure S2). Differences in sensitivity towards L-asparaginase and vincristine 
were not statistically significant. 
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Absence of genetic aberrations in the PDGFRA locus
Oncogenic fusions involving the tyrosine kinase domain of PDGFRA are recurrent in 
adult myeloproliferative neoplasms, but have not been reported in pediatric BCP-ALL. 
Using fusion gene specific RT-PCRs, we did not detect any of the six PDGFRA fusions 
reported to date, including PDGFRA fused to FIP1L1, STRN, BCR, CDK5RAP2, ETV6, 
and KIF5B (Table S1).16-20
Novel translocations and other large structural aberrations affecting the PDGFRA locus 
may also be responsible for PDGFRA gene expression. We therefore performed FISH 
with three probes targeting regions upstream of FIP1L1 (green), between FIP1L1 and 
PDGFRA (red) and downstream of PDGFRA (green, see also scheme in Figure 2A). The 
cell line EOL1 served as a positive control, and showed the previously reported pattern 
of one wildtype allele and two alleles with an interstitial deletion (Figure S5). None of the 
tested primary BCP-ALL samples and cell lines with high or low PDGFRA expression 
showed interstitial deletions between FIP1L1 and PDGFRA or split FISH signals (Figure 
2A). The complete set of tested patients with high or low PDGFRA is available in the 
supplemental data published online (Figure S5). 
For a higher resolution of the genomic sequence within and outside of the PDGFRA gene, 
we applied targeted locus amplification to 17 cases for which viable cells were available. 
This technique allows amplification and sequencing of genomic regions that are in close 
proximity to a region of interest.21 Following cross-linking, digestion, and proximity-based 
re-ligation, targeted amplification was performed from a so-called anchor or viewpoint in 
the PDGFRA gene. Reads obtained in the following sequencing step therefore mapped to 
the genomic regions close to the viewpoint. With increasing distance from the viewpoint, 
genomic regions are less likely to be captured by proximity ligation and will yield a lower 
Table 1. Clinical characteristics of B-other patients with high PDGFRA expression. 
“Total” designates number of cases for whom data is available, “cases” designates the number of 
patients carrying presenting the clinical characteristic. Frequencies are calculated from these 
numbers. Fisher’s Exact test p-value is given, significant p-values are printed in bold. Odds ratio is 
given for cases with p ≤ 0.1. WBC: white blood cell count; HR: high risk; Event: Relapse, non-response 
after consolidation phase, or death. LC50: 50% lethal concentration of in vitro drug sensitivity 
testing as described previously, PRED: Prednisolone, VCR: Vincristine, ASP: Asparaginase.
Clinical 
feature
PDGFRA high PDGFRA low 
Total 
(n)
Cases 
(n)
Frequency 
(%)
Total 
(n)
Cases 
(n)
Frequency 
(%) p=
Odds ratio 
(95%-CI)
Age ≥10 22 9 41% 90 30 33% 0,62
WBC ≥50 22 4 18% 90 25 28% 0,43
Male 22 15 68% 90 50 56% 0,34
Treatment 
group HR 22 6 27% 87 39 45% 0,15
Relapse 22 2 9% 90 19 21% 0,24
Event 22 3 14% 90 26 29% 0,18
Death 22 2 9% 90 21 23% 0,24
PRED LC50 
≥ 0.1 µg/mL 7 1 14% 26 18 69% 0,03
0.08 (0.002 
-0.83)
VCR LC50 ≥ 
0.39 µg/mL 7 4 57% 25 15 60% 1
ASP LC50 ≥ 
0.033 µg/mL 7 6 86% 25 18 72% 0,64
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Figure 2: Genomics of PDGFRA high cases and Nalm6. 
(A) Schematic overview and representative results of interphase FISH probing the FIP1L1-PDGFRA 
locus in a case with high and a case with low PDGFRA expression. Red (left panel): probe spanning 
the CHIC2 gene; green (middle panel): probes upstream of FIP1L1 and downstream of PDGFRA, 
respectively. Merge (right panel): Overlay of red and green signal, blue: DNA stained by DAPI. 
(B) Targeted locus amplification performed from two viewpoints within the PDGFRA locus. Bars 
represent the mean coverage over a 10 kb bin plotted on the y-axis, while chromosomal position 
is indicated on the x-axis. Coverage around the viewpoint is capped for data visualization. 14 cases 
with high PDGFRA, one case with low PDGFRA, and two cell lines were tested.
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coverage. In case of translocations with breakpoints close to the viewpoint, coverage 
would increase on another chromosome. In case of interstitial deletions (e.g. causing the 
FIP1L1-PDGFRA fusion gene), sequencing coverage will drop steeply first and then rise 
again on a distant site. Two viewpoints were selected in intron 2 and exon 15 of PDGFRA. 
Using this technique on the positive control EOL1, we confirmed an interstitial deletion 
on chromosome 4 which rearranges FIP1L1 intron 12 to PDGFRA exon 12 (Figure 2B, 
top panel). The coverage pattern and sequence information obtained from Nalm6 and 
primary BCP-ALL samples with high PDGFRA expression did not indicate any genomic 
aberrations (Figure 2B). 
Secondary genetic aberrations in PDGFRA expressing BCP-ALL 
cases
Next, we used MLPA and array CGH data to evaluate the incidence of other genetic 
aberrations that were previously shown to be recurrent in pediatric BCP-ALL (Table 
2). The frequency of deletions in IKZF1, EBF1, RB1, BTG1, and TCF3 did not differ 
significantly between B-other patients with high or low PDGFRA expression. PAX5 and 
CDKN2A and/or B deletions were rare in patients with high PDGFRA (p = 0.01 and p 
= 0.03, respectively), and no loss of the entire chromosome-arm 9p was observed (p = 
0.02). No ETV6 deletion (p = 0.003), high CRLF2 expression (p = 0.04), or chromosome 
21 amplification (p = 0.006) was found in PDGFRA-high patients. In contrast, 63% of 
patients with high PDGFRA expression carried ERG deletions (10/16), compared to 
0% in PDGFRA low B-other cases (0/71, p<0.001). Consequently, all ERG-deleted cases 
expressed high levels of PDGFRA (Figure S6). 
Table 2. Molecular characteristics of B-other patients with high PDGFRA expression. 
The frequency of aberrations in known B-cell differentiation factors and other genes associated with 
BCP-ALL was evaluated by array CGH data and/or MLPA and compared between PDGFRA high 
and low expressing B-other patients. The p-value calculated by a Fisher’s exact test is given. chr21 
aberration: partial or complete amplification of chromosome 21, including germline trisomy. IKZF1 
Δ4-7: deletion of exons 4 to 7 in IKZF1. Odds ratio is only given for significant associations.
PDGFRA high PDGFRA low 
Biological feature Total (n)
Cases 
(n)
Frequency 
(%)
Total 
(n)
Cases 
(n)
Frequency 
(%) p=
Odds ratio  
(95%-CI)
ERG intragenic 
deletion 16 10 63% 71 0 0% <0.001 ∞ (19.1 - ∞)
chr21 amplification 19 0 0% 84 23 27% 0.006 0 (0 - 0.63)
High CRLF2 22 0 0% 90 16 18% 0.038 0 (0 – 0.97)
9p-deletion 19 0 0% 83 19 23% 0.02 0 (0 – 0.82)
ETV6 deletion 22 0 0% 87 23 26% 0.003 0 (0 – 0.57)
PAX5 deletion 22 3 14% 85 36 42% 0.013 0.22 (0.04 – 0.82)
CDKN2A or B 
deletion 22 5 23% 87 43 49% 0.031 0.30 (0.08 – 0.96)
IKZF1 deletion 22 2 9% 85 25 29% 0.057
IKZF1 Δ4-7 22 2 9% 85 5 6% 0.63
EBF1 deletion 22 0 0% 85 4 5% 0.58
RB1 deletion 22 1 5% 86 6 7% 1
BTG1 deletion 22 1 5% 86 8 9%s 0.683
TCF3 deletion 16 1 6% 71 19 27% 0.1
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PDGFRα is actively signaling in BCP-ALL cells
Next, we confirmed protein expression and activation of PDGFRα by western blot, using 
Nalm6 and xenograft-derived material of a PDGFRA-high BCP-ALL case. Nalm6 cells 
were first starved and afterwards stimulated with recombinant PDGFR-ligand PDGF-BB. 
Western blot analysis revealed that the ligand activates the phosphorylation of PDGFRA 
and reduces the total PDGFRA levels (Figure 3). Exposure to the PDGFR inhibitors 
imatinib and CP673451 abrogated the ligand-induced activation of PDGFRA. High 
levels of phosphorylation were also detected in untreated and in ligand-treated primary 
BCP-ALL cells, which were not starved to avoid drastic reduction of cell viability. As in 
the Nalm6 cell line, PDGFR inhibitors clearly reduced phosphorylation of PDGFRα in 
primary BCP-ALL cells (Figure 3B). This effect persisted for at least 30 minutes (Figure 
S7). 
PDGFRα signaling is not essential for the survival of PDGFRA 
expressing BCP-ALL cells
The sensitivity of BCP-ALL cells to PDGFRα inhibition was evaluated in an ex vivo 
co-culture model including bone marrow MSC. This model has been previously 
shown to improve the survival of primary BCP-ALL cells and also serves as a model of 
microenvironment-mediated drug resistance.(13, 14) In co-culture with MSC cell survival 
of PDGFRA-high cells was improved by about 3-fold compared to culture without MSC 
(Figure S8). A smaller benefit was observed for PDGFRA-low expressing cells. 
The cell line EOL1 was highly sensitive to PDGFR inhibitors (imatinib and CP673451) in 
culture with and without MSC, while Nalm6 showed reduced viability only at the highest 
inhibitor concentration (Figure 4A). Primary BCP-ALL samples with high PDGFRA 
expression were marginally sensitive to imatinib, but not to CP673451, in mono-culture 
(Figure 4B, left side, red symbols) and in co-culture with MSC (Figure 4B, right side). 
No cytotoxic effect of PDGFR inhibitors was observed in cases with low PDGFRA 
expression (Figure 4B blue symbols). For Nalm6 and three BCP-ALL samples with 
sufficient material, the assay was repeated with recombinant human PDGF-BB included. 
Figure 3: Western blot for PDGFRA activation. 
Western blot for phosphorylated (Y762) and total PDGFRA protein in (A) the cell line Nalm-6 
and (B) patient derived xenograft cells of patient A (labeled A*). Cells were treated with 10ng/
mL recombinant human PDGF-BB for 10 minutes, either with or without 10µM Imatinib or 1µM 
CP673451. Arrow heads indicate the expected band. Total protein load was analyzed by staining for 
β-actin.
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Figure 4: Ex vivo sensitivity of cell lines and primary leukemic cells to PDGFR inhibitors in an 
in vitro co-culture model. 
(A) Cell lines and (B) primary leukemic cells were cultured with or without MSC and exposed to a 
range of Imatinib (0.2µM – 1.6µM – 12.5µM) or CP673451 (0.02µM – 0.16µM – 1.25µM) for four 
days. Cell survival was analyzed by flow cytometry and is depicted relative to the untreated control. 
Vehicle represents the respective vehicle control for imatinib (water) or CP673451 (DMSO) treated 
conditions. 
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This ligand exposure did not sensitize to PDGFR inhibition (Figure S9). Therefore, the 
reduction in phosphorylated PDGFRα upon exposure to inhibitors (Figure 3) does not 
coincide with induction of cell death.
Discussion
Therapies targeting oncogenic signaling pathways in addition to standard chemotherapy 
may be a treatment strategy for children with BCP-ALL who respond poorly or relapse. 
It may also be able to replace highly toxic agents and reduce side effects. Here, we have 
identified a group of BCP-ALL cases with high expression of the receptor tyrosine 
kinase PDGFRα, which we subsequently evaluated as treatment target. Two thirds of the 
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cases carried ERG-deletions, and vice versa all ERG-deleted cases show high PDGFRA 
expression. Therefore, high PDGFRA expression likely characterizes the newly discovered 
DUX4-rearranged subtype with frequent ERG-deletions.8-10
Western blot experiments in cell line and primary BCP-ALL cells showed ligand-
dependent activation of PDGFRα and inhibition by imatinib and CP673451. However, 
ex vivo drug testing by means of a previously established co-culture model showed that 
the activation of PDGFRα is not predictive for sensitivity to these inhibitors. Clinical 
baseline characteristics of PDGFRA-high cases were not significantly different from 
those of B-other cases with low PDGFRA expression, although the small group size may 
have limited the analysis. Nonetheless, we found a marked ex vivo sensitivity towards 
prednisolone in PDGFRA-high cases. This is in line with the good prognosis reported for 
ERG-deleted/DUX4-rearranged leukemia.5, 8, 9
Oncogenic fusions of tyrosine kinases other than BCR-ABL1 fusions occur in about 3% 
of BCP-ALL cases and are currently being evaluated as treatment targets.23, 24 Fusion 
genes involving PDGFRA have been described in different forms of myeloproliferative 
neoplasms, and fusion genes of the closely related PDGFRB are recurrently found in 
BCR-ABL1-like BCP-ALL.18, 25-28 These cases are routinely and successfully treated with 
imatinib. Amplifications, rearrangements, and intragenic deletions of PDGFRA have 
been found in glioblastoma multiforme.29 Amplification of PDGFRA in these cases 
results in overexpression, which is sufficient for constitutive activation.30 Interestingly, 
imatinib is also not an effective therapy in these patients.31 In the present study, we did 
not detect genomic aberrations that could explain high PDGFRA expression: Fusion-
specific PCRs to all known translocations were negative, FISH to the genomic region 
around FIP1L1 and PDGFRA showed no interstitial deletion or translocation affecting 
the PDGFRA locus, and targeted locus amplification revealed no structural aberrations 
affecting the PDGFRA gene. Furthermore, the validation of PDGFRA transcript levels 
by RT-qPCR showed consistent results for primer pairs designed to the 5’, middle, and 3’ 
located part of the transcript. This suggests that the PDGFRA transcript is intact and not 
shortened due to alternative splicing or gene fusions. The PDGFRα protein detected on 
western blot was detected at the expected molecular weight. Taken together, these results 
support the conclusion that the here characterized group of patients expresses wildtype 
PDGFRA transcript and protein. 
BCP-ALL cases with high levels of PDGFRA showed few aberrations in PAX5 and 
CDKN2A/B, no aberrations in the CRLF2 pathway, and no gains in chromosome 21. 
Rather, they are characterized by frequent ERG-deletions. ERG-deleted cases are known to 
be limited to a subgroup of BCP-ALL cases with a characteristic gene expression profiles.7 
This so-called R6 cluster, which includes but is not limited to ERG deleted cases, has 
recently been suggested to represent the newly identified DUX4-rearrangements.8 The 
identification of DUX4-rearrangements on genomic level is challenging due to varying 
integration sites and many repeats in the genome. Transcript-directed assays are hindered 
by a high GC content and high homology, and our attempts to detect DUX4 transcripts 
have failed. Therefore direct evidence linking DUX4-rearrangements and high PDGFRA 
expression is lacking, but several indications exist. Yasuda et al. have shown that Nalm6 
carries a DUX4-rearrangement.9 In addition, we evaluated the extensive dataset on DUX4 
DUX4-rearranged leukemia published by Zhang et al.10 In their analysis, PDGFRA is 
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Supplemental Data 
Supplemental Table 1: Overview of fusion gene specific RT-PCRs for PDGFRA-rearrangement.
Primer pairs used to detect previously reported rearrangements of PDGRFA. 
Fusion 
partner
Forward primer Reverse primer Tested 
samples (n)
FIP1L11 ACCTGGTGCTGATCTTTCTGAT TGAGAGCTTGTTTTTCACTGGA 49
FIP1L11 ACCTGGTGCTGATCTTTCTGAT GCTCCCAGCAAGTTTACA 49
STRN2 TCTGAGTTAACAGATTCTGCCTC GCTCCCAGCAAGTTTACA 49
BCR3 TACAAGCCTGTGGACCGTGT GCTCCCAGCAAGTTTACA 49
CDK5RAP24 CAAAGGAGACTGCACCATCCGT GCTCCCAGCAAGTTTACA 49
ETV65 ACTGTAGACTGCTTTGGGATTAC GCTCCCAGCAAGTTTACA 49
KIF5B6 TGAACAGCAGATCCAGAGCCATA GCTCCCAGCAAGTTTACA 49
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Supplemental Figure S1: RT-qPCR for PDGFRA. RT-qPCR for PDGFRA mRNA levels in 
primary BCP-ALL samples, cell lines, and primary MSC with high (grey background) or low (white 
background) expression levels measured on gene expression arrays. *marks samples that showed 
high levels on gene expression arrays but not by RT-qPCR.
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Supplemental Figure S2: Ex vivo drug sensitivity towards the 3 major therapeutic agents with 
prognostic relevance. LC50-values for prednisolone, vincristine, and L-asparaginase in primary 
B-other BCP-ALL cases with high or low PDGFRA expression. Ex vivo sensitivity was determined 
by means of an MTT assay as previously described and compared using a Mann-Whitney U test.1 
**: p<0.01
Low PDGFRA (n=26) High PDGFRA (n=7)
0.001
0.01
0.1
1
10
100
LC
50
 P
re
dn
is
ol
on
e 
(µ
g/
m
L)
Low PDGFRA (n=25) High PDGFRA (n=7)
0.001
0.01
0.1
1
10
100
LC
50
 V
in
cr
is
tin
e 
(µ
g/
m
L)
Low PDGFRA (n=25) High PDGFRA (n=7)
0.001
0.01
0.1
1
10
100
LC
50
 L
-A
sp
ar
ag
in
as
e 
(IU
/m
L)
VincristinePrednisolone
L-Asparaginase
** n.s.
n.s.
120
Supplemental Figure S4: PDGFRA gene expression in ERG-deleted B-other cases. PDGFRA gene 
expression was determined by the same probe sets as presented in Figure 1, and groups separated 
according to the deletion status of ERG. 
Supplemental Figure S3: Complete FISH results of tested BCP-ALL samples. (A) EOL-1 and 
Nalm-6 cell lines. (B) 25 of 26 patient samples with high PDGFRA expression. (C) 10 representative 
cases of BCP-ALL cases with low PDGFRA expression. Figure S6
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Supplemental Figure S5: Effect of PDGFR inhibition on primary BCP-ALL cells cultured with 
and without ligand. Nalm6 and three primary BCP-ALL samples with high PDGFRA expression 
(patients I, IV, and V) were tested in mono- and co-culture for sensitivity towards PDGFR inhibitors 
as in Figure 2C, but with or without recombinant ligand (50ng/mL PDGF-BB). Each dot represents 
one patient, matched samples with or without PDGF-BB are connected by lines. Dashed line 
indicates 100% survival relative to the untreated control, ‡ indicates PDX sample of patient I, which 
was used for western blot analysis in Figure 2A.
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Abstract
The FGF receptor signaling pathway is recurrently involved in leukemogenic processes. 
Oncogenic fusions of FGFR1 with various fusion partners were described in myeloid 
proliferative neoplasms, and overexpression and FGFR3 mutations are common in 
multiple myeloma. In addition, fibroblast growth factors are abundant in the bone 
marrow, and they were shown to enhance the survival of acute myeloid leukemia cells. 
Here we investigate the effect of FGFR stimulation on pediatric BCP-ALL cells in vitro, 
and search for mutations with targeted next-generation sequencing of mutational 
hotspots in FGFR1, FGFR2, and FGFR3. In 481 primary BCP-ALL cases, 28 samples 
from 19 unique relapsed BCP-ALL cases, and twelve BCP-ALL cell lines we found that 
mutations are rare (4/481 = 0.8%, 0/28 and 0/12) and do not affect codons which are 
frequently mutated in other malignancies. However, recombinant ligand FGF2 reduced 
the response to prednisolone in many BCP-ALL cell lines in vitro. We therefore conclude 
that FGFR signaling represents a possibly important signaling pathway by which the 
microenvironment protects BCP-ALL cells from chemotherapy, but that activating 
mutations in this receptor tyrosine kinase family are very rare. 
Introduction
Despite generally excellent outcome for children with pediatric B-cell precursor acute 
lymphoblastic leukemia (BCP-ALL), therapeutic options are limited for refractory or 
relapsed cases. Small molecule inhibitors of oncogenic pathways, such as those targeting 
ABL-, MEK, and JAK kinase families, have shown (pre-)clinical efficacy and may be 
added to chemotherapy in the future. Here we studied the role of fibroblast growth factor 
receptor (FGFR) signaling in pediatric BCP-ALL. 
FGFs are not only essential in hematopoietic development, but also influence bone 
formation by regulating expansion and stemness of mesenchymal stromal cells.1,2 FGF2 
is expressed in the hematopoietic and stromal compartments of the bone marrow.1 
FGFR fusions have been described in atypical myeloproliferative disorders which may 
involve lymphoma or present as BCP-ALL.3 High FGFR3 expression is a hallmark of 
t(4;14)-positive multiple myeloma, and activating mutations are recurrently detected 
in this context.4-6 Furthermore, FGFR signaling has been shown to contribute to drug 
resistance in chronic myeloid leukemia.7 Thus, oncogenic FGFR signaling contributes 
to hematologic malignancies, but so far information on its role in pediatric BCP-ALL is 
limited. We therefore applied a customized targeted sequencing approach for mutational 
hotspots of FGFR1, FGFR2, and FGFR3 and evaluated the effect of recombinant FGF2 on 
in vitro prednisolone sensitivity in BCP-ALL cell lines.
Methods
Patient material and cell lines
The study comprised children with BCP-ALL with age at diagnosis ranging from 0 
to 18 years. Written informed consent was obtained from parents or guardians, and 
institutional review boards approved the use of excess diagnostic material for research 
purposes. Clinical characteristics were kindly provided by the Dutch Childhood 
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Oncology Group (the Hague, Netherlands). These studies were conducted in accordance 
with the Declaration of Helsinki. Mononuclear cells were isolated using density gradient 
centrifugation with Lymphoprep (Axis Shield, Norway) as previously described.8 All 
samples contained at least 90% leukemic blasts. Cytogenetic subtypes were determined by 
karyotype, fluorescence in-situ hybridization (FISH), and/or fusion-gene specific PCR. 
BCR-ABL1-like cases were identified using microarray gene expression profiling by the 
means of a 110 probeset classifier.9 Leukemic cell lines were obtained from the German 
Collection of Microorganisms and Cell Cultures (DSMZ, Germany) and routinely 
validated by DNA fingerprinting. Unless indicated otherwise, all cell lines were cultured 
in RPMI-1640 supplemented with 10 to 20% fetal calf serum and penicillin, streptomycin 
and fungizone (all Life technologies). 
In vitro cytotoxicity assays
The IC50 of prednisolone was determined in an MTS assay based on a six-step range 
from 250 to 0.08 µg/mL (Nalm6, 697, RCH-ACV, MHH-CALL3) or 1 to 0.003µg/mL 
(MHH-CALL2, MHH-CALL4, SupB15, Tom1). For these assays, cells were tested for 
viability in the prednisolone concentration range with or without 50ng/mL recombinant 
human FGF2 (Bio-Rad) and with or without 1µM AZD4547 (Selleckchem). After four 
days incubation at 37°C and 5% CO2, cell viability was evaluated using MTS. LC50-values 
were calculated as the prednisolone concentration at which 50% of cells survived relative 
to the respective prednisolone-free control of each condition. To avoid redundancies with 
abundant cytokines in fetal calf serum (FCS), these assays were performed under reduced 
serum conditions (2% FCS for cells usually cultured in 10% FCS, and 4% FCS for those 
usually cultured with 20% FCS). Sensitivity towards AZD4547 was measured similarly, 
but at normal serum concentrations (10µM-0.3nM).
Sequencing and code availability
DNA was isolated using Trizol reagent (Life Technologies), or in case of three cell lines 
using the DNeasy Kit (Qiagen). For TruSeq Custom Amplicon sequencing (Illumina, 
USA), sequencing libraries were prepared from 100-250ng genomic DNA. Successful 
library preparation was confirmed using the Labchip GX genomic analyzer (Caliper Life 
Sciences Benelux N.V., the Netherlands). Samples were then pooled equimolarly and 
sequenced on an Illumina MiSeq in paired-end reads of 250bp each. Targeted regions 
and the analysis script can be provided upon request. Next, sequence reads were aligned 
to the 1000 genomes human reference sequences (version b37, GATK resource bundle, 
Broad Institute, USA) using BWA v0.7.1010 and GATK indel realigner v.3.3-0. Single 
nucleotide variants were called with Freebayes v0.9.18-2411, Varscan v.2.3.712, Bcftools 
v1.013, and GATK v3.3-014. The resulting variant call format files were annotated using 
snpEff and snpSift v.4.1a15 and dbNSFP v.2.716. For reliable detection of high-confidence 
mutations, variants were filtered based on several criteria: For each sample, variants were 
excluded if they were reported by only one caller, coverage was <100 reads, or <20 reads 
supported the variant allele. Overall, recurrent variants (n≥10) were excluded if variant 
allele frequency (VAF) never exceeded 2% or if the distribution was unequal between 
runs. Furthermore, variants were only considered if they were non-synonymous, unlikely 
to be germline variants and not known SNPs. Mutational hotspots are indicated in Figure 
1A and were obtained from literature and the COSMIC database (v79, released 14th 
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November 2016).6
Results
Using the TruSeq Custom Amplicon technique we screened for mutations in 481 primary 
BCP-ALL cases at initial diagnosis, in 28 relapse BCP-ALL samples (representing 19 
unique patients) and in twelve BCP-ALL cell lines. The regions covered by the custom 
amplicons are indicated in Figure 1A, and were selected to cover previously reported 
mutational hotspots of FGFR1, FGFR2, and FGFR3 (indicated as black bar above 
each gene). In 481 unique patients we only found 4 non-synonymous FGFR variants 
(0.8%). These variants were detected in samples taken at initial diagnosis, one FGFR1 
(D129A) mutation, two FGFR2 mutations (V274I and D522N), and one FGFR3 (F384I) 
mutation (Figure 1A, above gene schematics). No mutations were detected in the B-cell 
precursor ALL cell line panel or in the 28 relapse samples of 19 unique patients. Only 
the FGFR1 D129A and FGFR2 V274I mutations were predicted to be deleterious to the 
protein function by the SIFT, Polyphen, LRT, and MutationTaster tools.17 Variant allele 
frequencies (VAF) varied between 8.4% (FGFR2 D522N) and 52.9% (FGFR3 F384I). 
None of these mutations represents a frequently observed pathogenic mutation, such as 
those reported in multiple myeloma, according to literature and the COSMIC database 
(v79, indicated below each gene in Figure 1A). 
FGFR variants occurred in two ETV6-RUNX1-rearranged cases, one BCR-ABL1-like 
with a JAK2 translocation, and one high hyperdiploid, and high white blood cell count 
(≥50 cells/nL) was found in 2/4, high minimal residual disease (percentage blasts in bone 
marrow on day 33 of therapy ≥0.1% relative to level at diagnosis) in 1/3 (1 without data 
available). The JAK2 translocated case with the FGFR1 D129A mutation experienced a 
relapse 1 year after diagnosis. In conclusion, FGFR variants occurred in various subtypes 
and patients did not consistently present with poor or good prognostic factors.
FGFR signaling has been previously implicated in therapy resistance.7 To evaluate the effect 
of FGF receptor stimulation on BCP-ALL cells, we evaluated the effect of recombinant 
FGF2 on the cytotoxicity of the spearhead drug prednisolone in vitro. In four of the eight 
tested cell lines exposure to 50ng/mL recombinant human FGF2 resulted in two- to three-
fold higher IC50-values for prednisolone (Figure 1B). The resistance induced by the 
ligand FGF2 was reversed by exposure to 1 µM of FGFR inhibitor AZD4547. AZD4547 as 
single agent reduced viability in BCP-ALL cell lines at higher concentrations (5 to 20µM, 
Figure 1C), except for Nalm6 and RCH-ACV cell line (20-40% cell death induced at 1 µM 
AZD4547). Therefore, the prednisolone IC50-values were corrected for cell viability of 
prednisolone-free conditions to account for possible effects of FGF2 and/or AZD4547 on 
cell proliferation and survival. Notably, the FGFR inhibitor was not effective in primary 
leukemic cells carrying a D129A point mutation in FGFR1 (Figure 1D). Unfortunately no 
viable leukemic cells were available for other mutated BCP-ALL cases.
Discussion
Here we screened 481 pediatric BCP-ALL cases at initial diagnosis, 19 relapse BCP-ALL 
cases, and 12 BCP-ALL cell lines for variants in FGFR1, FGFR2, and FGFR3. We found 
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Figure 1: FGFR signaling is not essential to in pediatric BCP-ALL cells, but can reduce 
prednisolone sensitivity. 
(A) Schematic protein structure of the FGFR genes and the observed variants. Black bars indicate 
the regions covered by targeted amplicon sequencing. Variants printed in bold above the scheme 
represent variants observed in this study, variants below represent those frequently reported in the 
COSMIC database. Ig: Immunoglobulin-like domain, AD: acidic domain, TMD: transmembrane 
domain, TKD: tyrosine-kinase domain, A-loop: activation loop. (B) Effect of 50ng/mL recombinant 
human FGF2 on prednisolone sensitivity (IC50-values) in BCP ALL cell lines and reversal by the 
FGFR-inhibitor AZD4547 (1µM). Fold-change in prednisolone IC50 is depicted on the y-axis. Left: 
all evaluated cell lines in detail, right: mean fold changes of Nalm6, 697, RCH-ACV, Tom1, and 
MHH-CALL3 combined, ** p= 0.0012 by Wilcoxon matched pairs test.(C) In vitro response of BCP-
ALL cell lines to the FGFR-inhibitor AZD4547. Dashed line: 50% survival; Cytogenetic subtypes are 
indicated in brackets: DUX4: DUX4-rearranged leukemia, TP: TCF3-PBX1-rearranged, BA: BCR-
ABL1-rearranged, HD: high hyperdiploid karyotype, CRLF2: high CRLF2 expression, ER: ETV6-
RUNX1-rearranged. (D) Ex vivo response of primary BCP-ALL cells carrying an FGFR1 D129A 
mutation.
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a low frequency of variants among patients at initial diagnosis, and no variants in the 
relapse cohort or in cell lines. These data indicate that FGFR mutations are very rare in 
pediatric BCP-ALL. Due to the low incidence and a small relapse cohort, it remains to be 
determined whether these rare mutations have an effect on the clinical prognosis. With 
the limited data available, we conclude that this does not seem to be the case. 
The phenotypic effect of the described mutations is yet unclear, however, all mutations 
locate within functional domains of the FGFR proteins (Figure 1A, colored boxes). The 
FGFR1 D129A mutation affects the so-called acid box of the receptor, which has been 
shown to be essential for auto-inhibition and interaction with adhesion molecules.18,19 The 
FGFR2 mutations V274I and D522N locate in the ligand-binding immunoglobulin-like 
(Ig) domain and the tyrosine kinase domain (TKD), respectively. They might therefore 
alter ligand-binding and kinase activation. Last, the FGFR3 F384I mutation is located in 
the transmembrane domain (TMD), which is frequently affected by mutations that cause 
aberrant receptor dimerization (e.g. by insertion of a cysteine). Of note, a rare F384L SNP 
at the same location has been reported and was also found in our screen. No functional 
consequences have been reported for this SNP, and the high similarity between leucine 
and isoleucine suggests no effect of the F384I variant on FGFR3 function.20
Given the previous implications of FGFR signaling in resistance, we evaluated its effect 
on the efficacy of prednisolone in vitro.7 Our data indicate that the ligand FGF2 induced 
resistance to glucocorticoids which could be reversed by inhibition of FGFR. Traer et al. 
suggested that reactivation of the MAPK pathway by FGFR3 accounts for FGF-mediated 
resistance of BCR-ABL1-rearranged chronic myeloid leukemia cells to imatinib. In 
line with this observation, we and others have previously shown that MAPK pathway 
mediated signaling can also increase resistance towards prednisolone.21-23 Downstream-
located MAPK signaling may therefore be the mediator of FGF-induced glucocorticoid 
resistance, which could provide an alternative target for sensitization towards prednisolone 
in otherwise resistant cases. 
Together, our data demonstrates that FGFR-activating lesions are rare in newly diagnosed 
pediatric BCP-ALL, and were not enriched at the time of relapse. Activating mutations 
which are frequently observed in multiple myeloma or solid cancers were not observed 
in 481 newly diagnosed nor in 19 relapsed BCP-ALL cases.24 As such FGFR activating 
mutations were virtually absent, FGF2 ligand-mediated activation of FGFR-signaling 
may be more relevant for the sensitivity of leukemic cells to prednisolone.
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Abstract
Still 20% of pediatric acute lymphoblastic leukemia (ALL) patients relapse on or after 
current treatment strategies. Treatment failure is associated with resistance to prednisolone. 
We aimed to find new druggable targets that modulate prednisolone resistance. We 
generated microarray gene expression profiles of 256 pediatric ALL patient samples and 
identified a 3.4-fold increase in epithelial membrane protein 1 (EMP1) expression in in 
vitro prednisolone-resistant compared with -sensitive patients (p=0.003). EMP1 silencing 
in six precursor-B ALL (BCP-ALL) and T-ALL cell lines induced apoptosis and cell-cycle 
arrest leading to 84.1±4.5% reduction in survival compared with non-silencing control 
transduced cells (non-silencing control short hairpin, shNSC) (p=0.014). Moreover, 
EMP1 silencing sensitized to prednisolone up to 18.8-fold (p<0.001). EMP1 silencing 
also abrogated migration and adhesion to mesenchymal stromal cells (MSCs) by 78.3±9.0 
and 29.3±4.1% compared with shNSC (p<0.05). We discovered that EMP1 contributes to 
MSC-mediated prednisolone resistance. Pathway analysis indicated that EMP1 signals 
through the Src kinase family. EMP1-high BCP-ALL patients showed a poorer 5-year 
event-free survival compared with EMP1-low patients (77±2% vs. 89±2%, p=0.003). 
Multivariate analysis taking along white blood cell count, age, prednisolone resistance 
and subtype identified EMP1 as an independent predictor for poor outcome in BCP-ALL 
(p=0.004, hazard ratio: 2.36 (1.31–4.25). This study provides preclinical evidence that 
EMP1 is an interesting candidate for drug development to optimize treatment of BCP-
ALL. 
Introduction
Survival rates of pediatric acute lymphoblastic leukemia (ALL), the most common 
pediatric cancer, have improved enormously over the past decades. However, still 20% 
of B-cell precursor ALL (BCP-ALL) and 25% of T-ALL patients relapse during or shortly 
after completion of contemporary treatment protocols for newly diagnosed pediatric 
ALL.1 Prednisolone is the spearhead drug used in multi-drug treatment of pediatric ALL 
and in vivo and in vitro response to prednisolone predicts long-term clinical outcome.2 
Moreover, relapsed ALL patients acquire prednisolone resistance disproportional to 
other anti-leukemic agents.3 It is therefore necessary to find new druggable targets to 
reverse prednisolone resistance. Prednisolone, a glucocorticoid, diffuses passively into 
the cell, where it binds the glucocorticoid receptor. Consequently, glucocorticoid receptor 
chaperone proteins are released whereafter glucocorticoid receptor dimers can be formed. 
Dimerized glucocorticoid receptor acts as a transcription factor by either binding to 
positive or negative glucocorticoid response elements in the DNA, or by binding to 
other transcription factors, such as NF-κB or AP-1.4 As a result, a large number of genes 
are either turned on or off. Due to this complexity, still little is known about the exact 
cause of resistance to glucocorticoids. To examine the gene expression pattern that might 
cause prednisolone resistance in more detail, we performed microarray analysis of 256 
children with newly diagnosed ALL that were tested in vitro to be prednisolone sensitive, 
intermediate resistant or resistant. We identified epithelial membrane protein 1 (EMP1) as 
one of the most discriminative genes. EMP1 is a small hydrophobic four-transmembrane 
glycoprotein of 160 amino acids.5 EMP1 has been implicated as a cell junction protein at 
138
the plasma membrane;6,7 however, little is known about the exact function. It has been 
shown to be involved in cell proliferation, is identified as a c-Myc target,8 is correlated with 
brain9 and breast carcinogenesis,10 and was demonstrated to be a biomarker of gefitinib 
resistance in non-small lung carcinoma.11 We are the first to identify a significant role for 
EMP1 in pediatric ALL. We have discovered that silencing of EMP1 inhibited leukemic 
survival, sensitized leukemic cells to prednisolone and abrogated migration and adhesion 
to mesenchymal stromal cells (MSCs). Moreover, we identified EMP1 as an independent 
predictor for poor outcome in BCP-ALL. Taken together, these results point to EMP1 
as a potential new druggable target to tackle leukemia and potentially increase current 
survival rates.  
Materials and Methods
Cell culture and primary cells
Bone marrow and peripheral blood samples were collected from children alleged 
to suffer from newly diagnosed ALL and before start of initial therapy. Normal bone 
marrow samples were obtained from children who were suspected for a malignancy 
but turned out to be negative for a hematological disorder. Informed consent was 
given by patients or parents/guidance to use excess of diagnostic material for research 
purposes as approved by the local institutional review board. Mononuclear cells were 
isolated by lymphoprep density gradient centrifugation, as previously described.12,13 
Only samples with ≥90% leukemic blasts upon processing were used in the present 
study. The genetic subtype of each patient, that is, hyperdiploid (>50 chromosomes), 
ETV6-RUNX1+, TCF3-PBX1+, MLL- rearrangement, BCR-ABL1+, BCR-ABL1-like, or 
B-other (negative for aforementioned genomic lesions) was determined by means of 
fluorescent in situ hybridization, PCR and by utilizing the 110-probeset classifier.14 An 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (see below 
for details) was used to select cases being in vitro highly sensitive, intermediate resistant 
or highly resistant to prednisolone; 74, 60 and 42 of BCP-ALL cases and 27, 34 and 19 
T-ALL respectively, overall 256 samples. In total, data obtained from 373 BCP-ALL and 
116 T-ALL cases were included to study the prognostic value of EMP1 expression levels. 
All leukemic cell lines and HEK293T cells were obtained from DSMZ (Braunschweig, 
Germany). Reh, 697, NALM6 and SEM are BCP-ALL cell lines with an ETV6-RUNX1, 
TCF3-PBX1, t(5;12) and an MLL-AF4 rearrangement, respectively. Jurkat is a tetraploid 
T-ALL and SupT1 is a T-lymphoblast cell line. All cell lines were resistant to prednisolone 
as determined by an MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)- 2H-tetrazolium) assay (Supplementary Table S2). HEK293T, a human 
embryonal kidney cell line, was used for the production of viral particles. hMSC-TERT 
cells are human MSCs modified with an increased telomerase activity and were a gift of 
Dr D Campana, St. Jude Childrens’ Research Hospital, Memphis, USA.15 Cell viability 
and cell count were determined by a trypan blue exclusion staining assay and analyzed by 
MACSQuant flow cytometer (Miltenyi Biotec, Leiden, Netherlands). 
Microarrays 
RNA was extracted by means of Trizol isolation (Invitrogen, Bleiswijk, Netherlands) 
according to the manufacturer’s protocol and RNA quality and integrity determined with 
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the 2100 bioanalyzer (Agilent, Amstelveen, Netherlands). The Affymetrix One-Cycle 
cDNA Synthesis kit (Santa Clara, CA, USA) and the GeneChip IVT Labeling kit (Santa 
Clara, CA, USA) were used to synthesize cRNA. RNA processing and hybridization to the 
Affymetrix U133 Plus 2.0 GeneChip oligonucleotide microarray were performed according 
to the manufacturer’s protocol. Gene-expression values were calculated with Affymetrix 
Microarray Suite version 5.0. Expression signals were scaled to the target intensity of 500 
and log transformed. Only arrays with scaling factor <10 and GAPDH cRNA integrity 
(3’/5’) <3 were used for subsequent analysis. All arrays were Robust Multichip Average 
and variance stabilization and normalization 2 (VSN2) normalized16 and differentially 
expressed genes between in vitro prednisolone-resistant and prednisolone-sensitive 
patients were identified with Limma R Package taking along prednisolone intermediate 
patients and using subtype as a confounder in the statistical environment R, version 
2.15.0. Correction for multiple tests was performed according to the false discovery rate 
method.17 All EMP1 probe sets were statistically differentially expressed between in vitro 
prednisolone-sensitive and -resistant patients. Probeset 201324_at was used for further 
analysis, as this probeset showed the most reliable differential expression between in vitro 
prednisolonesensitive and -resistant BCP-ALL patients.
Lentiviral production and infection
pLKO.1 Mission short-hairpin RNA vectors were purchased from Sigma- Aldrich 
(Zwijndrecht, Netherlands), that is, a non-silencing control SHC002 (shNSC) and 
TRCN0000117944 against EMP1 (shEMP1). Lentiviral helper pMD2.G (Addgene 
plasmid 12259) and psPAX2 (Addgene plasmid 12260) were provided by Prof. D Trono 
(Geneva, Switzerland). Infection occurred during 45 min 1800 r.p.m. spin-oculation of 
0.5×106 cells/ml with 2.5 transducing units/cell (Sigma, Zwijndrecht, Netherlands). After 
24 h, infected cells were positively selected for puromycin resistance. Quantitative RT-
PCR RNA was extracted using a Rneasy minikit (Qiagen, Venlo, Netherlands) according 
to the manufacturer’s protocol, whereafter cDNA was synthesized. EMP1 mRNA levels 
were quantified by incorporation of SYBR Green (Thermo Scientific, Breda, Netherlands) 
by quantitative real-time PCR (Applied Biosystems 7900HT, Life Technologies, Bleiswijk, 
Netherlands). Primers for EMP1 were 50-TTGCTGGCTGGTATCTTT-30 (forward) 
and 50-TTGAGGGCATCTTCACTG-30 (reverse). Primers used for the reference 
gene RPS20 were 50-AAGGGCTGAGGATTTTTG-30 (forward) and 50-CGTTGCG 
GCTTGTTAG-30 (reverse). Protein isolation and western blot analysis Proteins were 
isolated with protein lysis buffer, details see Supplementary information. Subsequently, 
the supernatant was used for the luminex (see below) and the remaining pellet harboring 
membrane proteins was sonicated on ice (Branson Sonifier 250) in Laemmli Sample 
Buffer. Protein concentrations were quantified with the 2-D Quant Assay (Amersham 
Biosciences, Piscataway, NJ, USA). Protein (25 mg) was loaded on Bio-Rad Mini-Protean 
gels (TGX pre-cast anyKD) and transferred onto nitrocellulose membranes (Bio-Rad, 
Veenendaal, Netherlands). Membranes were blocked with 5% bovine serum albumin 
and probed with 1:200 anti-EMP1 (Santa Cruz, Heidelberg, Germany; sc-50467) and 
anti-b-actin 1:20 000 (Abcam, Cambridge, UK; ab6276) in 5% bovine serum albumin, 
followed by IRDye 800CW- and IRDye 680CW-labeled secondary antibody (Li-COR, 
Leusden, Netherlands), respectively. Protein levels were quantified using the Odyssey 3.0 
application software (Li-COR). 
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Luminex 
Protein phosphorylation was determined with the 9-plex Multi-Pathway Magnetic Bead 
Panel (Millipore #46-680MAG, Amsterdam, Netherlands) and Milliplex 8-plex Human 
Src Family kinase kit (Millipore #48-650MAG) following the manufacturer’s protocol. To 
both kits, b-Tubulin beads (Millipore #64-713MAG) and GAPDH beads (Millipore #46-
667MAG) were added to correct for protein load. See Supplementary information for 
detailed information. Apoptosis measurement Cell viability was assessed with an Annexin 
V/Propidium iodide staining. Fractions of Annexin V/Propidium iodide double-positive 
and Annexin V single-positive cells were quantified on a MACSQuant flow cytometer 
(Miltenyi Biotec).
Cell-cycle distribution assay 
Cell-cycle distribution was analyzed using the FITC BrdU Flow Kit (B&D Pharmingen, 
Breda, Netherlands) following the manufacturer’s instructions. See Supplementary 
information for detailed information. 
In vitro drug-resistance assay
Cellular cytotoxicity of prednisolone (Bufa Pharmaceutical Products, Uitgeest, 
Netherlands) was determined by the in vitro MTT assay for patients’ samples and the 
MTS assay for cell lines.2,13 See Supplementary information for detailed information. 
Cell adhesion assay
Subconfluent (80%) hMSC-TERT cells were irradiated with 30 Gy and co-cultured either 
in a 6-well plate with 2×106 Maroon-labeled (Cellvue, eBiosciences, Vienna, Austria) 
Reh cells in plain AIMV (Gibco, Life Technologies, Bleiswijk, Netherlands) for 24 h in 
the case of flowsort experiments, or overnight in a 24-well plate with 0.4×106 leukemic 
cells in plain AIMV (Gibco) in the case of adhesion experiments of EMP1-silenced cells. 
Hereafter, non-adherent leukemic cells were harvested from the supernatant (suspension 
cells), and adherent leukemic cells were harvested by trypsinizing the supernatant-
depleted hMSC-TERT layer with Trypsin-EDTA (Gibco) for 5 min at 37°C, 5% CO2. 
Suspension and adherent cells were quantified both by trypan blue exclusion assays 
and by the MACSQuant flow cytometer. In the case of the flowsort experiment, the 
adherent Maroonlabeled leukemic cells were separated from unlabeled hMSC-TERT 
cells by fluorescence activated cell sorting (BD Biosciences FACSAria cell sorter, Breda, 
Netherlands) and total RNA of the suspension and adherent cells was isolated. 
Transwell migration assay
Subconfluent hMSC-TERT layers were cultured in a 24-well plate at 37°C, 5% CO2, 
whereafter they were irradiated with 30 Gy and placed on plain AIMV (Gibco) 48 h 
before migration assay. In indicated experiments, medium was collected from hMSC-
TERT layers after 48 h of culture and was subsequently used as a conditioned medium. 
Maroon-labeled leukemic cells (0.4×105) were transferred on top of a 3-µm pore 
polycarbonate membrane insert. In this transwell assay, leukemic cells were allowed to 
migrate overnight at 37°C in 5% CO2 to the bottom compartment that contained either 
an hMSC-TERT layer, or conditioned medium collected from hMSC-TERT after 48 h 
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Figure 1. EMP1 expression is increased in prednisolone-resistant leukemic cells. shEMP1 
efficiently silences the expression of EMP1 and reduces cell proliferation. (A) Microarray expression 
(x axis) was confirmed with qRT-PCR (y axis). qRT-PCR and microarray RNA expression correlated 
significantly (Spearman R=0.88, P<0.01). (B) EMP1 mRNA levels in 12 prednisolone-sensitive and 
11 prednisolone-resistant BCPALL patients and 3 normal bone marrow samples were analyzed by 
means of qRT-PCR. (C) EMP1 mRNA levels were measured 168 h after infection with shEMP1 or 
an shNSC in six leukemic cell lines. Values were adjusted for expression of the housekeeping gene 
RPS20 and are relative to the levels seen in shNSC-transduced cells of each cell line (set to 100%). 
(D) Protein levels of EMP1 were assessed by western blotting at 168 h after shEMP1 and shNSC 
transduction. EMP1 protein levels were corrected for b-actin and are relative to shNSC-transduced 
cells of each cell line (set to 100%). A representative western blot for a BCP-ALL cell line, that is, 
ETV6-RUNX+  and a T-ALL cell line, that is, tetraploid T-ALL, is shown. (E) Cell proliferation of 
EMP1-silenced cells and shNSC control cells was monitored over time by MACSQuant flow. Data 
are presented as mean plus s.e.m. of three independent experiments (*p<0.05, **p<0.01, ***p<0.001).
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or plain AIMV medium. Subsequently, the amount of leukemic cells in the bottom 
compartment was quantified by both trypan blue exclusion assays and the MACSQuant 
flow cytometer (Miltenyi Biotec).
MSCs and leukemic cells co-culture experiments 
Leukemic cells (0.4×105) alone (condition 1) or co-cultured on top of an 80% subconfluent 
30 Gy irradiated hMSC-TERT layer (condition 2) were cultured in 24-well plates 
in RPMI 10% fetal calf serum with or without 0.488 mg/ml prednisolone for 3 days. 
Hereafter, leukemic cells in condition 1 were directly harvested from the culture medium. 
In condition 2, the non-adherent leukemic cells were collected from the supernatant, 
whereafter the adherent leukemic cells were harvested by trypsinizing the supernatant-
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Figure 2. EMP1 silencing increases apoptosis and induces cell-cycle arrest. 
(A) EMP1 knockdown-induced apoptosis was assessed in six leukemic cell lines 168 h after 
transduction with the MACSQuant using an Annexin V/Propidium iodide (PI) staining. The 
percentage of apoptotic cells was calculated using the quadrant method. A representative fluorescence 
activated cell sorting plot is shown for REH. (B) Cell-cycle distribution of EMP1-silenced cells and 
non-silencing control cells was analyzed after 1 h BrdU incorporation, followed by BrdU-FITC and 
7-AAD staining. The percent of cells in G0/G1, S and G2/M is presented as means plus s.e.m. of 
three independent experiments (*P<0.05, **P<0.01).
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depleted hMSC-TERT layer. Suspension and adherent cells were counted by trypan blue 
exclusion assays and the MACSQuant flow cytometer. To determine whether hMSC-TERT 
cells consume prednisolone, and thereby lower the available prednisolone concentration 
in leukemia co-culture experiments, the hMSC-TERT layer was cultured with 0.488 mg/
ml prednisolone at 37°C, 5% CO2. After 3 days, this MSC-derived prednisolone medium 
was collected and transferred to leukemic cells. In parallel, leukemic cells were exposed to 
prednisolone exposed to 37°C, 5% CO2 for 3 days (similar to the MSC medium), and to a 
freshly made dilution of prednisolone. After 3 days, the cytotoxic effect of prednisolone 
in these three media conditions was compared by an MTS assay. 
Statistical analysis 
Spearman’s rank correlation coefficient was calculated to compare microarray gene 
expression results with qRT-PCR results. Data from other experiments were compared 
in unpaired T tests and Mann–Whitney U tests, p=0.05 was considered as statistically 
significant. The dose–response curves of prednisolone in combination with shNSC 
compared with shEMP1 were analyzed by repeated measurement one-way ANOVA, 
testing the interaction between short-hairpin RNA*prednisolone. Cumulative incidence 
of relapse (CIR) was calculated as time to relapse and nonresponse with death as a 
competing event in the statistical environment R version 2.15.0 using the method of 
Fine and Gray18 with the software packages mstate 0.2.619 and cmprsk 2.2-2.20 Event-free 
survival (EFS) was calculated as time to relapse, non-response, secondary malignancy 
and death in IBM SPPS Statistics 20 using Kaplan–Meier analysis and Cox proportional 
hazard analyses. Univariate and multivariate analysis on EFS were performed in IBM 
SPPS Statistics 20 using Cox proportional hazard analyses that were stratified for 
treatment protocol. More detailed information regarding materials and methods can be 
found in the Supplementary Information. 
Results
EMP1 expression is increased in prednisolone-resistant 
leukemic cells 
Gene expression profiling revealed that the mRNA levels of EMP1 were median 3.4-fold 
higher in leukemic cells of 74 prednisolone resistant compared with 42 sensitive BCP-
ALL patients calculated with limma taking along 60 prednisolone intermediate resistant 
patients and subtype as confounder (p=0.003, Supplementary Table S1). We verified this 
with qRT-PCR in 23 BCP-ALL patients (Figure 1a). qRT-PCR and microarray mRNA 
expression levels correlated significantly (Spearman R=0.88 p<0.0001, Figure 1a) and 
qRT-PCR confirmed that EMP1 was higher expressed in prednisolone-resistant patients 
compared with sensitive patients (Figure 1b, p<0.0001). Moreover, EMP1 expression was 
higher in BCP-ALL compared with normal bone marrow-derived mononuclear cells 
(p<0.03, Figure 1b). EMP1 was most differentially expressed in prednisolone-resistant 
B-other cases (23.5-fold, p=0.003), followed by BCR-ABL1-like cases (2.2-fold, p=0.04), 
ETV6-RUNX1+-rearranged cases (2.1-fold, p=0.05), and hyperdiploid cases (1.9-fold, 
p=0.1, Supplementary Figure S1). In T-ALL patients. EMP1 expression levels differed 
median 2.0-fold between 27 prednisolone-resistant and 19 sensitive cases (p=0.04, 
Supplementary Figure S1). Basal EMP1 expression levels in prednisolone- sensitive BCP-
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ALL patients were highest in hyperdiploid patients followed by BCR-ABL1-like cases 
(Supplementary Figure S1) 
EMP1 silencing increases apoptosis and induces partial cell-
cycle arrest 
To assess the role of EMP1 in prednisolone-resistant ALL, we silenced EMP1 in six 
different prednisolone-resistant leukemic cell lines, that is, an ETV6-RUNX1+ BCP-ALL, 
a TCF3-PBX1+ BCP-ALL, an t(5;12) BCP-ALL, an MLL-AF4+ BCP-ALL, a tetraploid 
T-ALL and a T-lymphoblast cell line. Robust EMP1 knockdown was achieved following 
lentiviral transduction to levels varying between 2.3±0.5 and 27.7±20% of those observed 
in cells transduced with shNSC (p<0.001 Figure 1c). Protein levels in EMP1-silenced 
cells were reduced up to 20.2±3.7% (p<0.05) of those observed in shNSC-transduced 
cells after 168 h (Figure 1d; Supplementary Figure S2). Silencing of EMP1 decreased cell 
proliferation in all six cell lines, resulting in a proliferation rate down to 16% of that seen 
for shNSC-transduced cells (p<0.05; Figure 1e). Annexin V/Propidium iodide staining 
revealed a significant increase in apoptosis in five out of six cell lines, with a maximum 
increase of 2.4-fold (p<0.05, Figure 2a, a representative fluorescence activated cell sorting 
plot is shown for TEL-AML+ BCP-ALL). BrdU incorporation assays showed a significant 
reduction in EMP1-silenced cells in S phase in all six cell lines up to 1.7-fold (p<0.05, 
Figure 2b). Four out of six cell lines demonstrated an increase in EMP1-silenced cells 
in G0/G1 phase and/or G2/M phase, with a maximum increase of 1.5-fold and 2.1-fold, 
respectively (p<0.01, Figure 2b). Available shEMP1 constructs present in the Sigma-
Aldrich short-hairpin RNA library were tested and only one construct provided sufficient 
knockdown of EMP1 (Supplementary Figure S3). As independent validation experiment, 
we performed siRNA-mediated knockdown experiments of EMP1 and confirmed a 
significant inhibition of proliferation similar to shEMP1 results (Supplementary Figure 
S4). We were unable to study shEMP1- mediated knockdown in primary patients’ 
ALL cells, since these primary cells only survive for 96 h in ex vivo cultures and EMP1 
protein knockdown only becomes evident after 168 h (Supplementary Figure S2). For 
similar reasons, we were not able to reach sufficient knockdown of EMP1 using siRNA-
mediated knockdown in primary patients’ ALL cells. Knockdown of EMP1 sensitizes to 
prednisolone We next evaluated whether inhibiting EMP1 expression sensitized leukemic 
cells toward prednisolone-induced apoptosis. Silencing of EMP1 expression rendered 
three out of six cell lines more sensitive toward prednisolone-induced apoptosis. (Figure 
3; Supplementary Table S2, Of note: The cytotoxic effect of prednisolone was corrected 
for death caused by silencing of EMP1 or shNSC.) The cytotoxicity of prednisolone 
in the other three cell lines did not change nor did the cells become more resistant to 
prednisolone (Figure 3). Silencing of EMP1 resulted in a fold-change reduction in LC50 
values for prednisolone of 4.3-fold in the TCF3-PBX1+ BCP-ALL, 1.6-fold in Tetraploid 
T-ALL and 18.7-fold in the T-lymphoblast cell lines (Supplementary Table S2, all 
p<0.001). siRNA-mediated knockdown of EMP1 also showed significant sensitization 
toward prednisolone of TCF3-PBX1+ BCP-ALL cells (Supplementary Figure S4). 
EMP1 is important for leukemic cell migration and cell 
adhesion 
Recently, the bone marrow microenvironment was demonstrated to contribute to 
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Figure 3. Knockdown of EMP1 sensitizes to prednisolone. 
Sensitivity to prednisolone after EMP1 knockdown was measured in a 3-day MTS assay. Sensitivity 
was corrected for cell death induced by EMP1 knockdown itself in the absence of prednisolone. Data 
are presented as mean plus s.e.m of three or more independent experiments (repeated measurement 
one-way ANOVA, ***P<0.001). 
resistance of leukemic cells to drugs.21,22 When we co-cultured leukemic cells with a 
human MSC layer (hMSC-TERT) (Figure 4a), we observed a 4.1-fold increase in EMP1 
mRNA levels in the fraction of leukemic cells that adhered to hMSC-TERT compared 
with the fraction that remained in suspension (Figure 4b). EMP1 expressions levels 
returned to normal after the adhered ALL fraction was cultured without hMSC-TERT 
for 72 h (Figure 4b). In five out of six cell lines viable EMP1-silenced cells adhered less 
to hMSC-TERT, up to 29.3±4.1% reduction, compared with shNSC-transduced control 
cells (p<0.01, Figure 4c). Next, we evaluated migration of EMP1-silenced cells placed in 
an upper compartment of a transwell assay (Figures 4d and e). The bottom compartment 
contained either an hMSC-TERT layer that was pre-incubated with AIMV for 48 h or did 
not contain an hMSC-TERT layer but only the preconditioned AIMV medium which had 
been collected from hMSC-TERT after 48 h of incubation. A bottom compartment with 
only plain AIMV was used as a negative control. Viable EMP1-silenced cells migrated 
less to the bottom compartment containing the hMSC-TERT layer or the preconditioned 
medium in all six cell line models, with a maximal reduction in migration by 78.3±9.0% 
in EMP1-silenced cells compared with shNSC-transduced control cells (p<0.05, Figure 
4d). To rule out that apoptosis induced by EMP1 knockdown is the explanation for the 
observed reduction in migration and adhesion, we analyzed the effect of MCL1 (anti-
apoptotic gene) knockdown and found that this also decreased cell proliferation, but in 
contrast to EMP1, did not hamper migration and adhesion of viable cells (Supplementary 
Figure S5). 
Role of EMP1 in bone marrow microenvironment-mediated 
prednisolone resistance 
Our preliminary observation that EMP1 is not only important in prednisolone resistance, 
but might be important in leukemic cell migration and adherence to hMSC-TERT 
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Figure 4. EMP1 is important in leukemic cell migration, adhesion to MSCs and might be 
important in bone marrow microenvironmentmediated prednisolone resistance (opposite 
page). 
(A, B) Maroon-labeled ETV6-RUNX1+ leukemic cells were co-cultured with hMSC-TERT for 24 
h. EMP1 mRNA levels were measured in non-adherent leukemic cells and adherent leukemic cells 
that were separated from hMSC-TERT by fluorescence activated cell sorting. Separated adherent 
leukemic cells were subsequently cultured without hMSC-TERT for 72 h. (C) Leukemic cells were 
cocultured on an MSC layer overnight, whereafter only viable non-adherent and adherent cells were 
quantified by means of the trypan blue exclusion assay and MACSQuant flow cytometer. (D, E) Non-
silencing control leukemic cells or EMP1-silenced leukemic cells were placed in AIMV medium 
into an upper compartment of a transwell assay and allowed to migrate to a lower compartment 
containing hMSC-TERT preconditioned for 48 h in AIMV or to a lower compartment with only 
preconditioned AIMV medium taken from MSCs. Migration of viable cells was assessed by trypan 
blue exclusion assay and MACSQuant flow cytometer. 
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prompted us to investigate the role of EMP1 in bone marrow microenvironmentmediated 
prednisolone resistance. We cultured EMP1-silenced cells with or without hMSC-TERT 
layer and with or without 0.488 mg/ml prednisolone for 3 days. We discovered that 
an hMSCTERT layer can rescue shNSC-transduced control cells from prednisolone-
induced apoptosis (Figure 4f). This was not caused by prednisolone-induced apoptosis of 
the MSCs, since hMSC-TERT cells are prednisolone resistant, nor by reduced availability 
of prednisolone in the medium due to consumption by hMSC-TERT (Supplementary 
Figures S6A and B). Most importantly, EMP1 knockdown partly prevented hMSC-
TERT-mediated prednisolone resistance (Figure 4f, p< 0.01). EMP1 signals through the 
Src kinase family and further downstream to JNK, STAT3, STAT5, CREB and NF-kB 
We next determined which signaling pathways are affected by EMP1. We demonstrate 
that EMP1 silencing in ETV6-RUNX1+ and MLL-AF4+ BCP-ALL, and Tetraploid T-ALL 
cell lines decreased phosphorylation of several Src kinases, that is, Src, Yes, Fgr, Blk 
and Hck, up to 55% (p<0.05, Figures 5a and b). Further downstream, EMP1 silencing 
resulted in decreased phosphorylation of JNK, STAT3, STAT5, CREB and NF-kB, up to 
80% reduction (p< 0.05, Figures 5a and b). p38 and ERK1/2 phosphorylation levels were 
below detection level in BCP-ALL cell lines (ND = not detectable). 
EMP1 status is an independent prognostic factor for clinical 
outcome in BCP-ALL 
EMP1 mRNA levels were determined by Affymetrix microarrays for 134 BCP-ALL and 
60 T-ALL patients treated on the German COALL97-03-protocol, and 239 BCP-ALL 
and 56 T-ALL patients treated on the Dutch ALL10 (DCOG) protocol. EMP1 expression 
status (that is, low or high expression levels) was based on the median cutoff value of 
mRNA levels detected by microarrays among a batch of BCP-ALL and a batch of T-ALL 
cases. In the combined analysis of the COALL and DCOG patients stratified for treatment 
protocol, EMP1-high BCP-ALL (n=187) patients had a significantly poorer EFS compared 
with EMP1-low BCP-ALL (n=186) patients with 5-year EFS rates of 77±3 and 89±2%, 
respectively (p<0.004, Figure 6a; Table 1). CIR analysis demonstrated a significant higher 
relapse and non-response risk for EMP1-high than EMP1-low cases in BCP-ALL (5-year 
CIR: 17±3 vs 9±2% P=0.02, Figure 6b). EFS and CIR curves per treatment protocol are 
depicted in Supplementary Figure S7. To evaluate the independent prognostic value of 
EMP1, we performed Cox’s multivariate regression analysis on all 373 BCP-ALL patients 
stratified according to treatment protocol using white blood cell count, age and EMP1 
expression status as covariates. We identified EMP1-high expression levels at diagnosis 
as an independent predictor (p<0.01) for poor outcome in BCP-ALL with a hazard ratio 
of 2.36 (95% confidence interval: 1.31–4.25, Table 1). The poor prognosis of EMP1-
high expressing BCP-ALL patients at diagnosis is independent of in vitro and in vivo 
prednisolone response (Supplementary Table S3) and subtype of ALL (Supplementary 
Table S4). Although we found a similar functional role for EMP1 in T-ALL cell line 
models and a trend for poorer outcome of EMP1-high cases in the T-ALL cohort, this 
Figure 4 continued: (F) Non-silencing control leukemic cells and (EMP1-silenced leukemic cells 
were cultured for 3 days with or without MSCs and with or without 0.488 mg/ml prednisolone. 
Hereafter, leukemic cells were harvested and cell survival was assessed by trypan blue exclusion 
assay and MACSQuant flow. Data are presented as mean plus s.e.m. of three or more independent 
experiments (*P<0.05, **P<0.01, ***P<0.001).
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Figure 5. EMP1 signals through the Src kinase family to activate JNK, STAT3, STAT5, CREB 
and NF-kB. 
(A, B) Phosphorylation levels of Src kinase family members and several key members of important 
cellular pathways were determined by means of a luminex assay in protein harvested from non-
silencing control cells and EMP1-silenced cells at 168 h after infection. Phosphorylation levels 
in shNSC-transduced control cells were put to 100% (dashed line). Phosphorylation levels were 
corrected for protein load by GAPDH and b-tubulin levels in the same sample. Data are presented 
as mean plus s.e.m. of REH and SEM BCP-ALL cell lines (n = 4) (A) and Jurkat T-ALL cell line 
experiments (n = 2) (B) (*P<0.05, **P<0.01, ***P<0.001). ND: not detectable, p38 and ERK1/2 
measurements in BCP-ALL were below the background level. 
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was not statistically significant neither in a treatment-protocol stratified analysis (Figures 
6c and d; Table 1B) nor in each of the protocols separately (Supplementary Figure S7; 
Supplementary Table S3). 
Discussion 
Prednisolone, a glucocorticoid, regulates transcription of numerous genes eventually 
leading to cell-cycle arrest and apoptosis in lymphocytes. These properties make 
glucocorticoids pivotal in the treatment of hematologic malignancies and have led to 
their inclusion in all chemotherapy protocols for lymphoid malignancies.23 Prednisolone 
resistance is a major driver of therapeutic failure.2 Children with T-ALL are more often in 
vitro resistant to prednisolone compared with children with the more favorable prognostic 
BCP-ALL immunophentoype.24 Elucidating causes of resistance to prednisolone remains 
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Figure 6. EMP1 status is an independent prognostic factor in BCP-ALL. 
EMP1 status was based on the median cutoff value of microarray mRNA expression levels seen in 
373 BCP-ALL (A, B) and 116 T-ALL (C, D). EFS (upper panels) and cumulative incidence of relapse 
and non-response (CIR) (lower panels) were calculated. EFS was calculated as time to relapse, non-
response, secondary malignancy and death using Kaplan– Meier analysis and Cox proportional 
hazard analyses. CIR was calculated as time to relapse and non-response with death as a competing 
event using the method of Fine and Gray.18 
challenging due to the multifactorial processes in which these glucocorticoids are involved. 
In this study, we identified a significant overexpression of EMP1 mRNA in leukemic cells 
taken from prednisolone-resistant ALL patients. We show that knockdown of EMP1 
moderately sensitized leukemic cells to prednisolone. Interestingly, a link between 
glucocorticoids and EMP1 family members has been shown before, as glucocorticoids can 
regulate the promoter activity of the homologous family members PMP22 and EMP2.25,26 
We show that EMP1 is important for leukemic cell survival, as silencing of EMP1 results 
in cell-cycle arrest and apoptosis. In line with this are several studies associating EMP1 
expression levels with cell cycle and cell survival.5,27,28 The potential observed role of EMP1 
in migration and adhesion of leukemic cells might be supported by the notion that EMP1 
regulates cell–cell contact,6,7 and contributes to integrin-mediated leukocyte migration 
and adhesion.11 These findings are important in relation to the tumor microenvironment, 
as this has a significant role in leukemic cell survival and in chemotherapy resistance. 
Chemokines secreted by MSCs, such as stem cell factor 1 and CXCL12, stimulate 
leukemic cell homing and survival.29,30 MSCs can also induce leukemic drug resistance 
through upregulation of the voltage-dependent channel hERG121, or rescue cells from 
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L-asparaginase by secreting asparagine.22 Furthermore, sequestration of ALL cells by 
MSCs may provide a physical barrier for chemotherapeutics. We show here that MSCs 
can protect leukemic cells against prednisolone-induced apoptosis and, moreover, that 
silencing of EMP1 reduces the protection by MSCs. These data suggest that EMP1 
contributes to microenvironment-induced prednisolone resistance. We furthermore 
determined which signaling pathways underlie EMP1-mediated effects. Recent studies 
in non-small lung carcinoma suggest that EMP1 increases EGFR signaling,11 and showed 
that EMP1 activates the PI3K/AKT pathway.31 We did, however, not find an association 
between EMP1 and EGFR signaling (Ariës et al., unpublished data), nor could we 
demonstrate an effect on AKT phosphorylation after EMP1 silencing in ALL (Figure 5). 
In contrast, we demonstrated that EMP1 mediates its effect through the Src kinase family, 
including Src, Fgr, Hck, Yes and Blk. This is in line with data showing that the family 
member EMP2 promotes Src and FAK phosphorylation.32 Src kinase family members are 
oncogenes that are essential in B-cell and T-cell receptor signaling.33,34 Silencing of EMP1 
also decreased the phosphorylation of CREB, NF-kB, JNK, STAT3 and STAT5 in our 
study. Src kinase activation was previously shown to affect the proliferation and migration 
of cells via these proteins.35 Furthermore, JNK and STAT pathways have proven to be 
important in cell survival of both BCP-ALL and T-ALL.36–38 We propose the following 
model; EMP1 most likely serves together with integrines11 as an anchor molecule essential 
Table 1. Univariate and multivariate analysis of EMP1 status and event-free survival.
A
BCP-ALL
Univariate analysis Multivariate analysis
Patients Events HR (95%-CI) p-value HR (95%-CI) p-value
EMP1 expression 
(mRNA)
<Median 186 16
≥Median 187 37 2.42 (1.34–4.35) <0.01 2.36 (1.31–4.25)  <0.01
Age at diagnosis 
(years)
Low <10 255 35
High ≥10 118 18  1.50 (0.84–2.67) 0.17
1.44 (0.80–
2.56) 0.22
WBC count (x 109/l)
Low <50 288 37
High≥50 85 16 1.58 (0.88–2.83) 0.13 1.46 (0.81–2.63 0.21
B
T-ALL
Univariate analysis Multivariate analysis
Patients Events HR (95%-CI) p-value HR (95%-CI) p-value
EMP1 expression 
(mRNA)
<Median 58 11
≥Median 58 19 1.75 (0.83-3.68) 0.14 1.76 (0.83-3.71) 0.14
Age at diagnosis 
(years)
Low <10 63 16
High ≥10 53 14 1.09 (0.53-2.25) 0.81 1.10 (0.53-2.25) 0.80
WBC count (x 109/l)
Low <50 36 8
High≥50 79 22 1.17 (0.52-2.64) 0.71 1.09 (0.48-2.48) 0.83
Abbreviations: BCP-ALL, B-cell precursor ALL; CI, confidence interval; EMP1, epithelial membrane protein 1; 
HR, hazard ratio; T-ALL, T acute lymphoblastic leukemia; WBC, white blood cell. Univariate and multivariate 
analysis of the indicated prognostic factors stratified according to treatment protocol (DCOG: Dutch, COALL: 
German) were performed by a Cox regression model in BCP-ALL (A) and T-ALL (B).
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Supplementa Data
Supplemental Table S1 This table is available on the Leukemia website 
https://images-nature-com.eur.idm.oclc.org/full/nature-assets/leu/journal/v28/n9/extref/
leu201480x2.pdf
Cell lineL C50  shNSC (µg/ml) LC50 shEMP1 (µg/ml)
REH 10487 +/- 672 10170 +/- 722
6970 .222 +/- 0.022 0.050 +/- 0.003 ***
NALM60 .396 +/- 0.005 0.421 +/- 0.022
SEM1 .175 +/- 0.117 1.980 +/- 0.270
Jurkat 9352 +/- 422 5914 +/- 389 ***
SupT1 8.138 +/- 0.3250 .435 +/- 0.007 ***
* In vitro Prednisolone resistance compared to LC50 values of ALL patients' cells as described in reference 13.
*** p<0.001
Resistant
Intermediate Resistant
Intermediate Resistant
Intermediate Resistant
Resistant
Intermediate Resistant
Table S3. Univariate and multivariate analysis of EMP1 status, age, white blood cell count, and 
in vitro and in vivo prednisolone resistance and prognosis. Univariate and multivariate analysis 
of the inidcated prognostic factors were performed by a Cox regression model based on
event-free survival and with riskgroup as stratum. In vitro prednisolone response data are only
available of COALL-97/03 patients, in contrast in vivo prednisolone response data are only 
available of DCOG-ALL10 patients.
Supplemental Table S2. Prednisolone resistance IC50 values of cell lines after shNSC or 
shEMP1 transfection.
* in vitro prednisolone resistance compated to IC50-values of primary ALL cells as described in 
reference 13. *** p < 0.001
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Table S4. Univariate and multivariate analysis of EMP1 status, age, white blood cell count and 
subtypes in BCP-ALL. 
Univariate and multivariate analysis of the indicated prognostic factors were performed by a Cox 
regression model stratified for treatment protocol (COALL/DCOG) based on event-free survival. 
The percent of 5-year event-free survival was analyzed using Kaplan-Meier statistics. WBC=white 
blood cell count; ER=ETV6-RUNX1+, HD=hyperdiploid, E2A=TCF3‐PBX1+, BO=B-other, 
BA=BCR-ABL1+, BAL=BCR-ABL1-like, MLL=MLL-rearranged. ER and HD belong to the low-risk 
group, E2A and BO to intermediate-risk group and BA, BAL and MLL to high-risk group.
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Figure S1. Differential expression of EMP1 between prednisolone resistant and sensitive 
patients per subtype of ALL. 
Microarray expression levels of EMP1 probeset 201324_at are compared between in vitro 
prednisolone sensitive (sens) and resistant (res) ETV6-RUNX1+, hyperdiploid (HD) (>50 
chromosomes), BCR-ABL1-like, B-other BCP-ALL patients and T-ALL patients indicated by |--|. 
Green block indicates patients with an EMP1 expression below the median. The median expression 
level differed between BCP and T-ALL cases because these patients were tested in two different 
batches of microarrays. Mann-Whitney comparison of basal EMP1 expression levels between 
prednisolone sensitive subtypes are indicated by O—O, all sensitive groups were compared and 
only the statistical significant ones are indicated.
shNSC shEMP1 shEMP1 shNSC 
t96 t168 
-  
EMP1 
sh
Figure S2. Knockdown of EMP1 protein expression became apparent after 168h.
EMP1 protien expression in NALM6 was assessed after 96h and 168h. Knockdown of EMP1 protein 
expression became apparent after 168h. We were therefore not able to achieve EMP1 knockdown in 
primary ALL cells, since these cells are viable for up to 96h.
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Figure S3. Only shEMP1-b yields sufficient EMP1 mRNA knockdown.
EMP1 mRNA expression was assessed at three different timepoints after transfection with three 
different shEMP1 constructs available TRCN 0000117943 (shEMP1-a), TRCN 0000117944 
(shEMP1-b) and TRCN 0000117945 (shEMP1-c). Only shEMP1-b yielded sufficient knockdown.
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Figure S4. EMP1 knockdown using siEMP1 inhibits leukemic cell proliferation and sensitizes 
cells towards prednisolone. 
The leukemic cell line 697, E2A-PBX1+, was transfected with siEMP1-Cy5 or with siScrl-Cy5. (A) 
Transfection efficiency at 72 hours after transfection was assessed by means of flow cytometry. 
(Mock; red line, siScrl; black line, siEMP1; blue line) (B) EMP1 mRNA levels were determined 
72 hours after transfection by qRT-PCR and calculated relative to siScrl after correcting for the 
housekeeping gene RPS20. (C) Leukemic cell survival 72 hours after transfection was evaluated with 
a trypan blue exclusion assay (*p<0.05). (D) Response to prednisolone was assessed in a three day 
MTT assay directly after transfection with either siScrl or siEMP1. Sensitivity was corrected for cell 
death induced by EMP1 knockdown without co-exposure to prednisolone. Data are presented as 
mean plus SEM of two experiments (*p<0.001). 
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Figure S5. MCL1 knockdown decreases proliferation, but not adhesion and migration. 
(A) : MCL1 mRNA levels were measured after treatment with shMCL1 or shNSC in REH: ETV6- 
RUNX1+ leukemic cells. Values were adjusted for expression of the housekeeping gene RPS20 and are 
relative to shNSC-transduced cells (NSC). (B) Cell proliferation of MCL1 silenced cells and shNSC-
transduced cells was monitored over time on the MACSQuant. (C) Leukemic cells were cocultured 
with mesenchymal stromal cells (hMSC-TERT) overnight, whereafter viable non-adherent and 
adherent cells were quantified by means of trypan blue exclusion assay and/or MACSQuant flow. 
(D) Non-silencing control or MCL1-silenced ETV6-RUNX1+ leukemic cells were placed in AIMV 
into an upper compartment of a transwell assay and allowed to migrate either to hMSC-TERT 
preconditioned for 48h in AIMV or to 48h preconditioned AIMV that was collected from hMSC-
TERT. Migration of viable cells was assessed by trypan blue exclusion assay and MACSQuant flow. 
Data are presented as mean plus SEM of a triplicate experiment.
Figure S6. Leukemic cell proliferation, MSCs and prednisolone. 
(A) Cell survival of hMSC-TERT after 3-day prednisolone exposure determined by an MTS assay. 
(B) Leukemic cell survival determined by a 3-day MTS assay with either fresh prednisolone in 
RPMI medium, prednisolone that was incubated for three days at 37 °C in RPMI medium, and 
prednisolone in RPMI medium that was harvested from hMSC-TERT after three days of incubation 
at 37 °C . Data are presented as mean plus SEM of three independent experiments (***p<0.001).
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Figure S7. EFS and CIR of EMP1 high versus EMP1 low patients per treatment protocol.
EMP1 status was determined by the median value of microarray mRNA expression for 134 BCP-
ALL (left) and 60 T-ALL patients (right) treated on the German COALL97-03-protocol (A and C 
panel), and 249 BCP-ALL (left) and 56 T-ALL (right) patients treated on the Dutch ALL10 protocol 
(B and D panel). 5-year event-free survival were analyzed using Kaplan-Meier statistics. Cumulative 
incidence of relapse was calculated with the method of Fine and Gray. 
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General Discussion and Perspective
Decades of clinical and pre-clinical research have achieved high rates of cure in children 
diagnosed with acute lymphoblastic leukemia (ALL). However, therapy is intense and has 
serious side effects. This changes the priorities and goals of therapy adaptations. With 
this context in mind, we evaluated several signaling pathways as therapeutic targets in 
pediatric BCP-ALL. Genetic aberrations often indicate relevant molecular pathways, 
because they constitutively activate or inactivate signaling pathways
The advent of next-generation sequencing has facilitated the identification of oncogenic 
drivers and led us to search for mutations and structural aberrations in four potential 
treatment targets. Secondly, we evaluated the in vitro response to drugs against these 
pathways, which also revealed resistance mechanisms. Ultimately, this work aimed to 
give suggestions for the clinical implementation of therapies targeting signaling pathways.
Targeting oncogenic signaling pathways in pediatric BCP-ALL
Kinases play a major role in sustained proliferation and anti-apoptotic signaling. The 
characteristic ATP-binding pockets of kinases offer many possibilities for small molecule-
binding, which initiated the development of specific inhibitors. This biological and 
clinical relevance is the basis for a large part of the work presented in this thesis. 
JAK2 aberrant leukemia comprises two distinct entities: in some cases chimeric fusion 
genes are generated by translocations, in others JAK2 mutations are thought to cause 
constitutive activation (Chapter 2). In general, tyrosine kinase fusions are primary 
oncogenic events and therefore excellent treatment targets. Discovery of the BCR-ABL1 
fusion gene as leukemic driver has led to implementation of ABL inhibitors as standard 
of care, which now serve as the prime example for targeted therapy in hemato-oncology. 
In our study, fusions involving JAK2 were, as expected, restricted to the BCR-ABL1-like 
subtype. These JAK2 fusions, as well as other kinase fusions discovered in recent years, 
may serve as therapy targets similarly to BCR-ABL1 but their suitability as therapeutic 
target has not been proven.1-4 Cellular context and additional mutations likely affect the 
vulnerability to targeted inhibition. Previous studies support the hypothesis that JAK2 
inhibitors are most effective in combination therapies.4,5 
JAK2 mutations occurred in BCR-ABL1-like and B-other cases and sporadically in 
high hyperdiploid leukemia. Importantly, all JAK2 mutations in R683 occurred in the 
background of high CRLF2 expression (chapter 2). While JAK2 fusions are known to 
be primary, leukemia-initiating lesions, JAK2 mutations were detected at a range of 
variant allele frequencies (VAF) and could be lost in patient-derived xenografts. They 
therefore represent secondary genetic aberrations. This is likely to affect the dependence 
of leukemic cells on JAK2-mediated signals. Although some of our data disagrees, it is 
generally thought that JAK2 mutations provide TSLP-independent growth signals by 
constitutively activating the JAK STAT pathway.6,7 Our data and previously published 
reports suggest that this indeed creates a dependency on JAK signaling.8-10 However, 
we also found that signaling rebound after inhibitor release, activation of alternative 
pathways, as well as microenvironment-mediated resistance could hinder the effect of 
JAK inhibitors in pediatric BCP-ALL. While these points do not generally contest JAK 
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inhibitor treatment, thorough genomic characterization at therapy initiation and close 
disease monitoring may be required.
The RAS family genes were some of the first oncogenes to be described. Germline RAS 
mutations increase the risk for malignancies, proving that RAS pathway activation is 
oncogenic, but insufficient on its own.11,12 However, these cases are rare, and frequent 
subclonal mutations show that RAS pathway mutations are usually secondary events in 
leukemia development. 
As the RAS protein itself is so far “undruggable”, targeting downstream effector pathways 
is so far the most promising approach.13 In line with other reports, our pre-clinical data 
suggests that inhibition of the MAPK pathway (the RAF-MEK-ERK signaling axis) is a 
promising approach in BCP-ALL.14 Carefully designed clinical studies are necessary to 
investigate whether these pre-clinical results can be replicated in patients. 
The RAS GTPases relate extracellular growth signaling from different cytokine receptors 
into an intracellular response. Three major pathways are activated by RAS signaling, but 
many others are indirectly connected. In this central position, the mutational activation 
of RAS cooperates with different oncogenic mechanisms. It is therefore not surprising 
that RAS mutations are found in different genomic backgrounds (chapter 3) and tumor 
types (reviewed by Pylayeva-Gupta et al.15). 
Deep sequencing allowed evaluation of tumor heterogeneity and detection of small 
subclones. As has been suggested by retrospective studies, we discovered that many 
children with BCP-ALL (20%) carry RAS pathway mutations only in a minor fraction 
of leukemic cells.14,16,17 Our data showed that the prognostic relevance of clonal RAS 
pathway mutations was different from that of subclonal mutations. This suggests that 
other mechanisms are driving the leukemia in cases with subclonal mutations. These 
may represent better treatment targets and should therefore be investigated. Despite this 
likely difference at diagnosis, cases with subclonal mutations recurrently relapsed with 
clonal RAS pathway mutations. Re-evaluating RAS pathway mutation status at relapse is 
therefore necessary to determine which patients are eligible to MEK inhibitor treatment.
It is noticeable that the RAS pathway and JAK2 have a similar role within the cancer 
cell: Both are intracellular effectors which relate external signals into a cellular response. 
In JAK2 mutant BCP-ALL, these signals are derived from TSLP-bound CRLF2, but in 
other diseases mutant JAK2 mimics activation of single chain receptors such as EPOR or 
MPL.18 In addition, JAK2 is known to transmit signals of many other receptors, e.g. the 
interferon receptor family, GCSF receptor family, and IL6 receptor.18 The RAS-mediated 
MAPK signaling transmits signals of many different receptors, such as growth factor 
receptors (e.g. FGFR, PDGFR, FLT3, CSF1R), G-protein coupled receptors, or cytokine 
receptors.19,20 Environmental signals likely play an important role during the early 
development, and genetic aberrations that constitutively activate growth and survival 
signaling can circumvent negative feedback regulation and dependence on external 
sources of the signal. 
However, the tumor microenvironment continues to play an important role also in JAK2 
and RAS mutant leukemia. For example, we and others have shown that CRLF2 activation 
strongly enhances signaling through mutant JAK2 (chapter 2). Regarding RAS activation, 
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it is important to keep in mind that RAS mutations actually inactivate its enzymatic 
function, which results in the failure to turn down signal generation. External signaling 
activation in the mutated background may also activate other components of the pathway 
which are not activated by the activating mutation alone. The partial dependence on 
environmental cues becomes obvious in in vitro culture systems. ALL cell survival is 
largely enhanced by co-culture with mesenchymal stromal cells (chapter 2, chapter 4, and 
ref.21 )
Indirect effects of the leukemic microenvironment have been described through CXCL12 
and ITGA4-mediated adhesion.22-26 Recently, additional effects have been shown to 
be mediated by tunneling nano-tubes, which are formed between ALL cells and the 
mesenchymal stromal cells.21,27 Tunneling nanotubes serve as transport structures for 
the transmission of autophagosomes, mitochondria, and the adhesion molecule ICAM, 
and disruption of tunneling nanotube formation reduces the cell survival benefit 
mediated by mesenchymal stromal cells in vitro. Such novel mechanisms are currently 
being discovered and will lead to a better understanding of the leukemic bone marrow 
environment, also with regard to cellular drug resistance (see below).
Looking for novel targets, we investigated the tyrosine kinases PDGFRα and FGFR1-3 
(chapters 4 and 5). FGFR signaling had been previously implicated in other hematologic 
malignancies, as well as fusions of PDGFRA.28-30 However, our investigations did not 
reveal recurrent genetic aberrations in these genes.
Despite being highly expressed in a distinct subgroup of BCP-ALL patients, inhibition 
of PDGFRα signaling had no effect on the survival of these leukemic cells. PDGFRA 
high cases were also sensitive to prednisolone, and not more resistant towards other 
chemotherapeutic drugs than other BCP-ALL cases. Combining PDGFRα inhibition 
with other therapeutics is therefore not likely to yield a benefit. 
Oncogenic FGFR signaling was previously demonstrated in multiple myeloma and CML, 
but in pediatric BCP-ALL virtually no mutations are present at initial diagnosis.28,30 In 
vitro drug testing with specific inhibitors showed no sensitivity towards inhibition of 
FGFR signaling in BCP-ALL cells. Receptor tyrosine kinases with high expression (e.g. 
PDGFRα) or relevance in other hematological subclasses (FGFR1-3) may be actively 
signaling, but those are not necessarily essential survival signals. 
With molecular characterization still ongoing, novel mediators of signaling pathways 
may still be discovered. We have found that the poorly studied EMP1 is a biomarker and 
mediator of prednisolone resistance (chapter 6). The structure of this molecule indicates 
a function in cell adhesion, and our studies assessing migration and adhesion of leukemic 
cells in vitro support this. In addition, we found that Src signaling is downregulated upon 
EMP1 knockdown. This example points out that not only classic growth factors, but 
also other cellular mechanisms such as cell adhesion affect cellular signaling pathways. 
Factors such as EMP1 should therefore also be included in a wider search for possible 
drug targets within signaling pathways. 
For the future of signaling-directed therapies, the experience of the past years has shown 
that resistance, e.g. caused by the microenvironment or tumor evolution, is almost 
inevitable. Managing resistance will be essential to achieve lasting treatment effects with 
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signaling-directed therapies. 
Anticipating and overcoming cellular drug resistance 
After the first successes in clinical application, several mechanisms for resistance towards 
kinase inhibitors were discovered. Although they are often specific to the inhibitors and 
targets, common principles can be identified that aid drug development.
First of all, efficacy can often be improved by compound optimization. As discussed in 
chapter 2, type-I inhibitors, which bind kinases in active conformation, are eventually less 
effective drugs than type-II inhibitors, which keep kinases in an inactive conformation. 
We and others observed rebound activation of JAK2 after inhibitor release, in cases with 
both mutations and fusions. Although the precise consequences have not been studied, it 
is possible that the reactivation after inhibitor release hinders the therapeutic efficacy of 
type I-JAK inhibitors. Recently, two novel type-II inhibitors were reported, which showed 
greater anti-tumor efficiency in myeloid and lymphoid leukemia with JAK2 aberrations.5 
Clinical studies are yet required to reveal superiority of these inhibitors. 
Lower target specificity may be a vice as well as a virtue: As shown in chapter 2, at least 
part of the difference observed between the efficiency of momelotinib and ruxolitinib 
may be due to inhibition of other targets, such as the kinase TBK1 and the BMP receptor 
ACVR1/ALK2 by momelotinib.31,32 Similarly, suppression of FGFR3 signaling was shown 
to be part of the anti-leukemic effect of the ABL1 inhibitor ponatinib.30 However, such 
reduced selectivity is also likely to cause an increased amount of side effects and, for 
example, requires additional safety measures for ponatinib therapy.33 
Even in molecules targeting the same kinases, differences in the chemical interaction 
may lead to variations in their efficacy. For example, the MEK inhibitor trametinib binds 
MEK1 as well as MEK2, while other candidates, such as cobimetinib or selumetinib, show 
higher selectivity towards MEK1 (FDA Memorandum on Cobimetinib Oct. 2015 and 
references 34 and 35). As MEK1 and MEK2 are thought to act redundantly, this selectivity 
may affect efficacy and facilitate development of drug resistance. In addition, Lito et al. 
and Hatzivassiliou et al. have shown that disrupting the interaction between MEK and 
RAF kinases by the inhibitor is essential for its effectiveness in RAS-mutant cancers.36,37 
In contrast, these MEK inhibitors were less effective towards BRAF mutant cancers.37 
The various genotypes that activate identical oncogenic pathways may therefore require 
tailored inhibitors. 
In addition to the chemical compounds, therapy schedules can be optimized to anticipate 
the development of resistance. For example, reactivating mutations are common in 
relapsed, imatinib-treated BCR-ABL1-rearranged leukemia in adults, and will very likely 
develop in other kinase fusion cases as well.38 In this type of leukemia, the aberrant kinase 
is central to the disease and only reactivation can restore the oncogenic effect of the 
aberrant kinase. The gatekeeper residue in the ATP binding pocket is crucial for binding 
of many kinase inhibitors, and mutations that block this interaction (e.g. ABL1 T315I) 
are selected for by therapy. As these mutations can be relatively easily anticipated, second 
generation drugs can be developed which bypass the resistance induced by specific 
mutations. Several generations and mutant-selective inhibitors are already available for 
the some kinases, such as BTK and ABL1.39,40 Notably, kinase domain mutations seem to 
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be rare in children with BCR-ABL1-rearranged BCP-ALL, where imatinib is integrated 
into an intense combination chemotherapy and often followed by hematopoietic stem 
cell transplantation.38,41,42
Pathway crosstalk and plasticity within signaling networks may also limit the efficacy of 
drugs targeting signaling molecules. So-called redundancy is the major way of resistance 
towards drugs targeting secondary aberrations. Our data and previously published reports 
suggest that secondary mutations in alternative pathways (e.g. RAS pathway) could 
bypass the therapeutic effects of JAK inhibition.17,43 This could also explain the varying 
degree of sensitivity towards MEK and JAK inhibitors observed in vitro (e.g. chapters 2 
and 3). Further support for the hypothesis comes from xenograft studies: CRLF2-driven 
leukemia grows in mice, despite mouse TSLP being unable to activate human CRLF2 
(own observation and reference 44). In one xenograft, we observed a KRAS-mutant 
clone outgrowing the JAK2-mutant clone. This suggests that CRLF2 signaling may be 
less relevant for leukemia propagation than for initiation, at least in some cases. Revealing 
the relevant downstream effects of secondary aberrations will improve therapy through 
combination approaches (see below). 
In addition to these intracellular mechanisms of resistance, we and others have shown 
that also the micro-environment contributes to resistance to targeted therapy, e.g. 
through cytokine secretion and cell-cell contact (chapters 2, 5 and 6).45-48 Inhibiting the 
effects of cytokines secreted in the leukemic niche, e.g. FGF2 or CXCL12, can overcome 
environment-mediated therapy resistance.30,49-51 It is important to note that chemokines, 
such as CXCL12 or CX3CL1, may indirectly affect therapy response by changing 
migration towards and egress from the leukemic bone marrow.23,52,53 Furthermore, the 
newly described tunneling nanotubes were shown to mediate cellular resistance towards 
prednisolone.21 Further investigations, especially utilizing in vivo models, are warranted 
to identify new potential targets in the leukemic niche.
Clonal diversity allows selection for therapy resistance in all cancers. Therapy represents 
a selective pressure, which will select for those cells that a capable to adapt to the effects 
of therapy. With regard to secondary aberrations, we made an interesting observation in 
RAS mutant ALL after relapse: In more than half of all cases several RAS mutant clones 
co-existed at initial diagnosis. In the small cohort of relapsed cases we investigated, this 
clonal diversity seemed to be reduced to single, clonal mutations driving the relapsed 
leukemia. It is tempting to speculate that these relapses may be more susceptible to MEK 
inhibitor therapy because they were derived from a single, MEK-dependent leukemic 
cell. 
In conclusion, all therapeutic strategies and targeted therapy in particular, need to embrace 
tumor evolution. The logical consequence is combination therapy, which changes the 
selective pressures to eradicate all leukemic cells. In the future, it may be tailored to the 
molecular aberrations found in individual cases.
Combination therapies
With a quickly growing number of drugs and targets, a vast amount of combination 
therapies is conceivable. Some data is already available to pre-select combinations that 
should be evaluated in further studies, and more detailed knowledge on the mode of 
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action of old and new drugs will allow more informed decisions and designs. 
Molecular explanations and evidence-based suggestions for combination strategies are 
not yet fully revealed. Unfortunately, only few pre-clinical studies address the interaction 
of targeted therapeutics with standard of care drugs so far.4,5,54 Especially with regard 
to development of resistance, however, combining targeted therapy with broadly acting 
cytotoxic drugs could be valuable. By using optimal combinations and enhancing efficacy 
of some standard therapeutics, other drugs with severe side effects might become 
obsolete. We and others showed that MEK inhibitors synergize with glucocorticoids 
in vitro (chapter 2).55-59 Interestingly, many RAS pathway mutant cases were resistant 
to chemotherapy, indicating that inhibitors such as trametinib may be beneficial when 
applied in combination with glucocorticoids as the spearhead drug in the treatment of 
ALL.
Identification of redundant pathways may also yield more effective therapies. For 
example, JAK inhibitors have been shown to be more effective in combination with PI3K/
mTOR inhibition in JAK2 mutant BCR-ABL1-like ALL.8,10 The previously mentioned link 
between RAS and JAK2 mutations provides a rationale to also asses a combination of JAK 
and MEK inhibition in JAK2 mutant leukemia. Additionally, combination of two drugs 
targeting the same pathway has proven beneficial in RAS- or RAF-mutant melanoma and 
lung cancer, most likely through more effective signaling inhibition as compared with 
single-agent therapy.60-62
Especially for cases where current therapies often fail, e.g. TCF3-LF- or MLL-rearranged 
ALL, radically new therapies are needed. Immunotherapy has shown great successes 
to eradicate cancer cells and is quickly becoming available to more patients. However, 
resistance or non-response will likely arise as well, and the combination with small 
molecule inhibitors could boost treatment success.63-65 
Clinical implementation: The importance of biomarkers 
and clinical studies
Unfortunately, most targeted therapy approaches have stayed behind the expectations, 
and criticism is rising.66,67 It should be noted that these conclusions are derived from trials 
in adult patients, very often with carcinomas. Comparable studies evaluating the benefit 
of targeted therapy in children with cancer are still limited, mainly due to the rarity of 
different cancer types in children and the relatively low frequency of (relapsed) cases. 
International collaborative studies are essential to enroll sufficient numbers of patients 
in early clinical trials.68
Many targeted therapeutics have disappointed because the effect size observed in pre-
clinical models was not replicated in clinical settings. Responses were often of short 
duration and remain difficult to predict. Biomarkers for patient selection will therefore 
become increasingly important in pre-clinical and clinical studies. In addition, the 
combination approaches require carefully controlled studies that also delineate the risks 
of possible drug interactions in combination therapy.
The vast majority of children with BCP-ALL achieve a complete remission with standard 
chemotherapy, and refractory disease is rare (represented in Figure 1A). This raises the 
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question whether targeted therapy should be aimed at preventing or at treating relapses. As 
a result, two main possibilities for treatment adaptation exist: Identification of actionable 
lesions could be performed at diagnosis and trigger inclusion of targeted therapy up-
front (Figure 1B). Alternatively, targeted therapy could be initiated after relapse as part of 
treatment intensification (Figure 1C). 
The data presented in this thesis suggests that MEK inhibitors could be applied in the 
latter setting. While RAS pathway mutations were common at diagnosis and certainly 
affect a significant number of patients, only a minority of these children are at risk for 
relapse. While children with RAS mutations had a poorer prognosis in certain therapy 
settings, the effect size was relatively small and requires confirmation. In contrast, RAS 
pathway mutations are poor prognostic at relapse, and survival chances were considerably 
lower.14,69 
JAK2 inhibitors may be promising adjuvant therapy for BCR-ABL1-like BCP-ALL with 
JAK2-rearrangements and mutations. Both JAK2-rearranged and -mutant leukemia 
Diagnosis Treatment Remission Relapse
time
Diagnosis Treatment TreatmentRemission CureRelapse
time
+
A
B
C
Diagnosis Treatment
Remission
 = Cure Relapse
time
+
Figure 1: Possible therapeutic strategies for targeted therapy in pediatric BCP-ALL. 
Currently, treatment failure (relapse) in pediatric BCP-ALL usually appears after a temporary 
remission (A). Targeted therapy might be included upfront for cases with high risk of treatment 
failure (B), or at relapse for those cases where upfront inclusion is not justified e.g. due to good 
prognostic features or risk of toxic side effects (C).
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Summary
Despite large improvements, therapy success for children with BCP-ALL currently 
stagnates at an event-free survival rate of 85%. After therapy, children frequently suffer 
from life-long side effects of therapy, and patients who relapse have a far worse prognosis. 
Several oncogenic signaling pathways have been identified that are activated by genetic 
aberrations and contribute to leukemogenesis. In this thesis we evaluated different 
signaling pathways and their potential implication in therapeutic strategy.
In chapter 2 we searched for mutations and gene fusions of the kinase JAK2 among a 
large cohort of BCP-ALL patients. They mostly occur among BCP-ALL patients lacking 
the classical cytogenetic aberrations (therefore termed B-other) and in BCP-ALL patients 
whose gene expression profile resembles that of BCR-ABL1-rearranged leukemia (BCR-
ABL1-like). The cytotoxic effects of JAK inhibitors in vitro varied: While cells with JAK2 
fusion genes were effectively killed by ruxolitinib and momelotinib, cells carrying JAK2 
mutations responded best in presence of the cytokine TSLP. We further discovered 
potential limits to JAK inhibitor therapy due to biochemical properties of the inhibitor, 
activation of alternative signaling pathways, and microenvironment-mediated drug 
resistance. Based on our results we conclude that JAK inhibitor therapy may be of benefit 
for patients with JAK2 aberrations, but cases with JAK2 mutations should be monitored 
closely for disease progression.
In chapter 3 we evaluated the clinical and therapeutic significance of RAS pathway 
mutations. We discovered that these mutations were largely restricted to 4 genes central 
to the pathway, and that they frequently occurred in a small fraction of leukemic cells 
(subclonal mutations). Clonal mutations associated with in vitro drug resistance and a 
higher chance of relapse in certain settings, while subclonal mutations had no significant 
effect on poor prognostic characteristics or on prognosis itself. We further show that 
the MEK-inhibitor was highly effective in killing RAS mutant BCP-ALL cells and could 
sensitize them to prednisolone. We conclude that these MEK inhibitors could potentially 
be tested in patients at high risk for relapse or after relapse if the leukemic cells carry a 
RAS pathway mutation. 
In chapter 4 we investigate the phenomenon of high PDGFRA expression in a group 
of pediatric BCP-ALL patients. We show that many of these cases carry ERG-deletions 
on chromosome 21, and that there is no evidence for genetic aberrations affecting the 
PDGFRA gene locus on chromosome 4. Despite detectable PDGFRα activation, the 
PDGFR inhibitors imatinib and CP673451 had no cytotoxic effect in vitro. Targeting 
PDGFRα is therefore unlikely to be of therapeutic relevance in pediatric BCP-ALL.
In chapter 5 of this thesis we investigated the fibroblast growth factor receptor in pediatric 
BCP-ALL. We found that the fibroblast-growth factor FGF2 can decrease the sensitivity 
of leukemic cell lines towards prednisolone. With targeted next-generation sequencing 
we searched for somatic mutations in the FGFR1, 2 and 3 genes, and found that there are 
few mutations and that these are usually outside the known mutational hotspot regions. 
While the link with therapy resistance warrants further investigation, FGFR signaling 
likely plays a less important role in BCP-ALL than, for example, the RAS pathway.
A completely novel therapeutic target for pediatric ALL was suggested in chapter 6 of this 
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thesis. We showed that EMP1 expression is increased in in vitro prednisolone-resistant 
BCP-ALL, and is a poor prognostic marker. Knock-down of EMP1 increased sensitivity 
to prednisolone and decreased migration towards and adhesion to mesenchymal stromal 
cells. Pathway analysis revealed that EMP1-silencing reduced the phosphorylation of Src-
family kinases in ALL cell lines. Downstream targets included STAT proteins as well as 
JNK and CREB. We conclude that EMP1 is integrating micro-environmental signals via 
the Src kinase pathway and serves as prognostic biomarker and potential therapeutic 
target in pediatric ALL.
Overall, the results of this thesis show that several signaling pathways may be relevant 
to the development and progression of pediatric BCP-ALL. However, not all represent 
valuable treatment targets because the inhibitory effects are transient, reversible, or can 
be circumvented by activation of alternative pathways. Future investigations should be 
aimed at finding accurate biomarkers for efficacy, generating combination strategies of 
pathway inhibitors and chemotherapeutic drugs, and overcoming cellular resistance, 
especially with respect to the leukemic micro-environment.
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Nederlandse samenvatting
Ondanks grote vooruitgang in de lange termijn prognose van kinderen met acute 
lymfatische leukemie (ALL) door steeds betere behandelprotocollen, stagneert het 
genezingspercentage nu rond de 85%. Behalve het feit dat 15% van de kinderen met ALL 
niet geneest, is de andere keerzijde van de intensieve, 2 tot 3 jaar durende behandeling 
het optreden van ongewenste bij-effecten op zowel korte als lange termijn. Er zijn 
verschillende signaalpaden ontdekt die vaak over-reactief zijn in leukemiecellen. Deze 
activatie wordt vaak veroorzaakt door mutaties in genen die betrokken zijn bij het 
doorgeven van signalen van buiten de cel naar binnenin de cel en die dan aanzetten tot 
overmatig delen van de witte bloedcellen, met als gevolg leukemie. In dit proefschrift 
hebben we het optreden van mutaties in verschillende signaalpaden onderzocht en 
getest of deze mutaties doelwit voor nieuwe meer doelgerichte medicijnen (precision 
medicines) kunnen zijn waardoor de leukemiecellen selectiever gedood kunnen worden 
en er mogelijk minder kans is op bijwerkingen van de (chemo)therapie. 
In hoofdstuk 2 onderzochten we de frequentie van afwijkingen in het DNA coderend voor 
het JAK2 kinase, een gen betrokken bij het activeren van een celdelingsprogramma. In het 
DNA kunnen zowel kleine mutaties (puntmutaties) als grote versmeltingen van 2 genen 
(zogenaamde fusiegenen) optreden die beide leiden tot een hyperactivatie van JAK2. Deze 
afwijkingen werden onderzocht in B-cel acute lymfatische leukemie, een vorm die bij 
85% van de kinderen met ALL voorkomt. De meeste mutaties in JAK2 komen voor in de 
groep waar klassieke cytogenetische afwijkingen ontbreken (daarom B-others genoemd) 
en in patiënten waarvan het genexpressieprofiel lijkt op BCR-ABL1-positieve leukemie 
(BCR-ABL1-like genoemd). De celdodende effecten van JAK-remmers varieerden in 
onze laboratoriumstudies: cellen met JAK2-fusiegenen werden effectief gedood door 
ruxolitinib en momelotinib, terwijl cellen met alleen puntmutaties in JAK2 minder snel 
dood gingen en afhankelijk waren van het cytokine TSLP dat de JAK eiwitten indirect 
kan aanschakelen. We ontdekten verder potentiële beperkingen van JAK-remmers zoals 
het feit dat deze remmers juist tot activering van alternatieve signaalpaden kunnen 
leiden waarvan bekend is dat deze het overleven en delen van leukemiecellen stimuleren. 
Bovendien ontdekten we dat mesenchymale cellen die in het beenmerg belangrijk zijn 
voor de overleving van gezonde witte bloedcellen, ook de leukemiecellen ongevoeliger 
maakten voor de JAK remmers. Op basis van deze resultaten concluderen we dat JAK 
remmers effectief kunnen zijn voor patiënten met JAK2 fusiegenen, maar veel minder 
voor patienten met een JAK2 puntmutatie. In de klinische praktijk moet hierbij het 
effect op het aantal leukemiecellen maar vooral ook het optreden van (nieuwe) mutaties 
gemonitored worden.
In hoofdstuk 3 hebben we het belang van mutaties in het RAS signaalpad geëvalueerd. 
We ontdekten dat deze mutaties grotendeels beperkt zijn tot 4 sleutelgenen, en dat 
mutaties vaak in een klein percentage van de leukemiecellen (subklonale mutaties) 
gevonden wordt. Klonale mutaties waren geassocieerd met resistentie voor cytostatica 
in het laboratorium en met een hogere kans op het terugkomen van de leukemie in de 
patient(recidief genoemd). Daarentegen waren subklonale mutaties niet voorspellend 
voor de prognose van de patient. We zagen dat RAS gemuteerde cellen heel gevoelig 
waren voor de remmer trametinib, en bovendien maakte deze remmer de leukemiecellen 
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ook gevoeliger voor prednisone. Een combinatie van beide medicijnen ligt daarom voor 
de hand om te gaan gebruiken in de klinische praktijk.
In hoofdstuk 4 onderzochten we het fenomeen van hoge PDGFRA expressie in een 
groep kinderen met B-other en BCR-ABL-like leukemie. Dit gen is belangrijk voor het 
delen maar ook uitrijpen (differentieren) van witte bloedcellen. We ontdekten dat veel 
patienten met hoge PDGFRA expressie deleties hebben van het ERG gen, maar dat er 
geen aanwijzingen zijn voor genetische afwijkingen in het PDGFRA gen zelf. Ondanks 
dat PDGFRα geactiveerd was in deze patienten, hadden de PDGFR-remmers imatinib en 
CP673451 geen effect in onze laboratoriumstudies. We concludeerden dat PDGFRA geen 
goed doelwit is in de behandeling van kinderen met ALL.
In hoofdstuk 5 van dit proefschrift onderzochten we de mutatiefrequentie in FGFR1, 2, 
en 3 de fibroblast growth factor receptor, welke betrokken is bij celdelingen. We waren 
geinteresseerd in deze receptor omdat we ook vonden dat stimulatie van deze receptor 
(met het zogenaamde FGF2 ligand) tot minder gevoeligheid voor prednisolone leidde 
van de leukemiecellen. Ons mutatie-onderzoek leverde echter weinig afwijkingen op in 
de 3 FGFR-familie genen. Verder onderzoek naar de link met prednisolone resistentie is 
nodig, maar vermoedelijk speelt FGFR signalering geen prominente rol in kinderleukemie 
omdat er weinig tot geen mutaties voorkomen in deze genen.
Een volledig nieuw therapeutisch doelwit voor kinderleukemie staat beschreven in 
hoofdstuk 6, namelijk het membraan-gebonden eiwit EMP1. We hebben aangetoond 
dat EMP1 expressie verhoogd is in prednisolon resistente ALL, en dat deze verhoogde 
expressie vooral voorkomt bij patienten met een slechte prognose. Het uitzetten van 
dit EMP1 gen in het laboratorium, verhoogde de gevoeligheid voor prednisolon en 
verminderde de migratie van leukemiecellen naar mesenchymale beenmerg cellen. We 
toonden aan dat de Src-familie van kinases een belangrijke rol speelt bij het doorgeven van 
signalen opgepikt door EMP1 naar het binnenste van de cel toe. Onze studie suggereert 
dat EMP1 de potentie heeft om als target te dienen voor nieuw te ontwikkelen medicijnen 
in de behandeling van kinder ALL.
Samenvattend beschrijven we in dit proefschrift welke signaalpaden geactiveerd zijn in 
kinderen met ALL. Echter, niet alle signaalpaden zijn geschikt als therapeutisch doelwit 
omdat de remmende effecten kortdurend, omkeerbaar of omzeild kunnen worden door 
activering van alternatieve signaalpaden in de leukemiecellen en/of omzeild kunnen 
worden door de ondersteunende werking van mesenchymale cellen in het beenmerg. 
Het vervolgonderzoek zal zich dan ook richten op het vinden van goede combinaties van 
precision medicines en traditionele cytostatica (zoals prednisolon) en het doorbreken 
van de leukemisch beenmerg (micromilieu) gemedieerde medicijn-resistentie. 
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List of Abbreviations
aCGH   array comparative genomic hybridization
ALL   acute lymphoblastic leukemia
AML   Acute myeloblastic leukemia
ASP   L-asparaginase
BA   BCR-ABL1-positive
BAL   BCR-ABL1-like
BCP-ALL  B-cell precursor acute lymphoblastic leukemia
BO   B-other
CI   confidence interval
CIR   cumulative incidence of relapse and non-response
CLL   chronic acute lymphoblastic leukemia
CML   chronic myeloblastic leukemia
COALL   Cooperative study group for childhood acute lymphoblastic leukemia
COG   Childhood oncology group
DCOG   Dutch Childhood Oncology Group
DLSO   downstream located specific oligo
EFS   Event-free survival
ER   ETV6-RUNX1
FISH   fluorescence in-situ hybridization
HD   High hyperdiploid
HR   high risk 
HR-S   high risk standard
HSC   hematopoietic stem cell
iAMP21   intrachromosomal amplification of chromosome 21
IQR   inter-quartile range
JMML   Juvenile myelomonocytic leukemia
LC50   50% lethal concentration
LR-R   low risk reduced
LR-S   low risk standard
MAPK   mitogen-activated protein kinases
MLL   mixed lineage leukemia
MLPA   Multiplex ligation-dependent probe amplification
MR   medium risk
MRD   minimal residual disease
MSC   mesenchymal stromal cell
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MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NHR   non-high risk
NSG   NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)
OR   odds ratio
PDX   patient-derived xenograft
PPR   prednisone poor response
PRED   prednisolone
SEM   standard error of the mean
shEMP1   short-hairpin agains EMP1
shNSC   short-hairpin non-silencing control
SNP   single-nucleotide polymorphism
SNV   single-nucleotide variant
SR   standard risk
T-ALL   T-cell acute lymphoblastic leukemia
TCF3r   TCF3-rearranged
TKD   tyrosine kinase domain
TKI   tyrosine kinase inhibitor
TLA   targeted locus amplification
TMD   transmembrane domain
ULSO   upstream located specific oligo
VAF   Variant allele frequency
VCR   vincristine
WBC   white blood cell count
wt   wildtype
